[go: up one dir, main page]

EP2611777B1 - N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer - Google Patents

N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer Download PDF

Info

Publication number
EP2611777B1
EP2611777B1 EP11758024.1A EP11758024A EP2611777B1 EP 2611777 B1 EP2611777 B1 EP 2611777B1 EP 11758024 A EP11758024 A EP 11758024A EP 2611777 B1 EP2611777 B1 EP 2611777B1
Authority
EP
European Patent Office
Prior art keywords
phenyl
pyridin
ylmethyl
urea
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP11758024.1A
Other languages
German (de)
French (fr)
Other versions
EP2611777A1 (en
Inventor
Kenneth W. Bair
Timm R. Baumeister
Alexandre J. Buckmelter
Karl H. Clodfelter
Bingsong Han
Jian Lin
Dominic J. Reynolds
Chase C. Smith
Zhongguo Wang
Xiaozhang Zheng
Po-Wai Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Forma TM LLC
Original Assignee
Genentech Inc
Forma TM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Forma TM LLC filed Critical Genentech Inc
Publication of EP2611777A1 publication Critical patent/EP2611777A1/en
Application granted granted Critical
Publication of EP2611777B1 publication Critical patent/EP2611777B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • FK866 (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl) acrylamide induces apoptosis in HepG2 cells without having primary effects on cellular energy metabolism.
  • WO 2010/142735 discloses pyridinyl derivatives as nicotinamide phosphotransferase inhibitors.
  • the quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
  • the terms “treat” or “treatment” are synonymous with the term “prevent” and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop.
  • these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • pharmaceutically acceptable or “pharmacologically acceptable” is meant a material which is not biologically or otherwise substantially undesirable, i.e., the material may be administered to an individual without causing any substantially undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • variable e.g., aryl, heterocycle, R 2 , etc.
  • its definition on each occurrence is independent of its definition at every other occurrence.
  • N-oxide(s) forms with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • N-oxide(s) forms with a N atom member of said heteroaryl denotes a heterorayl group containing a nitrogen atom that forms a N-oxide.
  • Illustrative and non limiting examples of such N-oxides are:
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • deuterium as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
  • halo as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • aminoalkoxy as used herein means a substituent having at least one amino group and at least one alkoxy group.
  • nitrogen bonded heterocycles and heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
  • nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • heterocycloalkyl refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • ring atoms per ring selected from C atoms and N, O, and S heteroatoms.
  • Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to: and the like.
  • Numerical ranges are intended to include sequential whole numbers. For example, a range expressed as "from 0 to 4" would include 0, 1, 2, 3 and 4.
  • chemotherapeutic agent and “antineoplastic agent” generally refer to agents, which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis.
  • agents also known as “antineoplatic agents”
  • salts are also within the scope of this disclosure.
  • Reference to a compound of the Formula herein is understood to include reference to salts thereof unless otherwise indicated.
  • the term "salt(s)" denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
  • a compound of the Formulas contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)" as used herein.
  • a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (C 1 -C 10 )alkyl, (C 3 -C 7 ) cycloalkyl, benzyl, or R-carbonyl is a natural ⁇ -aminoacyl or natural ⁇ -aminoacyl, -C(OH)C(O)OY 1 wherein Y 1 is H, (C 1 -C 6 )alkyl or benzyl,-C(OY 2 )Y 3 wherein Y 2 is (C 1 -C 4 ) alkyl and Y 3 is (C 1 -C 6 )alkyl, carboxy(C 1 -C 6 )alkyl, amino(C 1 -C 4 )alkyl or mono-N- or
  • the compounds disclosed may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure.
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs, such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • the present disclosure has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis; irritable bowel syndrome and other conditions disclosed herein or that are known to those skilled in the art.
  • An aspect of the present disclosure concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
  • Still another embodiment of the disclosure is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 2 is H, and Ar 1 , z, X, A, Q, R 2 and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is heterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is arylalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is H, R 2 is spiroheterocycloalkyl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is heteroaryl, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • R 1 is alkyl
  • R 2 is spiroheterocycloalkyl
  • Ar 1 , z, X, A, Q, and R 3 are as defined.
  • R 1 is alkyl
  • R 2 is cycloalkyl substituted or fused as described earlier
  • Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 is alkyl, R 2 is aryloxy with the aryl substituted or fused as described earlier, and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R 1 and R 2 are joined together to form, along with the N, a piperazinyl (unsubstituted or substituted as described earlier), and Ar 1 , z, X, A, Q, and R 3 are as defined.
  • NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is aryl, R 1 is H, A is phenyl, R 2 is heterocycloalkyl, and z, X, L, Q, and R 3 are as defined.
  • NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is aryl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is heteroaryl, R 1 is H, R 2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • NR 1 R 2 is acyclic, where the various moieties are independently selected, Ar 1 is piperidinyl, R 1 is H, R 2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R 3 are as defined.
  • NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is tetrahydronaphthyridinyl, and z, X, L, A, Q, and R 3 are as defined.
  • NR 1 R 2 is cyclic, where the various moieties are independently selected, Ar 1 is aryl, NR 1 R 2 is azetidinyl, A is phenyl and z, X, L, Q, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar 2 is aryl, and z, R 1 and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar 2 is aryl, R 1 is cycloalkyl, and z, X, L, n, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is a straight chain alkyl, Ar 2 is aryl, n is 1, R 1 is heteroaryl, and z, X, L, n, and R 3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar 1 is heteroaryl, R is H, n is 1, Ar 2 is aryl, R 1 is CF 3 , and z, X, L, n, and R 3 are as defined.
  • R 1 is selected from the group consisting of cyclopentyl, CF 3 , phenyl, naphthalenyl, pyrimidinyl, oxazolyl, 8-oxatricyclotridecahexaenyl and thienyl.
  • this disclosure discloses compounds of Formula III and Pharmaceutically acceptable salts, solvates, ester or isomers thereof.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, n is 1 and Ar 2 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenol and R 1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar 1 is pyridine, Ar 2 is phenyl and R 1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • the plates were then washed three times with 1% acetic acid, dried, and treated with 100 ⁇ L of 10mM Tris-Base solution. The plates were then read in a microplate reader at an absorbance of 570 nm. Background was generated on a separate plate with media only.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Description

    Priority claim
  • This application claims priority from U. S. provisional applications Serial No. 61/379,812 , and 61/379,819 both filed September 3, 2010 , Serial No. 61/386,037 , and 61/386,044 both filed September 24,2010 , Serial No. 61/478,995 filed April 26, 2011 and Serial No. 61/480,423 filed April 29, 2011 .
    • Field of the Invention
  • The present invention relates to compounds and composition for inhibition of Nicotinamide phosphoribosyltransferase ("NAMPT") and uses of said compounds or compositions.
    • Background of the Invention
  • Nicotinamide adenine dinucleotide (NAD) plays fundamental roles in both cellular energy metabolism and cellular signaling. In energy metabolism, the chemistry of the pyridine ring allows NAD to readily accept and donate electrons in hydride transfer reactions catalyzed by numerous dehydrogenases.
  • The preparation of a class of compounds, comprising several subclasses, which act as inhibitors of the formation of nicotinamide adenyl nucleotide, and their use thereof as anti-tumor agents, is already described in the patient applications WO00/50399 , WO97/48695 , WO97/48696 , WO97/48397 , WO99/31063 , WO99/31060 , WO99/31087 , WO99/31064 , WO00150399 and WO03/80054 .
  • One of these inhibitors, (E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-(pyridine-3-yl)-acrylamide also known as APO866, FK866, WK175, or WK22.175 and hereinafter referred to as FK866 [International Non-proprietary Name], is especially described in the literature as an anticancer agent. FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer. It has been demonstrated in the prior art that FK866 interferes with nicotinamide adenyl dinucleotide (also known and hereinafter referred to as NAD) biosynthesis and induces apoptotic cell death without any DNA damaging effects.
  • Additionally, FK866 ((E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl) acrylamide) induces apoptosis in HepG2 cells without having primary effects on cellular energy metabolism. (Hasmann M, Schemainda I. FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis. Cancer Res 2003;63:7436-7442. [PubMed: 14612543]) Instead of causing immediate cytotoxicity, it inhibits NAMPT and depletes the cells of NAD, suggesting that FK866 could be a promising agent against cancer cells that rely on nicotinamide to synthesize NAD. The crystal structure of the NAMPT-FK866 complex reveals that the compound binds at the nicotinamide-binding site of NAMPT to inhibit its activity. FK866 has been tested in a murine renal cell carcinoma model and shown to display anti-tumor, antimetastatic, and anti-angiogenic activities (Drevs J, et al. Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 2003;23:4853-4858. [PubMed:14981935]).
  • In a mouse mammary carcinoma model, FK866 also induces a delay in tumor growth and an enhancement in tumor radiosensitivity accompanied with dose-dependent decreases in NAD levels, pH, and energy status. A chemosensitizing effect of FK866 has also been observed on anti-neoplastic 1-methyl-3-nitro-1-nitrosoguanidinium (MNNG)-induced cell death in THP-1 and K562 leukemia cell lines (Pogrebniak A, et al. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 2006;11:313-321. [PubMed: 17052966]).
  • The efficacy of GMX1777 was evaluated in xenograft models and the pharmacokinetic profile of GMX1778 and its effect on nicotinamide adenine dinucleotide cellular levels was measured by liquid chromatography/mass spectrometry. (Beauparlant P., et al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs. 2009 Jun;20(5):346-54).
  • GMX1777 is a water-soluble intravenously administered prodrug of GMX1778 that Gemin X in-licensed from LEO Pharma (LEO numbers: EB1627 and CHS828, respectively). These compounds and other substituted cyanoguanidines have the structures of Table 1. None of the compounds of the present invention are cyanoguanidines.
    Figure imgb0001
    • Substituted cyanoguanidines with defined pharmacological effects:
    1. A Cytotoxic CHS 828;
    2. B Potassium channel openers pinacidil (B1) and 12 g of compound as described in Perez-Medrano et al (B2); and
    3. C Histamine-II receptor antagonist cimetidine. (from Lövborg et al. BMC Research Notes 2009 2:114 doi:10.1186/1756-0500-2-114)
  • More recently, CHS-828 has been identified as a NAMPT inhibitor (Olesen UH, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804. [PubMed: 18201551]). CHS-828 has been shown that this compound potently inhibits cell growth in a broad range of tumor cell lines, although the detailed mechanism for this inhibitory effect of CHS-828 remains undetermined (Ravaud A, et al. Phase I study and guanidine kinetics of CHS-828, a guanidine-containing compound, administered orally as a single dose every 3 weeks in solid tumors: an ECSG/EORTC study. Eur J Cancer 2005;41:702-707. [PubMed: 15763645]). Both FK866 and CHS-828 are currently in clinical trials for cancer treatments.
  • There are numerous uses for drugs which inhibit NAMPT.
  • Lack of NAMPT expression strongly affects development of both T and B lymphocytes. By using mutant forms of this protein and a well-characterized pharmacological inhibitor (FK866), authors demonstrated that the ability of the NAMPT to regulate cell viability during genotoxic stress requires its enzymatic activity. Collectively, these data demonstrate that NAMPT participates in cellular resistance to genotoxic/oxidative stress, and it may confer to cells of the immune system the ability to survive during stressful situations such as inflammation. (Rongvaux, A., et al. The Journal of Immunology, 2008, 181: 4685-4695).
  • NAMPT may also have effects on endothelium (EC) in relation to high glucose levels, oxidative stress and on aging. It is also believed that NAMPT may enable proliferating human EC to resist the oxidative stress of aging and of high glucose, and to productively use excess glucose to support replicative longevity and angiogenic activity. WO2010/023307 discloses urea and thiourea compounds for use as a medicament for the treatment of a disease or a condition caused by elevated level of nicotiamide phophoribosyltrasferease.
  • WO 00/50417 discloses dihydroquinazoline compounds for treatment of cancer.
  • US 3994905 discloses use of 3-pyridylmethyl aryl ureas as rodenticides.
  • WO 2010/142735 discloses pyridinyl derivatives as nicotinamide phosphotransferase inhibitors.
  • WO 2011/109441 discloses compounds for nicotinamide phosphotransferase inhibition.
  • DE10053794 discloses amino- and amidosulfonamide compounds that have 5HT6-antagonist features for treatment of diseases of the central neural system.
    • Summary of the Invention
  • An aspect of the invention is the provision of compounds of Formula IIIA:
    Figure imgb0002
     wherein:
    • Ra is 1, 2, 3 or 4 Ra groups, each independently selected from the group consisting of hydrogen, amino, oxo, halo, alkoxy, alkyl, haloalkyl, -N(alkyl)2, -NH(CO)O-alkyl, 1H-pyrazolyl, 1H-imidazolyl, and -C(O)NH2; and wherein said pyridine can comprise a N-oxide formed with its N atom member;
    • R1 is NR3R4 wherein R3 is H, alkyl or -S(O)2alkyl and R4 is alkyl, hydroxyalkyl, -S(O)2alkyl, -(CH2)qcycloalkyl, -(CH2)qheterocycloalkyl, aryl, arylalkyl-, or -
      (CH2)qheteroaryl;
      haloalkyl;
      cycloalkyl;
      aryl;
      heterocycloalkyl; or
      heteroaryl,;
      wherein each of said cycloalkyl, aryl, heterocycloalkyl or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group
      consisting of:
      • halo, cyano, alkyl, hydroxyl, hydroxyalkyl, hydroxyalkoxy, haloalkyl, alkoxy, alkylalkoxy, haloalkoxy, arylalkenyl-, aryloxy, benzyloxy, oxo, -(CH2)q-NRbRc, -(CH2)q-CONRbRc,-S(O)2-alkyl, -S(O)2NH-alkyl, -S(O)2-heterocycloalkyl, -S(O)2-CF3, -C(O)alkyl, -C(O)aryl,-C(O)alkylenylaryl, -C(O)O-alkyl, -(CH2)qcycloalkyl, cycloalkylalkoxy-, aryl, arylalkyl-,-(CH2)qheteroaryl, and -(CH2)qheterocycloalkyl;
      • wherein each of said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by
      • one or more halo, nitro, haloalkyl, haloalkoxy, oxo, cyano, alkyl, haloalkyl, or alkoxy;
    • Rb and Rc are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, -S(O)2alkyl and cycloalkyl or Rb and Rc can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S and O; and
    • q is 0 or 1; and
    • pharmaceutically acceptable salts thereof,
    • with the proviso that the compounds of Formula IIIA are not:
      • N-[4-(phenylsulfanyl)phenyl]-N,-(3-pyridinylmethyl)urea;
      • N,N-diethyl-4-[[[(3-pyridinylmethyl)amino]carbonyl]-amino]benzenesulfonamide;
      • 4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide;
      • 1-[4-(benzylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
      • 1-{4-[(naphthalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
      • 1-{4-[(2-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
      • 3-(pyridin-3-ylmethyl)-1-{4-[(pyridin-3-ylmethyl)sulfamoyl]phenyl}urea;
      • 3-(4-[(2-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
      • 3-{4-[(2-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea; or
      • 3-{4-[(2-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea.
  • Another aspect of this invention is the provision of pharmaceutical compositions comprising a compound of the invention and a pharmaceutically acceptable carrier.
  • Another aspect of this invention is the provision of a compound of or a pharmaceutical composition of the present invention for use in a method for inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal.
  • Another aspect of this invention is the provision of a compound of the present invention for use in inhibiting Nicotinamide phosphoribosyltransferase ("NAMPT") in a patient.
  • Still another aspect of this invention is a compound of the present invention for use in treating, preventing, inhibiting or eliminating a disease or condition in a patient by inhibiting NAMPT in said patitent, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast casncer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, gragt-versus- host disease, Alzhemier's disease, cerbrovascular accident, artherosclerosis, diabetes, glomerulonephritits, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, leukemia, lymphomas, squamous cell cancers, kidney cancer, uretral and bladder cancers, cancers of head and nexk, cancers of the brain and central nervous system.
  • Another preferred embodiment is a pharmaceutical formulation comprising a pharmaceutically acceptable compound of the present invention, which provides, upon administration to a human, a decrease in tumor burden and/or metastases. The pharmaceutical formulation can be administered by oral means or other suitable means.
  • Yet another aspect is the compound or the pharmaceutical formulation of the present invention for use in treatment of cancer.
  • Yet another embodiment is the compound or the pharmaceutical formulation of the present invention for use in treatment of ovarian cancer, colon cancer or breast cancer.
  • Yet another embodiment is the compound or the pharmaceutical formulation of the present invention for use in treatment of leukemia.
  • Yet another embodiment is the compound or the pharmaceutical formulation of the present invention for use in treatment of colon cancer before or after surgical resection and/or radiation therapy.
  • Yet another embodiment is the compound or the pharmaceutical formulation of the present invention for use in treatment of cancer before or after surgical resection and/or radiation therapy, including adjunctive therapy to treat nausea, with or without dexamethasone.
  • Yet another embodiment is the compound or the pharmaceutical formulation of the present invention for use in treatment of cancer before or after surgical resection and radiation therapy, including adjunctive therapy with one or more additional therapeutic agents, or their pharmaceutically acceptable salts thereof. Non-limiting examples of such additional therapeutic agents include cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or doxorubicin)); taxanes (e.g. taxotere, taxol); topoisomerase II inhibitors (such as etoposide); topoisomerase I inhibitors (such as irinotecan (or CPT-11), camptostar, or topotecan); tubulin interacting agents (such as paclitaxel, docetaxel or the epothilones); hormonal agents (such as tamoxifen); thymidilate synthase inhibitors (such as 5-fluorouracil or 5-FU); anti-metabolites (such as methoxtrexate); alkylating agents (such as temozolomide, cyclophosphamide); Farnesyl protein transferase inhibitors (such as, SARASAR™.(4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,-6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoehtyl]-1-piperidine- carboxamide, or SCH 66336), tipifarnib (Zarnestra® or R115777 from Janssen Pharmaceuticals), L778,123 (a farnesyl protein transferase inhibitor from Merck & Company, Whitehouse Station, N.J.), BMS 214662 (a farnesyl protein transferase inhibitor from Bastol-Myers Squibb Pharmaceuticals, Princeton, N.J.); signal transduction inhibitors (such as, Iressa® (from Astra Zeneca Pharmaceuticals, England), Tarceva® (EGFR kinase inhibitors), antibodies to EGFR (e.g., C225), GLEEVEC® (C-abl kinase inhibitor from Novartis Pharmaceuticals, East Hanover, N.J.); interferons such as, for example, intron® (from Merck & Company), Peg-Intron® (from Merck & Company); hormonal therapy combinations; aromatase combinations; ara-C, adriamycin, cytoxan, and gemcitabine.
  • Other anti-cancer (also known as anti-neoplastic) agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATIN®. from Sanofi-Synthelabo Pharmaceuticals, France), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene,
  • Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade®, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, C225, and Campath, 5-fluorouracil and leucovorin, with or without a 5-HT3 receptor inhibitor (e.g., dolansetron, granisetron, ondansetron) with or without dexamethasone.
  • If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described herein (or as known to those skilled in the art) and the other pharmaceutically active agents or treatments within its dosage range. For example, the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108,2897). The compounds of the invention may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. A combination treatmentis not limited in the sequence of administration, compounds of Formula (I) disclosed here may be administered either prior to or after administration of the known anticancer or cytotoxic agent For example, the cytotoxic activity of the cyclindependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.
  • Any of the aforementioned methods may be augmented by administration of fluids (such as water), loop diuretics, one or more of a chemotherapeutic or antineoplastic agent, such as leucovorin and fluorouracil, and an adjunctive chemotherapeutic agent (such as filgrastim and erythropoietin), or any combination of the foregoing.
  • Yet disclosed is a method for administering a compound of the instant invention to a subject (e.g., a human) in need thereof by administering to the subject the pharmaceutical formulation of the present invention.
  • Yet disclosedis a method of preparing a pharmaceutical formulation of the present invention by mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable additives or excipients.
  • For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.
  • Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.
  • Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.
  • Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.
  • The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.
  • The compounds of this invention may also be delivered subcutaneously.
  • Preferably the compound is administered orally or intravenously.
  • Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.
  • The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 1000 mg, preferably from about 1 mg to about 500 mg, more preferably from about 1 mg to about 250 mg, still more preferably from about 1 mg to about 25 mg, according to the particular application.
  • The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.
  • The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.
  • Another aspect of the invention is a pharmaceutical composition comprising a compound according to the invention and a cell rescuing agent In a certain embodiment according to the invention, the cell rescuing agent is selected from the group consisting of nicotinamide, nicotinamide mononucleotide (NMN) and nicotinic acid.
    • Definitions
  • As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. If a definition is missing, convention definition as known to one skilled in the art controls.
  • "Patient" includes both human and animals.
  • "Mammal" means humans and other mammalian animals.
  • The term "inhibitor" refers to a molecule such as a compound, a drug, an enzyme activator or a hormone that blocks or otherwise interferes with a particular biologic activity.
  • The terms "effective amount" or "therapeutically effective amount" refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in a disease. An appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. Thus, the expression "effective amount" generally refers to the quantity for which the active substance has therapeutic effects. In the present case the active substance is the inhibitor of the formation of Nicotinamide phosphoribosyltransferase (NAMPT).
  • As used herein, the terms "treat" or "treatment" are synonymous with the term "prevent" and are meant to indicate a postponement of development of diseases, preventing the development of diseases, and/or reducing severity of such symptoms that will or are expected to develop. Thus, these terms include ameliorating existing disease symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise substantially undesirable, i.e., the material may be administered to an individual without causing any substantially undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
  • "Carrier materials" or what are also referred to as "excipients" include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility and the release profile properties of the desired dosage form. Exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. "Pharmaceutically compatible carrier materials" may comprise, e.g., acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like. See, e.g., Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. 1975.
  • As used herein, the term "subject" encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like. Examples of non-mammals include, but are not limited to, birds, fish and the like. In one embodiment of the present disclosure, the mammal is a human.
  • As used herein, "alkyl" means a straight chain or branched saturated chain having from 1 to 10 or 1 to 6 (C1-C6) carbon atoms. Representative saturated alkyl groups include, but are not limited to, methyl, methyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-ethyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl and the like, and longer alkyl groups, such as heptyl, and octyl and the like. An alkyl group can be unsubstituted or substituted. Alkyl groups containing three or more carbon atoms may be straight, branched or cyclized. As used herein, "lower alkyl" means an alkyl having from 1 to 6 carbon atoms.
  • As used herein, an "alkenyl group" includes an unbranched or branched hydrocarbon chain having one or more double bonds therein. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Ilustrative alkenyl groups include, but are not limited to, (C2 -C8) or (C2 -C6) alkenyl, groups, such as ethylenyl, vinyl, allyl, butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, hexadienyl, 2-ethylhexenyl, 2-propyl-2-butenyl, 4-(2-methyl-3-butene)-pentenyl and the like. An alkenyl, group can be unsubstituted or substituted.
  • The term "hydroxyalkyl" denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxy group. Examples of hydroxyalkyl include, but ar not limited to, meththyl, ehtyl propyl, isopropyl, isobutryl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by OH, as well as those hydroxyalkyl groups specifically illustrated b the examples herein below.
  • As used herein, "alkynyl, group" includes an unbranched or branched hydrocarbon chain having one or more triple bonds therein. The triple bond of an alkynyl group can be unconjugated or conjugated to another unsaturated group. Suitable alkynyl groups include, but are not limited to, (C2-C6) alkynyl, groups, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, methylpropynyl, 4-methyl-1-butynyl, 4-propyl-2-pentynyl, 4-butyl-2-hexynyl and the like. An alkynyl group can be unsubstituted or substituted.
  • The term "haloalkyl" denotes an alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Examples of haloalkyl include, but ar not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl wherein one or more hydrogen atoms are replaced by Cl, F, Br or I atom(s), as well as those haloalkyl groups specifically illustrated by the examples herein below. Among the preferred halloalkyl groups are monofluoro-, difluoro- or trifluoro-methyl, -ethyl or -propyl, for example 3,3,3,-trifluoropropyl, 2-fluroethyl, 2,2,2-triffuoroethyl, fluoromethyl, triffuoromethyl.
  • The terms "trifluoromethyl," "sulfonyl," and "carboxyl" include CF3, SO2, and CO2H, respectively.
  • The term "oxo" means a =O group.
  • The term alkylhydroxy or hydroxyalkyl means an alkyl group as defined above, wherein at least one of the hydrogen atoms of the alkyl group is replaced by an OH group.
  • The term "alkoxy" as used herein includes -O-(alkyl), wherein alkyl is defined above.
  • The term "haloalkoxy" denotes an alkoxy group as defined above wherein at least one of the hydrogen atoms of the alkoxy group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
  • The term "hydroxyalkoxy" means an alkoxy group as defined herein, wherein at least one of the hydrogen atoms of the alkoxy group is replaced by an OH group.
  • The term "aminoalkyl" as used herein means a group having one or more nitrogen atoms and one or more alkyl groups as defined above on the nitrogen.
  • "Aralkyl" or "arylalkyl" means an aryl-alkyl-group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.
  • "Heteroarylalkyl" means a heteroaryl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.
  • "Heterocyclylalkyl" means a heterocyclyl moiety as defined herein linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.
  • It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.
  • When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in the Formulas, its definition on each occurrence is independent of its definition at every other occurrence.
  • The term "N-oxide(s) forms with a N atom member of said heteroaryl" denotes a heterorayl group containing a nitrogen atom that forms a N-oxide. Illustrative and non limiting examples of such N-oxides are:
    Figure imgb0003
    Figure imgb0004
  • The expression: "wherein said pyridine can comprise a N-oxide formed with its N atom member" denotes the following formula:
    Figure imgb0005
  • As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • The term "deuterium" as used herein means a stable isotope of hydrogen having odd numbers of protons and neutrons.
  • The term "halo" as used herein means a substituent having at least one halogen selected from fluorine, chlorine, bromine, and iodine.
  • The term "cyano" as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.
  • The term "amino" as used herein means a substituent containing at least one nitrogen atom.
  • The term "(amino)alkoxy" as used herein means a substituent having at least one amino group and at least one alkoxy group.
  • The term "aryloxy" as used herein means a substituent of the form Ar-O- where Ar is an aryl group as defined herein.
  • The term "benzyloxy" denotes a benzyl-O- group.
  • The term "arylakenyl" denotes an aryl group, as defined herein, attached to the rest of the molecule by an alkenyl, group as defined herein.
  • The term "cycloalkylalkoxy-" denotes a cycloalkyl group as defined herein, attached to the rest of the molecule by an alkoxy group as defined herein.
  • The term "methylenedioxy" as used herein means a functional group with the structural formula -O-CH2-O- which is connected to the molecule by two chemical bonds via the oxygens.
  • As used herein, "alkoxyalkyl" means -(alkyl)-O-(alkyl), wherein each "alkyl" is independently an alkyl group defined above.
  • The term "(alkoxyalkyl)amino" as used herein means a substituent having at least one alkoxyalkyl group as defined above and at least one amino group as defined above.
  • The term "spirocycloalkyl" as used herein means a spiro group (containing no heteroatom) linked in a spiro manner to a cycloalkyl group. A non-limiting example would be the moiety shown below:
    Figure imgb0006
  • The term "spiroheterocycloalkyl" as used herein means a spiro group (containing no heteroatom) linked in a spiro manner to a heterocycloalkyl group. A non-limiting example would be the moiety shown below:
    Figure imgb0007
  • The term "heterospiroheterocycloalkyl" as used herein means a spiro group (containing a hetero atom such O, N or S) linked in a spiro manner to a heteocycloalkyl group. A non-limiting example would be the moiety shown below:
    Figure imgb0008
  • "Aryl" as used herein means a monovalent aromatic hydrocarbon radical of 6-20 or 6-10 carbon atoms derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system. Aryl includes bicyclic radicals comprising an aromatic ring fused to a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring. Exemplary aryl groups include, but are not limited to, radicals derived from benzene, naphtalene, anthracene, biphenyl, indene, indane, 1,2-dihydronapthalene, 1,2,3,4-tetrahydronapthalene, and the like. Aryl groups may be optionally substituted independently with one or more substituents described herein. Illustrative examples of aryl groups include, but are not limited to, the following moieties:
    Figure imgb0009
    Figure imgb0010
     and the like.
  • Illustrative substituted aryls include:
    Figure imgb0011
    Figure imgb0012
    Figure imgb0013
    Figure imgb0014
    Figure imgb0015
    Figure imgb0016
    Figure imgb0017
    Figure imgb0018
    Figure imgb0019
    Figure imgb0020
    Figure imgb0021
    Figure imgb0022
    Figure imgb0023
    Figure imgb0024
    Figure imgb0025
    Figure imgb0026
    Figure imgb0027
    Figure imgb0028
    Figure imgb0029
    Figure imgb0030
    Figure imgb0031
    Figure imgb0032
    Figure imgb0033
    Figure imgb0034
    Figure imgb0035
    Figure imgb0036
    Figure imgb0037
    Figure imgb0038
    Figure imgb0039
    Figure imgb0040
    Figure imgb0041
    Figure imgb0042
    Figure imgb0043
    Figure imgb0044
    Figure imgb0045
    Figure imgb0046
     and the like.
  • As used herein, the term "heteroaryl" refers to a monocyclic, or fused polycyclic, aromatic heteocycle (ring structure having ring atoms selected from carbon atoms as well as nitrogen, oxygen, and sulfur heteroatoms) having from 3 to 24 ring atoms per ring. The term "heteroaryl" as used herein also includes monovalent aromatic radical of a 5-, 6-, or 7-membered ring and includes fused ring systems (at least one of which is aromatic) of 5-10 atoms containing at least one heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Spiro moieties are also included within the scope of this definition. Heteroaryl groups may be optionally substituted independently with one or more substituents described herein. 5 or 6 membered heteroaryl can be selected from the group consisting of optionally substituted pyridinyl, pyrimidinyl, thiazolyl, imidazolyl, oxazolyl, isoxazolyl, pyrazolyl, pyridinone and benzimidazolyl.
  • By way of example and not imitation, carbon bonded heterocycles and heteroaryls are bonded at position 2, 3, 4, 5, or 6 of a pyridine, position 3, 4, 5, or 6 of a pyridazine, position 2, 4, 5, or 6 of a pyrimidine, position 2, 3, 5, or 6 of a pyrazine, position 2, 3, 4, or 5 of a furan, tetrahydrofuran, thiofuran, thiophene, pyrrole or tetrahydropyrrole, position 2, 4, or 5 of an oxazole, imidazole or thiazole, position 3, 4, or 5 of an isoxazole, pyrazole, or isothiazole, position 2 or 3 of an aziridine, position 2, 3, or 4 of an azetidine, position 2, 3, 4, 5, 6, 7, or 8 of a quinoline or position 1, 3, 4, 5, 6, 7, or 8 of an isoquinoline. Further examples of carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyiazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl.
  • By way of example and not limitation, nitrogen bonded heterocycles and heteroaryls are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, 1H-indazole, position 2 of an isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or β-carboline. Still more typically, nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
  • Illustrative examples of heteoaryl and substituted heteroaryl groups include, but are not limited to the following moieties:
    Figure imgb0047
    Figure imgb0048
    Figure imgb0049
    Figure imgb0050
    Figure imgb0051
    Figure imgb0052
    Figure imgb0053
    Figure imgb0054
    Figure imgb0055
    Figure imgb0056
    Figure imgb0057
    Figure imgb0058
    Figure imgb0059
    Figure imgb0060
    Figure imgb0061
    Figure imgb0062
    Figure imgb0063
    Figure imgb0064
    Figure imgb0065
    Figure imgb0066
    Figure imgb0067
    Figure imgb0068
    Figure imgb0069
    Figure imgb0070
    Figure imgb0071
    Figure imgb0072
    Figure imgb0073
    Figure imgb0074
    Figure imgb0075
    Figure imgb0076
    Figure imgb0077
     and the like.
  • The term "bicyclic heteroaryl" means a structure having atoms arranged in two rings fused together with at least two atms common to each ring, and at leat one of the rings being a heteroaryl ring. Non limiting examples of bicyclic heteroaryl comprise 5 to 13 or 5 to 10 membered bicyclic heteroaryl-groups comprising 1,2,3 or 4 heteroatoms independently selected from N, S, or O:
    Figure imgb0078
    Figure imgb0079
    Figure imgb0080
    Figure imgb0081
    Figure imgb0082
    Figure imgb0083
    Figure imgb0084
    Figure imgb0085
    Figure imgb0086
    Figure imgb0087
    Figure imgb0088
     and the like.
  • Further examples of bicyclic heteroaryls include but are not limited to:
    Figure imgb0089
    Figure imgb0090
  • These bicyclic heteroaryl groups can be substituted as defined herein.
  • As used herein, the term "cycloalkyl" refers to a saturated or partially saturated, monocyclic or fused or spiro polycyclic, carbocycle having from 3 to 24 (C3-C24), 3 to 12(C3-C12), 3 to 10 (C3-C10) or 3 to 6 (C3-C6) ring atoms per ring. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:
    Figure imgb0091
    Figure imgb0092
    Figure imgb0093
    Figure imgb0094
    Figure imgb0095
     and the like.
  • As used herein, the term "heterocycloalkyl" refers to a monocyclic, or fused or spiro, polycyclic, ring structure that is saturated or partially saturated and has from 3 to 24 ring atoms per ring selected from C atoms and N, O, and S heteroatoms. Illustrative examples of heterocycloalkyl and substituted heterocycloalkyl groups include, but are not limited to:
    Figure imgb0096
    Figure imgb0097
    Figure imgb0098
    Figure imgb0099
    Figure imgb0100
    Figure imgb0101
    Figure imgb0102
    Figure imgb0103
    Figure imgb0104
    Figure imgb0105
    Figure imgb0106
    Figure imgb0107
    Figure imgb0108
    Figure imgb0109
    Figure imgb0110
    Figure imgb0111
    Figure imgb0112
    Figure imgb0113
    Figure imgb0114
    Figure imgb0115
    Figure imgb0116
    Figure imgb0117
    Figure imgb0118
    Figure imgb0119
    Figure imgb0120
    Figure imgb0121
    Figure imgb0122
    Figure imgb0123
    Figure imgb0124
    Figure imgb0125
    Figure imgb0126
    Figure imgb0127
    Figure imgb0128
    Figure imgb0129
    Figure imgb0130
    Figure imgb0131
    Figure imgb0132
    Figure imgb0133
     and the like.
  • Numerical ranges, as used herein, are intended to include sequential whole numbers. For example, a range expressed as "from 0 to 4" would include 0, 1, 2, 3 and 4.
  • As used herein, the term "substituted" means that the specified group or moiety bears one or more suitable substituents.
  • As used herein, the term "unsubstituted" means that the specified group bears no substituents.
  • As used herein, the term "optionally substituted" means that the specified group is unsubatituted or substituted by one or more substituents.
  • When a multifunctional moiety is shown, the point of attachment to the core is indicated by a line. For e.g. (cycloalkyloxy)alkyl- refers to alkyl being the point of attachment to the core while cycloalkyl is attached to alkyl via the oxy group.
  • The expression "adjunctive chemotherapeutic agent" generally refers to agents which treat, alleviate, relieve, or ameliorate the side effects of chemotherapeutic agents. Such agents include those which modify blood cell growth and maturation. Examples of adjunctive chemotherapeutic agents include, but are not limited to, filgrastim and erythropoietin. Other such adjunctive chemotherapeutic agents include those which inhibit nausea associated with administration of the chemotherapeutic agents, such as a 5-HT3 receptor inhibitor (e.g., dolansetron, granisetron, or ondansetron), with or without dexamethasone.
  • The terms "chemotherapeutic agent" and "antineoplastic agent" generally refer to agents, which treat, prevent, cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect malignancies and their metastasis. Examples of such agents (also known as "antineoplatic agents") include, but are not limited to, prednisone, fluorouracil (e.g., 5-fluorouracil (5-FU)), anastrozole, bicalutamide, carboplatin, cisplatin, chlorambucil, cisplatin, carboplatin, docetaxel, doxorubicin, flutamide, interferon-alpha, letrozole, leuprolide, megestrol, mitomycin, oxaliplatin, paclitaxel, plicamycin (Mithracin™), tamoxifen, thiotepa, topotecan, valrubicin, vinvlastin, vincristine, and any combination of any of the foregoing. Additional such agents are described later.
  • "Nicotinamide phosphoribosyltransferase" also named NAMPT, NMPRT, NMPRTase or NAmPRTase, (International nomenclature: E.C. 2.4.2.12) is a key enzyme in nicotinamide adenyl dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide.
  • It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise.
  • When used as a therapeutic agent the inhibitors of the formation of nicotinamide phosphoribosyltransferase (NAMPT) described herein may be administered with one or more physiologically acceptable excipients. A physiologically acceptable carrier or excipient is a formulation to which the compound can be added to dissolve it or otherwise facilitate its administration.
  • The dosage forms of the present invention, may contain a mixture of one or more compounds of this invention, and may include additional materials known to those skilled in the art as pharmaceutical excipients. Such pharmaceutical excipients include, for example, the following: Stabilizing additives may be incorporated into the delivery agent solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution. The stabilizing additives may be employed at a concentration ranging from about 0.1 and 5% (W/V), preferably about 0.5% (W/V). Suitable, but non-limiting, examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine. The preferred stabilizing additives are gum acacia, gelatin and methyl cellulose.
  • Acidifying agents (acetic acid, glacial acetic acid, citric acid, fumaric acid, hydrochloric acid, diluted hydrochloric acid, malic acid, nitric acid, phosphoric acid, diluted phosphoric acid, sulfuric acid, tartaric acid); Aeosol propellants (butane, dichlorodifluoro-methane, dichlorotetrafluoroethane, isobutane, propane, trichloromonofluoromethane); Air displacements (carbon dioxide, nitrogen); Alcohol denaturants (denatonium benzoate, methyl isobutyl ketone, sucrose octacetate); Alkalizing agents (strong ammonia solution, ammonium carbonate, diethanolamine, diisopropanolamine, potassium hydroxide, sodium bicarbonate, sodium borate, sodium carbonate, sodium hydroxide, trolamine); Anticaking agents (see glidant); Antifoaming agents (dimethicone, simethicone); Antimicrobial preservatives (benzalkonium chloride, benzalkonium chloride solution, benzelthonium chloride, benzoic acid, benzyl alcohol, butylparaben, cetylpyridinium chloride, chlorobutanol, chlorocresol, cresol, dehydroacetic acid, ethylparaben, methylparaben, methylparaben sodium, phenol, phenylethyl alcohol, phenylmercuric acetate, phenylmercuric nitrate, potassium benzoate, potassium sorbate, propylparaben, propylparaben sodium, sodium benzoate, sodium dehydroacetate, sodium propionate, sorbic acid, thimerosal, thymol); Antioxidants (ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium formaldehyde sulfoxylate, sodium metabisulfite, sodium thiosulfate, sulfur dioxide, tocopherol, tocopherols excipient); Buffering agents (acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid, lactic acid, phosphoric acid, potassium citrate, potassium metaphosphate, potassium phosphate monobasic, sodium acetate, sodium citrate, sodium lactate solution, dibasic sodium phosphate, monobasic sodium phosphate); Capsule lubricants (see tablet and capsule lubricant); Chelating agents (edetate disodium, ethylenediaminetetraacetic acid and salts, edetic acid); Coating agents (sodium carboxymethylcellulose, cellulose acetate, cellulose acetate phthalate, ethylcellulose, gelatin, pharmaceutical glaze, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methacrylic acid copolymer, methylcellulose, polyethylene glycol, polyvinyl acetate phthalate, shellac, sucrose, titanium dioxide, carnauba wax, microcystalline wax, zein); Colorants (caramel, red, yellow, black or blends, ferric oxide); Complexing agents (ethylenediaminetetraacetic acid and salts (EDTA), edetic acid, gentisic acid ethanolmaide, oxyquinoline sulfate); Desiccants (calcium chloride, calcium sulfate, silicon dioxide); Emulsifying and/or solubilizing agents (acacia, cholesterol, diethanolamine (adjunct), glyceryl monostearate, lanolin alcohols, lecithin, mono- and di-glycerides, monoethanolamine (adjunct), oleic acid (adjunct), oleyl alcohol (stabilizer), poloxamer, polyoxyethylene 50 stearate, polyoxyl 35 caster oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, propylene glycol diacetate, propylene glycol monostearate, sodium lauryl sulfate, sodium stearate, sorbitan monolaurate, soritan monooleate, sorbitan monopalmitate, sorbitan monostearate, stearic acid, trolamine, emulsifying wax); Filtering aids (powdered cellulose, purified siliceous earth); Flavors and perfumes (anethole, benzaldehyde, ethyl vanillin, menthol, methyl salicylate, monosodium glutamate, orange flower oil, peppermint, peppermint oil, peppermint spirit, rose oil, stronger rose water, thymol, tolu balsam tincture, vanilla, vanilla tincture, vanillin); Glidants and/or anticaking agents (calcium silicate, magnesium silicate, colloidal silicon dioxide, talc); Humectants (glycerin, hexylene glycol, propylene glycol, sorbitol); Plasticizers (castor oil, diacetylated monoglycerides, diethyl phthalate, glycerin, mono- and di-acetylated monoglycerides, polyethylene glycol, propylene glycol, triacetin, triethyl citrate); Polymers (e.g., cellulose acetate, alkyl celloloses, hydroxyalkylcelloloses, acrylic polymers and copolymers); Solvents (acetone, alcohol, diluted alcohol, amylene hydrate, benzyl benzoate, butyl alcohol, carbon tetrachloride, chloroform, corn oil, cottonseed oil, ethyl acetate, glycerin, hexylene glycol, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, mineral oil, peanut oil, polyethylene glycol, propylene carbonate, propylene glycol, sesame oil, water for injection, sterile water for injection, sterile water for irrigation, purified water); Sorbents (powdered cellulose, charcoal, purified siliceous earth); Carbon dioxide sorbents (barium hydroxide lime, soda lime); Stiffening agents (hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, polyethylene excipient, stearyl alcohol, emulsifying wax, white wax, yellow wax); Suspending and/or viscosity-increasing agents (acacia, agar, alginic acid, aluminum monostearate, bentonite, purified bentonite, magma bentonite, carbomer 934p, carboxy-methylcellulose calcium, carboxymethylcellulose sodium, carboxymethycellulose sodium 12, carrageenan, microcrystalline and carboxymethylcellulose sodium cellulose, dextrin, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum); Sweetening agents (aspartame, dextrates, dextrose, excipient dextrose, fructose, mannitol, saccharin, calcium saccharin, sodium saccharin, sorbitol, solution sorbitol, sucrose, compressible sugar, confectioner's sugar, syrup); Tablet binders (acacia, alginic acid, sodium carboxymethylcellulose, microcrystalline cellulose, dextrin, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxypropyl methylcellulose, methycellulose, polyethylene oxide, povidone, pregelatinized starch, syrup); Tablet and/or capsule diluents (calcium carbonate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, microcrystalline cellulose, powdered cellulose, dextrates, dextrin, dextrose excipient, fructose, kaolin, lactose, mannitol, sorbitol, starch, pregelatinized starch, sucrose, compressible sugar, confectioner's sugar); Tablet disintegrants (alginic acid, microcrystalline cellulose, croscarmellose sodium, corspovidone, polacrilin potassium, sodium starch glycolate, starch, pregelatinized starch); Tablet and/or capsule lubricants (calcium stearate, glyceryl behenate, magnesium stearate, light mineral oil, polyethylene glycol, sodium stearyl fumarate, stearic acid, purified stearic acid, talc, hydrogenated vegetable oil, zinc stearate); Tonicity agent (dextrose, glycerin, mannitol, potassium chloride, sodium chloride); Vehicle: flavored and/or sweetened (aromatic elixir, compound benzaldehyde elixir, iso-alcoholic elixir, peppermint water, sorbitol solution, syrup, tolu balsam syrup); Vehicle: oleaginous (almond oil, corn oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, mineral oil, light mineral oil, myristyl alcohol, octyldodecanol, olive oil, peanut oil, persic oil, seame oil, soybean oil, squalane); Vehicle: solid carrier (sugar spheres); Vehicle: sterile (bacteriostatic water for injection, bacteriostatic sodium chloride injection); Viscosity-increasing (see suspending agent); Water repelling agent (cyclomethicone, dimethicone, simethicone); and Wetting and/or solubilizing agent (benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamer, polyoxyl 35 castor oil, polyoxyl 40, hydrogenated castor oil, polyoxyl 50 stearate, polyoxyl 10 oleyl ether, polyoxyl 20, cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaureate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, tyloxapol). This list is not meant to be exclusive, but instead merely representative of the classes of excipients and the particular excipients which may be used in dosage forms of the present invention.
  • The compounds disclosed can form salts which are also within the scope of this disclosure. Reference to a compound of the Formula herein is understood to include reference to salts thereof unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of the Formulas contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formulas may be formed, for example, by reacting a compound of Formulas with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
  • Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website)..
  • Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.
  • All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the disclosure and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the disclosure.
  • Pharmaceutically acceptable esters of the compounds disclosedare also considered to be part of the disclosure. Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C1-4alkyl, or C1-4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1-20 alcohol or reactive derivative thereof, or by a 2,3-di(C6-24)acyl glycerol.
  • Prodrugs and solvates of the compounds disclosedare also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term "prodrug" means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of the instant Formulas or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
  • For example, if a compound of the instant Formulas or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C1-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarboloxy)ethyl having from 4 to 7 carbon atoms, 1-metbyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, and the like.
  • Similarly, if a compound of the instant Formulas contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N-(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl- α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.
  • If a compound disclosedincorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR'-carbonyl where R and R' are each independently (C1-C10)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl, -C(OH)C(O)OY1 wherein Y1 is H, (C1-C6)alkyl or benzyl,-C(OY2)Y3 wherein Y2 is (C1-C4) alkyl and Y3 is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1-C4)alkyl or mono-N- or di-N,N-(C1-C6)alkylaminoalkyl, -C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N- or di-N,N-(C1-C6)alkylamimo morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.
  • One or more compounds disclosed may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the disclosure embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H2O.
  • One or more compounds disclosedmay optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSeiTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
  • Compounds disclosed, and salts, solvates, esters and prodrugs thereof may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.
  • The compounds disclosed may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the various Formulas as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of the various Formulas may be atropisomers (e.g., substituted biaryls) and are considered as part of this disclosure. Enantiomers can also be separated by use of chiral HPLC column.
  • It is also possible that the compounds of the various Formulas may exist in different tautomeric forms, and all such forms are embraced within the scope of the disclosure. Also, for example, all keto-enol and imine-enamine forms of the compounds are disclosed.
  • All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of the various Formulas incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. Also, for example, all keto-enol and imine-enamine forms of the compounds are disclosed.) Individual stereoisomers of the compounds disclosedmay, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present disclosure can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms "salt", "solvate", "ester", "prodrug" and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
  • The present disclosure also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively.
  • Certain isotopically-labelled compounds of the various Formulas (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of the various Formulas can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.
  • Polymorphic forms of the compounds disclosed, and of the salts, solvates, esters and prodrugs of the compounds of the disclosed, are intended to be included in the present disclosure.
  • Benefits of the present disclosure include oral administration of an optimal amount of a nicotinamide phosphonbosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intravenous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intraperitoneal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intramural administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intramuscular administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include subcutaneous administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intra-tumor administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include intrathecal administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include subdural administration of an optimal amount of a nicotinamide phosphonbosyltransferase biosynthesis inhibitor.
  • Benefits of the present disclosure include periorbital administration of an optimal amount of a nicotinamide phosphoribosyltransferase biosynthesis inhibitor.
  • Based on these results, the present disclosure has important implications for the design of novel treatment strategies for patients with cancer, including leukemias and solid tumors, inflammatory diseases, osteoporosis, atherosclerosis; irritable bowel syndrome and other conditions disclosed herein or that are known to those skilled in the art.
    • Description of the Preferred Embodiments
  • An aspect of the present disclosure concerns compounds disclosed herein.
  • An aspect of the present disclosure concerns compounds which are or can be inhibitors of the formation of nicotinamide phosphoribosyltransferase.
  • An aspect of the present disclosure concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of tumors.
  • An aspect of the present disclosure concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer.
  • An aspect of the present disclosure concerns the use of an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of cancer, where the cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin's disease.
  • The present disclosure also describes one or more methods of synthesizing the compounds of the present invention.
  • The disclosure also describes one or more uses of the compounds of the present invention.
  • The disclosure also describes one or more uses of the compounds of the present invention with an adjunctive agent such as use with TNF, GCSF, or other chemotherapeutic agents
  • The disclosure also describes the pharmaceutical compositions of the present invention for one or more uses.
  • An aspect of the present disclosure concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases.
  • An aspect of the present disclosure concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of inflammatory diseases, such as Irritable Bowel Syndrome or Inflammatory Bowel Disease.
  • An aspect of the present disclosure concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the bone such as osteoporosis.
  • An aspect of the present disclosure concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease of the cardiovascular system, such as atherosclerosis.
  • An aspect of the present disclosure concerns the use as an inhibitor of the formation of nicotinamide phosphoribosyltransferase for the preparation of a medicament used in the treatment of disease or a condition caused by an elevated level of NAMPT.
  • Such disease or condition is one or more selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disordes, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spodylitis, graft-versus-host disease, Alzheimer's disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, leukemias, lymphomas, squamous cell cancers, kidney cancer, uretral and bladder cancers, cancers of head and neck, cancers of the brain and central nervous system (CNS).
  • The compounds of the invention can be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease.
  • More specifically, the compounds can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma, hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma, neutoblastoma, glioma and achwannomas; and other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
  • The compounds of the invention may induce or inhibit apoptosis.
  • The compounds of the invention may also be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pro-malignant cells that have already suffered an insult or inhibiting tumor relapse.
  • A further aspect of the disclosure is a method of inhibiting a NAMPT pathway in an animal, said method comprising administering to said animal a pharmaceutically acceptable amount of a compound of the invention to an animal in need thereof
  • A further aspect of the disclosure is a pharmaceutical formulation comprising a compound of the invention.
  • Another embodiment of the disclosure comprises a pharmaceutical formulation of the invention, wherein the pharmaceutical formulation, upon administration to a human, results in a decrease in tumor burden.
  • Still another embodiment of the disclosure is a pharmaceutical formulation, further comprising one or more of an antineoplastic agent, a chemotherapeutic agent, or an adjunctive chemotherapeutic agent
  • The pharmaceutical formulations of the invention may further comprise a therapeutic effective amount of an adjunctive chemotherapeutic agent.
  • The adjunctive chemotherapeutic agent may be an agent, which modifies blood cell growth and maturation Non-limiting examples of adjunctive chemotherapeutic agent are filgrastim, pegfilgrastim and erythropoietin.
  • The invention is also directed to the pharmaceutical formulation of the invention for use in treating or preventing a disorder associated with excessive rate of growth of cells. Non-limiting examples of disorder include cancer or metastasis from malignant tumors.
  • Another aspect of the invention is the pharmaceutical formulation of this invention for use in inhibiting tumor cell growth and rate of division in a mammal with cancer, or other disorder associated with abnormally dividing cells.
  • Another embodiment of the invention is the pharmaceutical formulation of this invention for use in treating bone plain due to excessive growth of a tumor or metastasis to bone in a mammal in need thereof
  • Also described is a method of prepaying a pharmaceutical formulation comprising mixing at least one pharmaceutically acceptable compound of the present invention, and, optionally, one or more pharmaceutically acceptable excipients or additives.
  • Further methods of synthesizing compounds of the present invention are described.
    • Compounds disclosed
  • The disclosure is directed to pharmaceutical compositions comprising one or more compounds as described herein and pharmaceutically acceptable salts, sovates, esters, prodrugs or isomers thereof. The disclosure further relates to molecules which are useful in inhibiting the enzyme nicotinamide phosphoribosyltransferase (NAMPT) and pharmaceutically acceptable salts, solvates, esters, prodrugs or isomers thereof.
  • An aspect of the disclosure is the provision of compounds and compositions for the NAMPT pathway in mammals having a compound of Formula I
    Figure imgb0134
     wherein
    • Ar1 is aryl, heteroaryl or heteocycloalkyl, wherein the heteroatom of each of said heteroaryl and heteocycloalkyl numbers 1, 2 or 3, and is independently selected from N, S or O, further wherein each of said aryl, heteroaryl and heterocycloalkyl may independently be either substituted or fused with aryl, heteroaryl or heterocycloalkyl, still further wherein any of said aryl, heteroaryl and heterocycloalkyl is either unsubstituted or optionally independently substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl),-C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, alkoxy-, -aryloxy-, (alkoxyalkyl)oxy-, (alkoxyalkyl)amino-, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -N(R3)-C(O)-O-alkyl, -N(R3)-C(O)-O-aryl,-cycloalkyl, -heterocycloalkyl, -aryl, -C(O)-aryl, -S(O)-aryl, and heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
    • X is a straight or branched C1-C6 alkyl;
    • L is selected from NHC(O)NH, OC(O)NH, NHC(O)O, OCH2C(O)NH, C(O)NH, NHC(S)NH, OC(S)NH, NHC(S)O, OCH2C(S)NH, or C(S)NH;
    • A is aryl, heteroaryl, heteocycloalkyl or C3 to C8 cycloalkyl, with each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl being either unsubstituted or optionally independently substituted with 1, 2, 3 or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), - C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, alkoxy-,-aryloxy-, (alkoxyalkyl)oxy-, (alkoxyalkyl)amino-, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -N(R3)-C(O)-O-alkyl, -N(R3)-C(O)-O-aryl, -cycloalkyl, -heteocycloalkyl, -aryl, -C(O)-aryl, -S(O)-aryl, and heteroaryl;
    • Q is C(O), S(O), S(O)2;
    • R3 is H, alkyl or arylalkyl-;
    • z is 0, 1 or 2; and
    • either:
      1. (i) (a) R1 is selected from H, a straight or branched C1 to C7 alkyl, straight or branched C1 to C7 alkoxy, straight or branched C1 to C4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, heterospirocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R1 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), -C(O)N(alkyl)2,-C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-,-alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heterocycloalkyloxy-, aminocarbonyl-, - CHO, -C(O)alkyl, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -S(O2)alkyl, -S(O2)F3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heterocycloalkyl, -aryl and heteroaryl, or (ii) fused with a cycloalkyl, -heterocycloalkyl, -aryl, or heteroaryl; and (b) R2 is selected from H, a straight or branched C1 to C7 alkyl, straight or branched C1 to C7 alkoxy, straight or branched C1 to C4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, heterospirocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R2 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2,-C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-, -alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heterocycloalkyloxy-, aminocarbonyl-, -CHO, -C(O)alkyl, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl,-S(O2)alkyl, -S(O2)CF3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heterocycloalkyl, -aryl, and heteroaryl, or (ii) fused with a cycloalkyl, -heterocycloalkyl, -aryl, or heteroaryl;
        or
      2. (ii) R1 and R2 are joined together to form, along with the N they are shown attached to in the formula, a C3-C8 heterocycloalkyl, a C3-C8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocycloalkyl or a heterospiroheterocycloalkyl, wherein each of said heterocycloalkyl, heterocycloalkenyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl can optionally contain one or more heteroatoms in addition to the N atom they are shown attached to in the formula, said heteroatoms being selected from N, S and O, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein each of said heterocycloalkyl, fused bicyclic heterocycloalkyl, fused tricyclic heterocycloalkyl, heterocycloalkenyl, spiroheteocycloalkyl and heterospiroheterocycloalkyl can be either unsubstituted or optionally independently substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2,-C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-, -alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heterocycloalkyloxy-, aminocarbonyl-, -CHO, -C(O)alkyl, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl,-S(O2)alkyl, -S(O2)CF3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heterocycloalkyl, -aryl, and heteroaryl;
      3. and pharmaceutically acceptable salts, solvates, esters and isomers thereof,
      with the proviso that the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidino-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • Another aspect of this disclosure is the provision of compounds and compositions for the NAMPT pathway in mammals having a compound of the Formula I, where X,L,Q, Ar1 and A are as defind in Formula I and R1 is selected from H, a straight or branched C1 to C7 alkyl, straight or branched C1 to C7 alkoxy, straight or branched C1 to C4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, spiroheterocycloalkyl and heterospiroheterocycloalkyl, wherein the heteroatoms of said heteroaryl and heterocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R1 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2,-C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -O-CHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-, -alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heterocycloalkyloxy-, aminocarbonyl-, -CHO, -C(O)alkyl, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -S(O2)alkyl. -S(O2)CF3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heteocycloalkyl, -aryl, and heteroaryl, or (ii) fused with a cycloalkyl,-heterocycloalkyl, -aryl, or heteroaryl ; and
    R2 is selected from H, a straight or branched C1 to C7 alkyl, straight or branched C1 to C7 alkoxy, straight or branched C1 to C4 hydroxyalkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl, arylalkyl-, heteroarylalkyl-, heterocycloalkylalkyl-, cycloalkylalkyl-, hydroxyalkyl-, alkoxyalkyl-, heterospirocycloalkyl and heterospiroheteocycloalkyl, wherein the heteroatoms of said heteroaryl and heteocycloalkyl in the moieties above are independently selected from one or more N, O and S, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein R2 can be either unsubstituted or optionally independently (i) either substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2,-C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-, -alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heteocyoloalkyloxy-, aminocarbonyl-, -CHO, -C(O)alkyl, -N(R3)-(O)-alkyl, -N(R3)C(O)-aryl, -S(O2)alkyl, -S(O2)CF3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heterocycloalkyl, -aryl, and heteroaryl, or (ii) fused with a cycloalkyl, - heterocycloalkyl, -aryl, or heteroaryl;
    with the proviso that the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholino-4-sulfonyl)phenyl]-1-(pyridino-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • Another aspect of this disclosure is the provision of compounds and compositions
    for the NAMPT pathway in mammals having a compound of the Formula I, where X,L,Q, Ar1 and A are as defind in Formula I and R1 and R2 are joined together to form, along with the N they are shown attached to in the formula, a C3-C8 heteocycloalkyl, a C3-C8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocyclaolkyl or a heterospiroheterocycloalkyl, wherein each of said heterocycloalkyl, heterocycloalkenyl, spiroheterocyclaolkyl and heterospiroheterocycloalkyl can optionally contain one or more heteroatoms in addition to the N atom they are shown attached to in the formula, said heteroatoms being selected from N, S and O, with the proviso that no two adjacent ring heteroatoms are both S or both O, further wherein each of said heterocycloalkyl, fused bicyclic heterocycloalkyl, fused tricyclic heterocycloalkyl, heterocycloalkenyl, spiroheterocyclaolkyl and heteospiroheteocycloalkyl can be either unsubstituted or optionally independently substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, hydroxyalkyl-, (hydroxyalkyl)oxy, -alkoxy, carboxy, (alkoxyalkyl)-, (heteroaryloxy)alkyl-, -NO2, (alkoxyalkyl)amino-, -alkylamino, dialkylamino, (heterocycloalkyloxo)alkyl-, aryloxy, heterocycloalkyloxy-, aminocarbonyl-, -CHO, -C(O)alkyl, -N(R3)-C(O)-alkyl, -N(R3)-(O)-aryl,-S(O2)alkyl, -S(O2)CF3, -cycloalkyl, alkylenedioxy (e.g, methylenedioxy), -heterocycloalkyl, -aryl, and heteroaryl; R3 is H, alkyl or arylalkyl with the proviso that the compound is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • In one embodiment, the disclosure relates to compounds of Formula I and pharmaceutically acceptable salts, solvates, ester or isomers thereof.
  • In the compounds of Formula I, the various moieties and substituents are independently selected.
  • The following embodiments are directed to Formula I as applicable. Further, the moieties aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier. Any one or more of the embodiments relating to Formula I below can be combined with one or more other embodiments of Formula I.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is aryl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heteroaryl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heterocycloalkyl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is aryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heteroaryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heterocycloalkyl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is aryl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heteroaryl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1 is heterocycloalkyl substituted as shown under Formula I, IA or IB, and z, X, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, X is a straight chain alkyl, and Ar1, z, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, X is a branched chain alkyl, and Ar1, z, L, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, L is -N(H)-C(O)-N(H)-, and Ar1, z, X, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Q is -S(O2)-, and Ar1, z, X, A, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R3 is H, and Ar1, z, X, A, Q, R1, and R2 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R3 is alkyl, and Ar1, z, X, A, Q, R1, and R2 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R3 is arylalkyl, and Ar1, z, X, A, Q, R1, and R2 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, z is 0, and Ar1, X, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, z is 1, and Ar1, X, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, z is 2, and Ar1, X, A, Q, R1, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, and Ar1, z, X, A, Q, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R2 is H, and Ar1, z, X, A, Q, R2 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are H, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is alkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is aryl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heteroaryl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heterocycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is alkoxy, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is hydroxyalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is aryloxy, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is arylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heteroarylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cycloalkylalkyl-, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heterocycloalkylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is alkoxyalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is spiroheterocycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is spiroheterocycloalkylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is alkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heteroaryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is aryloxy with the aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is arylalkyl with the aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heteroarylalkyl with the heteroaryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cycloalkylalkyl- with the cycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is heterocycloalkylalkyl with the heterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is spiroheterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is spiroheterocycloalkylalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is alkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is aryl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heteroaryl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heterocycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is cycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is aryloxy, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is arylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heteroarylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is cycloalkylalkyl-, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heterocycloalkylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is spiroheterocycloalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is spiroheterocycloalkylalkyl, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is alkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heteroaryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is cycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is aryloxy with the aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is arylalkyl with the aryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heteroarylalkyl with the heteroaryl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is cycloalkylalkyl- with the cycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is heterocycloalkylalkyl with the heterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is spiroheterocycloalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is alkyl, R2 is spiroheterocycloalkylalkyl substituted or fused as described earlier, and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is bicycloheptanyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cyclopropyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cyclobutyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cyclopentyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is cyclopentylmethyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is benzyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is furanyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is furanylmethyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is phenyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is naphthalenyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is biphenylmethyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is biphenyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is tolyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is pyridinyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is unsubstituted, pyridinylmethyl (substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is phenylethyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is benzyl (unsubstituted, substituted or fused as described earlier), R2 is benzyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is quinolinyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is oxazolyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is indazolyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is dihydrobenzodioxepinyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is pyrazolyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is terrahydronaphthalenyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is isoquinolinyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 is H, R2 is oxolanyl (unsubstituted, substituted or fused as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a heterocycloalkenyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a fused bicyclic heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a fused tricyclic heterocycloalkyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a spiroheterocycloalkyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a heterospiroheterocycloalkyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a piperidinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a piperazinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a morpholinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azapenyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azetidinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a oxaazabicyclooctanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azabicycloheptanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a dihydrobenzoxazinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a dihydroindolyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a thiomorpholinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azatricyclotrideca-pentaenyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azaspirodecanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a terrahydronaphthyridinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, an azabicyclooctanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a diazepanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a decahydroquinolyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a diazaspiroundecanyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, R1 and R2 are joined together to form, along with the N, a terahydroisoquinolinyl (unsubstituted or substituted as described earlier), and Ar1, z, X, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1, z, X, A, Q, and R3 are as defined, and R1 and R2 are the same or different, wherein said R1 and R2 independently are unsubstituted or substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of -C(O)NH2, alkyl, -C(O)NH-(alkyl),-C(O)N(alkyl)2, halo, morpholinyl, alkoxyalkyl-, alkenyl, alkyl, CF3, OH, CN, phenyl, isocyano, -N(H)C(O)CH3, phenylethyl-, -C(O)CH3, phenoxy, -S(O2)CH3, -S(O2)CF3, pyrazinyl, -OCHF2, OCF3, OCH2F, -C=CH,-CH=CH2, methylenedioxy, ethylenedioxy, benzyloxy, piperidinyl, -C(O)O-CH3, phenoxy, oxopiperaz-inyl, oxopyrrolidinylinethyl-, NH2, NH(alkyl, -N(alkyl)2, morpholinyloxoethyl-, oxopyrrolinylinethyl-, azapanyl, nitrophenyl-, cyclopropyl, hydroxymethyl-, (hydroxyalkyl)oxy-, isopropyl, ethyl, methyl and phenylpropenyl-.
  • An embodiment disclosed is the provision of a compound of Formula I, where the various moieties are independently selected, Ar1, z, X, A, Q, and R3 are as defined, and R1 and R2 are joined together to form, along with the N, a C3-C8 heterocycloalkyl, a C3-C8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocycloalkyl or a heterospiroheterocycloalkyl, wherein each of said C3-C8 heterocycloalkyl, a C3-C8 heterocycloalkenyl, a fused bicyclic heterocycloalkyl, a fused tricyclic heterocycloalkyl, spiroheterocycloalkyl or a heterospiroheterocycloalkyl independently is unsubstituted or bears one or more substituents which can be the same or different and are independently selected from the group consisting of-C(O)NH2, alkyl, -C(O)NH(alkyl), -C(O)N(alkyl)2, halo, morpholinyl, alkoxyalkyl-, alkenyl, alkyl, CF3, OH, CN, phenyl, isocyano, -N(H)C(O)CH3, phenylethyl-, -C(O)CH3, phenoxy, -S(O2)CH3, -S(O2)CF3, pyrazinyl, -OCHF2, OCF3, OCH2F, -C≡CH, -CH=CH2, methylenedioxy, ethylenedioxy, benzyloxy, piperidinyl, -C(O)O-CH3, phenoxy, oxopiperazinyl, oxopyrrolidinylmethyl-, NH2, NH(alkyl, -N(alkyl)2, morpholinyloxoethyl-, oxopyrrolinylmethyl-, azapanyl, nitiophenyl-, cyclopropyl, hydroxymethyl-, (hydroxyalkyl)oxy-, isopropyl, ethyl, methyl and phenylpropenyl-.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is aryl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is heteroaryl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is spiroheterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is heterospiroheterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is aryl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heteroaryl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is spiroheterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterospiroheterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, R2 is aryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, A is phenyl, R2 is heteroaryl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, A is phenyl, R2 is heterocycloalkyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, A is phenyl, R2 is spiroheterocycloalkyl, and z, X, L, Q, and R3 are as defined..
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is aryl, R1 is H, A is phenyl, R2 is heterospiroheterocycloalkyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl R1 is H, R2 is aryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heteoaryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is phenyl, R1 is H, R2 is aryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is phenyl, R1 is H, A is phenyl, R2 is heteroaryl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is phenyl, R1 is H, A is phenyl, R2 is heterocycloalkyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is phenyl, R1 is H, A is phenyl, R2 is spiroheterocycloalkyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is phenyl, R1 is H, A is phenyl, R2 is heterospiroheterocycloalkyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is aryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heteroaryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is heteroaryl, R1 is H, R2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridyl, R1 is H, R2 is aryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridyl, R1 is H, R2 is heteroaryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula Iwhere NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridyl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridyl, R1 is H, R2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridyl, R1 is H, R2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is aryl, A is phenol, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is heteroaryl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is heterocycloalkyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is spiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula Iwhere NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is pyridinylmethyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is piperidinyl, R1 is H, R2 is pyrrolyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is pyridinylmethyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is alkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is hydroxyalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is phenylalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is cycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is oxolanyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is quinolinyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is oxazolyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is spiroheterocycloakyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is heterospiroheterocycloalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is tetrahydronaphthalenyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is dihydrobenzodioxepinyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is acyclic, where the various moieties are independently selected, Ar1 is pyridinyl, R1 is H, R2 is alkoxyalkyl, A is phenyl, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is piperidinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is morpholinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is piperazinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azapenyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azetidinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is oxaazabicyclooctanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azabicycloheptanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is dihydrobenzoxazinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is dihydroindolyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is thiomorpholinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azatricyclotridecapentaenyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azaspirodecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azaspiroundecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is tetrahydronaphthyridinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azabicyclooctanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is diazepanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is decahydroquinolinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is diazaspiroundecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is tetrahydroisoquinolinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is piperidinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is morpholinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is piperazinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azapenyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azetidinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is oxaazabicyclooctanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azabicycloheptanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is dihydrobenzoxazinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is dihydroindolyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is thiomorpholinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azatricyclotridecapentaenyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azaspirodecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azaspiroundecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is tetrahydronaphthyridinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azabicyclooctanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is diazepanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is decahydroquinolinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is diazaspiroundecanyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is tetrahydroisoquinolinyl, and z, X, L, A, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is piperidinyl, A is phenol, and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is morpholinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is piperazinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azapenyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azetidinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is oxaazabicyclooctanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azabicycloheptanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is dihydrobenzoxazinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is dihydroindolyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is thiomorpholinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azatricyclotridecapentaenyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azaspirodecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azaspiroundecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic), where the various moieties are independently selected, Ar1 is aryl, NR1R2 is tetrahydronaphthyridinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is azabicyclooctanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is diazepanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is decahydroquinolinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is diazaspiroundecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is aryl, NR1R2 is tetrahydroisoquinolinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is piperidinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is morpholinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is piperazinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azapenyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azetidinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is oxaazabicyclooctanyl, A is phenol and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azabicycloheptanyl, A is phenol and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is dihydrobenzoxazinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is dihydroindolyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is thiomorpholinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azatricyclotridecapentaenyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azaspirodecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azaspiroundecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is tetrahydronaphthyridinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is azabicyclooctanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is diazepanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is decahydroquinolinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is diazaspiroundecanyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula I where NR1R2 is cyclic, where the various moieties are independently selected, Ar1 is heteroaryl, NR1R2 is tetrahydroisoquinolinyl, A is phenyl and z, X, L, Q, and R3 are as defined.
  • Another embodiment disclosed is the provision of compounds and compositions for the NAMPT pathway in mammals having a compound of the Formula II:
    Figure imgb0135
     wherein
    • Ar1 is aryl, heteroaryl or heteocycloalkyl, wherein the heteroatom of each of said heteroaryl and heteocycloalkyl numbers 1, 2 or 3, and is independently selected from N, S or O, further wherein each of said aryl, heteroaryl and heterocycloalkyl may independently be either substituted or fused with aryl, heteroaryl or heterocycloalkyl, still further wherein any of said aryl, heteroaryl and heterocycloalkyl is either unsubstituted or optionally independently substituted with one or more substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl),-C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, alkoxy-, -aryloxy-, (alkoxyalkyl)oxy-, (alkoxyalkyl)amino-, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -N(R3)-C(O)-O-alkyl, -N(R3)-C(O)-O-aryl,-cycloalkyl, -heterocycloalkyl, -aryl, -C(O)-aryl, -S(O)-aryl, and heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
    • R is H, a straight or branched C1-C6 alkyl, or arylalkyl;
    • n is 0, 1, 2, 3 or 4;
    • L is selected from NHC(O)NH, OC(O)NH, NHC(O)O, OCH2C(O)NH, C(O)NH, NHC(S)NH, OC(S)NH, NHC(S)O, OCH2C(S)NH, or C(S)NH, with the proviso that when L is C(O)NH, then n is 0;
    • Ar2 is aryl, heteroaryl, heterocycloalkyl or C3 to C8 cycloalkyl, with each of said aryl, heteroaryl, heterocycloalkyl and cycloalkyl being either unsubstituted or optionally independently substituted with 1, 2, 3 or 4 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, isocyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl),-C(O)N(alkyl)2, -C(O)NH(aryl), -C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl, alkenyl, alkynyl, alkoxy-,-aryloxy-, (alkoxyalkyl)oxy-, (alkoxyalkyl)amino-, -N(R3)-C(O)-alkyl, -N(R3)-C(O)-aryl, -N(R3)-C(O)-O-alkyl, -N(R3)-C(O)-O-aryl, -cycloalkyl, -heterocycloalkyl, -aryl, -C(O)-aryl, -S(O)-aryl, and heteroaryl;
    • X is S, S(O), S(O)2, O or C(O);
    • R1 is cycloalkyl, -CHzF3-z, aryl, heterocycloalkyl, heteroaryl, alkyl, - alkenyl, -alkynyl, (aryl)alkyl-, (heteroaryl)alkyl- or (heterocycloalkyl)alkyl-, (i) wherein each of said cycloalkyl, aryl, heterocycloalkyl, heteroaryl and alkyl is either unsubstituted or optionally substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of deuterium, halo, cyano, amino, aminoalkyl-, (amino)alkoxy-, -CONH2, -C(O)NH(alkyl), -C(O)N(alkyl)2, -C(O)NH(aryl),-C(O)N(aryl)2, -CHzF3-z, -OCHzF3-z, alkyl,- alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy- or (alkoxyalkyl)amino-, -cycloalkyl, -heterocycloalkyl, -aryl, -S(O)2-alkyl, -S(O)2-aryl, -S(O)2-CF3,-C(O)N(alkyl)2, -C(O)alkyl, -NH-C(O)-alkyl, -NH-C(O)-aryl, methylenedioxy, and heteroaryl, (ii) further wherein each of said cycloalkyl, aryl, heterocycloalkyl, and heteroaryl may additionally optionally be fused with independently selected aryl, heteroaryl, heterocycloalkyl or cyloalkyl;
    • R3 is H, alkyl or arylalkyl-;
    • z is 0, 1, or 2;
    • and pharmaceutically acceptable salts, solvates, esters, prodrugs and isomers thereof, with the proviso that the compound of Formula I is not 3-{1-[(4-methoxybenzene)sulfonyl]piperidin-4-yl}-1-(pyridin-3-ylmethyl)urea, or 1-(4-phenoxyphenyl)-3-(pyridin-3-ylmethyl)thiourea.
  • In the compounds of Formula II, the various moieties are independently selected.
  • The following embodiments are directed to Formula II as applicable. Further, the moieties aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier.Any one or more of the embodiments relating to Formual II below can be combined with one or more other embodiments of Formula II.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, and z, X, L, n, Ar2 , R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, and z, X, L, n, Ar2 , R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heterocycloalkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl fused with an aryl, heteroaryl or heterocycloalkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heterocycloalkyl fused with an aryl, heteroaryl or heteocycloalkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl substituted as shown under Formula II, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl substituted as shown under Formula n, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heterocycloalkyl substituted as shown under Formula II, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, and z, X, Ar2 , R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, and z, X, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, and z, X, Ar2 R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -O-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -O-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is aryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, and z, X, L, n, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, and z, X, L, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -O-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, and z, Ar2, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, Ar2 is aryl, and z, X, L, n, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, and z, X, L, n, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, and z, X, L, n, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, Ar2 is aryl, and z, X, L, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, n is 1, and z, X, L, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, n is 1, and z, X, L, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, and z, R1 and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound, of Formula II where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, n is 1, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, n is 1, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is cycloalkyl, and z, Y, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is cycloalkyl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, n is 1, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, n is 1, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branches chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -c(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, Ar2 is heteroaryl, R1 is aryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound, of Formula II where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, R1 is heteoaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, n is 1, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, n is 1, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is heteroaryl, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, Ar2 is heteroaryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, Ar2 is aryl, n is 1, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, Ar2 is aryl, n is 1, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O2)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -S(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -C(O)-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is H, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a straight chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar2 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is heteroaryl, R is a branched chain alkyl, n is 1, L is -N(H)-C(O)-N(H)-, X is -0-, Ar1 is aryl, R1 is CF3, and z, X, L, n, and R3 are as defined.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, Ar1 is selected from the group consisting of pyridinyl, imidazopyridinyl, pyrazolyl, quinolinyl and thienopyridinyl. Each of these moieties may be unsubstituted or optionally independently substituted with one or more groups which can be the same or different and are independently selected from the group consisting of NH2, -N(alkyl)2, (alkoxyalkyl)oxy-, and pyrazolyl.
  • An embodiment disclosed is the provision of a compound of Formula II, where the various moieties are independently selected, R1 is selected from the group consisting of cyclopentyl, CF3, phenyl, naphthalenyl, pyrimidinyl, oxazolyl, 8-oxatricyclotridecahexaenyl and thienyl. Each of these moieties may be unsubstituted or optionally independently substituted with one or more groups which can be the same or different and are independently selected from the group consisting of -C(O)NH2, -S(O2)CH3, F, Cl, Br, methylenedioxy, CF3, OCF3, alkyl, alkoxy, pyrazolyl, C(O)CH3 and phenoxy.
  • An especially preferred moiety for Ar1-(CHR)n-L- in Formula II is the moiety:
    Figure imgb0136
  • Another aspect disclosed is the provision of compounds and compositions for the NAMPT pathway in mammals derived from compounds of Formula I and Formula II and having the Formula III:
    Figure imgb0137
     wherein,
    • Ar1 is 5 to 12 membered heteroaryl comprising 1,2,3 or 4 heteroatom(s) independently selected from N, S or O, wherein said heteroaryl is unsubstituted or substituted by one or more Ra selected from the group consisting of -NH2, oxo, halo, haloalkyl, -NH(CO)O-alkyl, -C(O)NH2 and 3,4-dihydroxy-5-methyltetrahydrofurane; and wherein said heteroaryl can comprise one or more N-oxide(s) formed with a N atom member of said heteroaryl, with the proviso that no two adjacent ring heteroatoms are both S or both O;
    • Ar2 is aryl or 5 or 6 membered heteroaryl comprising 1,2,3 or 4 heteroatom(s) independently selected from N, S or O;
    • R is H, a straight or branched C1-C6 alkyl, or arylalkyl;
    • R1 is -NR3R4 wherein R3 is H, alkyl or -S(O)2alkyl and R4 is alkyl, hydroxyalkyl, -S(O)2alkyl, - (CH2)qcycloalkyl, -(CH2)qheterocycloalkyl, aryl, arylalkyl-, -(CH2)qheteroaryl; haloalkyl, cycloalkyl; aryl; heterocycloalkyl; or heteroaryl; wherein:
      • each of said cycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of:
        • deuterium, halo, cyano, alkyl, hydroxyl, hydroxyalkyl, hydroxyalkoxy, cyanoalkyl, haloalkyl, alkenyl, alkynyl, alkoxy, alkylalkoxy, haloalkoxy, arylalkenyl-, aryloxy, benzyloxy, oxo, -(CH2)q-NRbRc, -(CH2)q-CONRbRc, -S(O)2-alkyl, -S(O)2-aryl, -S(O)2NH-alkyl, -S(O)2N(alkyl)2, -S(O)2-heterocycloalkyl, -S(O)2-CF3, -C(O)alkyl, -C(O)aryl, -C(O)alkylenylaryl, -C(O)O-alkyl, -NH-C(O)alkyl, -NH-C(O)aryl, methylenedioxy, -(CH2)qcycloalkyl, cycloalkylalkoxy-, aryl, arylalkyl-, -(CH2)qheteroaryl, and -(CH2)qheterocycloalkyl,
        • wherein each of said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by one or more halo, nitro, haloalkyl, haloalkoxy, oxo, cyano, alkyl, haloalkyl, or alkoxy and;
      • each of said cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may optionally additionally be fused with independently selected aryl, heteroaryl, heterocycloalkyl or cycloalkyl to from a bicyclic or tricyclic group that may be substituted by one or more halo, cyano, alkyl or alkoxy;
    • R2 is O or absent,
    • Rb and Rc are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, -S(O)2alkyl and cycloalkyl or Rb and Rc can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S or O;
    • n is 0, or 1;
    • q is 0, 1 or 2;
    • and pharmaceutically acceptable salts, solvates, esters and isomers thereof,
    • with the proviso that the compound of Formula I is not 1-(pyridin-3-ylmethyl)-3-(4-sulfamoylphenyl)thiourea, 3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridine-4-ylmethyl)thiourea or 3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrdin-4-ylmethyl)thiourea.
  • In an embodiment, this disclosure discloses compounds of Formula III and Pharmaceutically acceptable salts, solvates, ester or isomers thereof.
  • In the compounds of Formula III, the various moieties are independently selected.
  • The following embodiments are directed to Formula III as applicable. Further, the moieties aryl, heteroaryl, heterocycloalkyl, cycloalkyl, spiroheterocycloalkyl and heterospiroheterocycloalkyl as well as their representative moieties in these embodiments can be independently unsubstituted or optionally substituted or optionally fused as described earlier.Any one or more of the embodiments related to Formula III below can be combined with one or morerother embodiments of Formula III.
  • An embodiment disclosed is the provision of a compound of Formula M, where the various moieties are independently selected and Ar2 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar2 is phenyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar2 has the following formula:
    Figure imgb0138
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar1 is pyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar1 has the following formula:
    Figure imgb0139
     where Ra is selected from the group consisting of -NH2, oxo, halo, haloalkyl, - NH(CO)O-alkyl, -C(O)NH2 and 3,4-dihydroxy-5-methyltetrahydrofurane.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar1 has the formula of:
    Figure imgb0140
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and n is 1.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and n is 1.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1 and Ar2 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula m, where the various moieties are independently selected, Ar1 is pyridine, n is 1 and Ar2 is phenyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and Ar2 is phenyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and Ar2 has the following formula:
    Figure imgb0141
     and Ar1 is pyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R is H.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R is H.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, n is 1 and R is H.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R is H.
  • .An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, n is 1, Ar2 is phenyl and R is H.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R is H.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is -NR3R4 wherein R3 is H, alkyl or -S(O)2alkyl and R4 is alkyl, hydroxyalkyl, - S(O)2alkyl, -(CH2)qcycloakyl, -(CH2)qheterocycloalkyl, aryl, arylalkyl-, -(CH2)qheteroaryl,
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is -NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is -NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is -NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is -NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is -NR3R4 wherein R3 is H and R4 is aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula IIII, where the various moieties are independently selected, Ar1 is pyridine and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenol and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenol and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is haloalkyl
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is haloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted C3-C12-cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted C3-C12cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12-cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12-cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted C3-C12cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12 cycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted C3-C12-cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubsituted or substituted C3-C12cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12-cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment disclosed is the provision of a compound of Formula III," where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted C3-C12cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted C3-C12-cycloalkyl, wherein the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]hepten, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted C6-C10-aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubsituted or substituted C6-C10-aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted C6-C10-aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenol and R1 is unsubstituted or substituted C6-C10aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted C6-C10-aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted C6-C10-aryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenol, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted C6-C10-aryl, wherein the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is aryl and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted heterocycloalkyl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidone, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidone, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidone, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxy-8-azaspiro[4.5]decane, and decahydroquinoline.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted heteroaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted heteroaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted heteroaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted heteoaryl.
  • An embodiment disclosed is the provision of a compound of Formula III" where the various moieties are independently selected, Ar2 is aryl and R1 is unsubstituted or substituted heteroaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted heteoaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted heteroaryl.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, or 3 heteroatoms selected from N, O and S.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6naphthyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azapiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, Ar2 is phenyl and R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine,oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, and R1 is unsubstituted or substituted unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine,oxo-2,3-dihydro-1H-indol, 3,4dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  • An embodiment disclosed is the provision of a compound of Formula III, where the various moieties are independently selected, Ar1 is pyridine, n is 1, Ar2 is phenyl and R1 is unsubstituted or substituted unsubatituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  • Another embodiment disclosed is the provision of a compound of Formula III where Ar1 is pyridine, n is 1, Ar2 is phenyl and the Formula becomes Formula III A:
    Figure imgb0142
     wherein R1 and Ra are as defined in Formula III with the proviso that the compounds are not N-[4-(phenylsulfonyl)phenyl]-N'-(3-pyridinylmethyl)urea, N,N-diethyl-4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide, or 4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide.
  • Another embodiment disclosed is compounds of Formula III where Ar2 is phenyl and Ar1 has the strucute of
    Figure imgb0143
     and the formula becomes Formula IIIB
    Figure imgb0144
     wherein:
    • Ra is one of more and can be selected from the group consisting of amino, oxo, halo, halo(C1-C6)alkyl,-NH(CO)O-(C1-C6)alkyl and -C(O)NH2; and wherein said pyridine can comprise a N-oxide formed with its N atom member;
    • R1 is NR3R4 wherein R3 is H, C1-C6-alkyl or -S(O)2(C1-C6)alkyl and R4 is (C1-C6)alkyl, hydroxy(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -(CH2)qcycloalkyl, -(CH2)qheterocycloalkyl, aryl, aryl(C1-C6)alkyl-,-(CH2)qheteroaryl;
      • halo(C1-C6)alkyl,
      • cycloalkyl;
      • aryl;
      • heterocycloalkyl; or
      • heteroaryl
      • wherein:
        • each of said cycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of:
          • halo, cyano, (C1-C6)alkyl, hydroxyl, hydroxy(C1-C6)alkyl, hydroxy(C1-C6)alkoxy, halo(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkyl(C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C2-C6)alkenyl-, aryloxy, benzyloxy, oxo, -(CH2)q-NRbRc, -(CH2)q-CONRbRc, -S(O)2-(C1-C6)alkyl, -S(O)2NH-(C1-C6)alkyl, -S(O)2-heterocycloalkyl, -S(O)2-CF3, -C(O)(C1-C6)alkyl, -C(O)aryl, -C(O) (C2-C6)alkylenylaryl, -C(O)O-(C1-C6)alkyl, -(C2)qcycloalkyl, cycloakyl(C1-C6)alkoxy-, aryl, aryl(C1-C6)alkyl-, -(CH2)qheteroaryl, and-(CH2)qheterocycloalkyl,
      wherein each of said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by one or more halo, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, oxo, cyano, (C1-C6)alkyl, halo(C1-C6)alkyl, or (C1-C6)alkoxy;
    • Rb and Rc are independently selected from the group consisting of H, (C1-C6)alkyl, hydroxy(C1-C6)alhyl, (C1-C6)alkoxy, aryle, (C1-C6)alkoxy(C1-C6)alkyl, -S(O)2(C1-C6)alkyl and (C3-C6)cycloalkyl or Rb and Rc can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S or O
    • q is 0 or 1; and
    • pharmaceutically acceptable salts thereof,
    • with the proviso that the compounds of Formula Ia are not
    • N-[4-(phenylsulfonyl)phenyl]-N'-(3-pyridinylmethyl)urea,
    • N,N-diethyl-4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide, or
    • 4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide.
  • An embodiment disclosed is compounds of Formula IIIB, wherein R1 is -NR3R4 wherein R3 is H, alkyl orS(O)2alkyl and R4 is alkyl, hydroxyalkyl, -S(O)2alkyl, -(CH2)qcycloalkyl, -(CH2)qheterocycloalkyl, aryl, arylalkyl-, -(CH2)qheteroaryl.
  • Another embodimetn of the invetion is compounds of Formula IIIB, where R1is NR3R4 wherein R3 is H and R4 is aryl.
  • Another embodiment disclosed is compounds of Formula IIIB wherein R1 is haloalkyl.
  • Another embodiment disclosed is compounds of Formula IIIB wherein R1 is unsubstituted or substituted C3-C12-cycloalkyl.
  • Still another embodiment disclosed is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted C3-C12-cycloalkyl and the cycloalkyl is selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptan, bicyclo[3.1.1]heptan, adamantane, and (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan.
  • Yet another embodiment disclosed is compounds of Formula IIIB wherein R1 is unsubstituted or substituted C6-C10-aryl.
  • A further embodiment disclosed is compounds of Formula IIIB wherein R1 is unsubstituted or substituted C6-C10-aryl and the aryl is selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl
  • Another embodiment disclosed is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted heterocycloalkyl.
  • One embodiment disclosed is compounds of Formula III B, wherein R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S.
  • One embodiment disclosed is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, and the heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidone, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline.
  • Another embodiment disclosed is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted heteroaryl.
  • Another embodiment disclosed is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1,2 or 3 heteroatoms selected from N, O and S.
  • Still another embodiment of the disclosure is compounds of Formula IIIB, wherein R1 is unsubstituted or substituted 5 to 12 heteroaryl comprising 1,2 or 3 heteroatoms selected from N, O and S, and the heteroaryl is selected from the group consisting of 1,3,4-oxadiazol, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indol, 3,4-dihydro-2H-1,5-benzodioxepin, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazol, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine Illustrative compounds of the invention are:
    Structure Chemical Name
    Figure imgb0145
         		1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea
    Figure imgb0146
         		3-{4-[(4-bromobenzene)sulfonyl]phenyl}-1-pyridin-3-ylmethyl)urea
    Figure imgb0147
         		3-(4-{[2-methyl-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0148
         		3-{4-[(4-methoxy-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0149
         		3-{4-[(2,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0150
         		1-[(6-aminopyridin-3-yl)methyl]-3-{4-[(4-fluorobenzene)sulfonyl]phenyl}urea
    Figure imgb0151
         		3-{4-[(3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0152
         		1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea
    Figure imgb0153
         		3-{4-[(4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0154
         		3-(4-{[2-fluoro-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0155
         		3-{4-[(2-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0156
         		3-{4-[(2-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0157
         		3-{4-[(3,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0158
         		1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethyl)benzene]sulfonyl}phenyl)urea
    Figure imgb0159
         		3-{4-[(2,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0160
         		1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea
    Figure imgb0161
         		N,N-dimethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]ben zamide
    Figure imgb0162
         		3-(4-{[2-methoxy-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0163
         		3-[4-(benzenesulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0164
         		3-{4-[(3-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0165
         		1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)benzene]sulfonyl}phenyl)urea
    Figure imgb0166
         		3-{4-[(5-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0167
         		3-[4-(benzenesulfonyl)phenyl]-1-{[6-(dimethylamino)pyridin-3-yl]methyl}urea
    Figure imgb0168
         		3-{4-[(4-chloro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0169
         		3-{4-[(2-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0170
         		3-{4-[(2,3-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0171
         		3-{4-[(2-chloro-6-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0172
         		3-(pyridin-3-ylmethyl)-1-[4-(pyrimidine-5-sulfonyl)phenyl]urea
    Figure imgb0173
         		3-{4-[(3,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0174
         		1-[6-(benzenesulfonyl)pyridin-3-yl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0175
         		3-{4-[(2,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0176
         		3-{4-[(2,5-difluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0177
         		3-{4-[(4-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0178
         		3-{4-[(2-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0179
         		3-{4-[(4-chloro-2-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0180
         		3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0181
         		3-{4-[(5-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-y]methyl)urea
    Figure imgb0182
         		3-{4-[(2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0183
         		3-{4-[(4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0184
         		3-[4-(2-methoxynphthalene-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0185
         		3-{[({4-[(4-chlorobenzene)sulfonyl]phenyl}carbamoyl)amino] methyl}pyridin-1-ium-1-olate
    Figure imgb0186
         		3-{4-[(3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0187
         		1-[4-(2H-1,3-benzodioxole-5-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0188
         		3-{4-[(3-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0189
         		3-(4-{[2-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0190
         		3-[4-(benzenesulfonyl)phenyl]-1-{[6-(2-methoxyethoxy)pyridin-3-yl]methyl}urea
    Figure imgb0191
         		3-{4-[(2,3-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0192
         		3-{4-[(4-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0193
         		1-{4-[(2-phenoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0194
         		3-(4-{[3-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0195
         		3-{4-[(2-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0196
         		3-{4-[(2,3-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0197
         		1-[4-(cyclopentanesulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0198
         		3-{4-[(2-fluoro-6-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0199
         		3-{4-[(2,5-dimethoxybenzene)sulfonyl]pheyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0200
         		1-(pyridin-3-ylmethyl)-3-[4-(trifluoromethane)sulfonylphenyl]urea
    Figure imgb0201
         		3-{4-[(2-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0202
         		3-[4-(3,5-dimethyl-l,2-oxazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0203
         		3-{4-[(4-chloro-3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0204
         		3-(4-{[2-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0205
         		3-{4-[(2-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0206
         		1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethyl)benzene]sulfonyl}phenyl)urea
    Figure imgb0207
         		3-(4-{[4-chloro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0208
         		3-{4-[(4-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0209
         		3-{4-[(2-fluoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0210
         		3-{4-[2-chloro-6-(propan-2-yl)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0211
         		3-{4-[(2-methoxy-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0212
         		3-(pyridin-3-ylmethyl)-1-[4-(pyridine-4-sulfonyl)phenyl]urea
    Figure imgb0213
         		3-{4-[(2-chloro-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0214
         		3-{4-[(2-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0215
         		3-{4-[(3-fluoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0216
         		3-{4-[(2,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0217
         		3-(pyridin-3-ylmethyl)-1-[4-(pyridine-3-sulfonyl)phenyl]urea
    Figure imgb0218
         		3-{4-[(3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0219
         		3-{4-[(2,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0220
         		3-{4-[(2,6-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0221
         		1-(4-{8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-6-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0222
         		3-(pyridin-3-ylmethyl)-1-[4-(pyridine-2-sulfonyl)phenyl]urea
    Figure imgb0223
         		3-{4-[(5-chloro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0224
         		3-(4-{[2-methoxy-5-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0225
         		3-(4-{[3-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0226
         		1-(pyridin-3-ylmethyl)-3-{4-[(2,4,6-trimethylbenzene)sulfonyl]phenyl}urea
    Figure imgb0227
         		3-{4-[(3-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-y]methyl)urea
    Figure imgb0228
         		3- {4-[(2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0229
         		3-{4-[(2,4-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0230
         		3-{4-[(2,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0231
         		3-{4-[(2-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0232
         		1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea
    Figure imgb0233
         		3-[4-(1-methyl-1H-pyrazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0234
         		3-[4-(5-methylthiophene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0235
         		3-{4-[(3,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0236
         		3-{4-[(2,6-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0237
         		3-[4-(2-methoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0238
         		3-{4-[4-(3-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0239
         		3-{4-[(4-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0240
         		1-[4-(phenylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0241
         		3-{4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0242
         		3-(4-{8-methyl-2,8-diazaspiro[5.5]undecane-2-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0243
         		1-(pyridin-3-ylmethyl)-3-(4-{4-[4-(trifluoromethyl)phenyl]piperazine-1-sulfonyl}phenyl)urea
    Figure imgb0244
         		3-{4-[(3,4-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0245
         		N-methyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyridine-2-carboxamide
    Figure imgb0246
         		3-{4-[(2R)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0247
         		3-(4-{[3-fluoro-5-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0248
         		3-{4-[(4-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0249
         		3-(4-{[3-(3-methoxyphenyl)pentan-3-yl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0250
         		3-{4-[(3-fluoro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin 3-ylmethyl)urea
    Figure imgb0251
         		3-(4-{[4-fluoro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0252
         		3-{4-[(4-methoxy-3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0253
         		3-(4-{[4-chloro-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0254
         		3-{4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0255
         		3-(4-{[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0256
         		1-[4-(3,5-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0257
         		(2S)-N,N-dimethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidine-2-carboxamide
    Figure imgb0258
         		methyl 4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperazine-1-carboxylate
    Figure imgb0259
         		3-{4-[(2-methoxyethyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0260
         		1-{4-[4-(2H-1,3-benzodioxol-5-yl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0261
         		3-{4-[(2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0262
         		N-(propan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0263
         		3-(4-{[(2-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0264
         		3-[4-(1-methyl-1H-indole-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0265
         		3-{[4-(piperidine-1-sulfonyl)phenyl]methyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0266
         		3-{4-[(2-fluoro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0267
         		3-{4-[(4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0268
         		1-[4-(cycloheptylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0269
         		1-{4-[4-(pyrazin-2-yl)piperazine-1-sulfonyl)phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0270
         		3-{4-[(5-methylpyridin3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0271
         		3-{4-[4-(2-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0272
         		1-(pyridin-3-ylmethyl)-3-(4-{[(1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea
    Figure imgb0273
         		1-(pyridin-3-ylmethyl)-3-(4-{4-[6-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea
    Figure imgb0274
         		3-{4-[(3-ethoxy-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0275
         		3-{4-[4-(2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0276
         		3-{4-[(6-ethylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0277
         		3-{4-[3-(2-methoxyethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0278
         		3-[4-(1-methyl-1H-indazole-7-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0279
         		3-{4-[(4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0280
         		N-cyclopropyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0281
         		3-{4-[(4-methoxy-3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0282
         		3-(4-{[2-methyl-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0283
         		3-(4-{[2-(3-methoxyphenyl)ethyl](methyl)sulfamoyl}phe nyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0284
         		N-[(3R)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidin-3-yl]acetamide
    Figure imgb0285
         		1-{4-[(4-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0286
         		3-{4-[(2,4-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0287
         		3-(4-{[3-(dimethylsulfamoyl)benzene]sulfonyl}phenyl )-1-(pyridin-3-ylmethyl)urea
    Figure imgb0288
         		3-{4-[(2-methoxy-6-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0289
         		3-{4-[(3-methanesulfonylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0290
         		3-{4-[(4-chloro-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0291
         		N-methyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperazin-1-yl}acetamide
    Figure imgb0292
         		3-{4-[(4-chloro-2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0293
         		3-(4-{[3-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0294
         		3-{4-[(1,5-dimethyl-1H-pyrazol-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0295
         		3-(4-{[3-(2-methoxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0296
         		3-{4-[4-(2,4-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0297
         		3-(4-{methyl[(1S)-1-phenylethyl]sulfamoyl}phenyl-1-(pyridin-3-ylmethyl)urea
    Figure imgb0298
         		1-(4-{8-azaspiro[4.5]decane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0299
         		3-{4-[(5-chloro-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0300
         		3-{4-[(2,4-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0301
         		3-{4-[(2,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0302
         		1-[4-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0303
         		1-{4-[(3S)-3-cyanopiperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0304
         		3-{4-[(2S)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0305
         		1-{4-[(5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0306
         		1-(4-{4-[2-(morpholin-4-yl)-2-oxoethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0307
         		1-{4-[(3-benzoylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0308
         		3-{4-[(6-methoxypyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0309
         		3-{4-[(3-chloro-4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0310
         		N-ethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0311
         		3-(4-{[4-(2-methoxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0312
         		3-[4-(6-methoxynaphthalene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0313
         		1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethyl)phenyl]sulfamoyl}phenyl)ur ea
    Figure imgb0314
         		3-{4-[cyclohexyl(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0315
         		3-{4-[(3-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0316
         		3-(4-{[4-(4-chlorophenoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0317
         		3-{4-[(2-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0318
         		3-(pyridin-3-ylmethyl)-1-[4-({4-[(pyrrolidin-1-yl)carbonyl]benzene}sulfonyl)phenyl]urea
    Figure imgb0319
         		3-(4-{[3-(2-hydroxyethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0320
         		3-{4-[(3-chloro-2,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0321
         		3-{4-[4-(2,5-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0322
         		3-[4-(3-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0323
         		3-{4-[4-(4-bromophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0324
         		3-{4-[(3-methylpyridin-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0325
         		3-{4-[(5-fluoro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0326
         		3-{4-[(4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0327
         		3-(4-{4-[2-(3,4-dichlorophenyl)acetyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0328
         		3-[4-({2-[(2S)-2-hydroxypropoxy]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0329
         		1-[4-(1H-indolo-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0330
         		3-{4-[(3-chloro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0331
         		3-(4-{[4-(ethoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0332
         		1-{4-[(1-phenylcyclopentyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0333
         		1-(pyridin-3-ylmethyl)-3-{4-[3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea
    Figure imgb0334
         		1-{4-[(3-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0335
         		3-{4-[(3,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0336
         		1-{4-[(pyridin-2-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0337
         		(3S)-N,N-diethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperidine-3-carboxamide
    Figure imgb0338
         		3-(pyridin-3-ylmethyl)-1-[4-(quinoline-6-sulfonyl)phenyl]urea
    Figure imgb0339
         		1-(4-{[(1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl]sulfamoyl}phenyl)-3-(pyridin-3-y]methyl)urea
    Figure imgb0340
         		3-[(5-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea
    Figure imgb0341
         		3-{4-[4-(3-chlorophenyl)-4-cyanopiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0342
         		3-[4-(4-methanesulfonylpiperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0343
         		1-(pyridin-3-ylmethyl)-3-[4-(1H-pyrrole-1-sulfonyl)phenyl]urea
    Figure imgb0344
         		3-{4-[(4-ethoxy-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0345
         		3-{4-[(4-propylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0346
         		3-{4-[4-cyano-4-(4-methoxyphenyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0347
         		3-(4-{[(4-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0348
         		1-[3-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0349
         		3-{4-[4-(3-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0350
         		1-{4-[(pyridin-3-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0351
         		3-(pyridin-3-ylmethyl)-1-[4-(thiomorpholine-4-sulfonyl)phenyl]urea
    Figure imgb0352
         		3-(4-{[2-chloro-5-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0353
         		3-(pyridin-3-ylmethyl)-1-[4-(pyrrolidine-1-sulfonyl)phenyl]urea
    Figure imgb0354
         		2-methyl-N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]phenyl}propanamide
    Figure imgb0355
         		1-[4-(cyclohexylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0356
         		1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperidine-4-carboxamide
    Figure imgb0357
         		3-(4-{[(4-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0358
         		3-{4-[(2-chloro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0359
         		3-(4-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0360
         		1-(4-{3-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0361
         		1-(4-{[2-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0362
         		1-(pyridin-3-ylmethyl)-3-{4-[(2,4,6-trimethylphenyl)sulfamoyl]phenyl}urea
    Figure imgb0363
         		1-[4-(4-cyclohexylpiperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0364
         		3-{4-[(2-chloro-4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0365
         		3-{4-[(5-fluoro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0366
         		3-[4-(methylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0367
         		1-[4-(phenoxathiine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0368
         		3-{4-[(3,5-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0369
         		N-(propan-2-yl)-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperazin-1-yl}acetamide
    Figure imgb0370
         		N,N-diethyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperazin-1-yl}acetamide
    Figure imgb0371
         		3-(pyridin-3-ylmethyl)-1-[4-(quinoline-8-sulfonyl)phenyl]urea
    Figure imgb0372
         		1-(4-{[4-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0373
         		3-{4-[4-(3,5-dichloropyridin-4-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0374
         		1-[4-(cyclobutylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0375
         		3-[4-(4-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0376
         		1-(pyridin-3-ylmethyl)-3-(4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea
    Figure imgb0377
         		1-{4-[4-(morpholin-4-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0378
         		1-[4-(4-benzyl-1,4-diazepane-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0379
         		N-[(3S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidin-3-yl]acetamide
    Figure imgb0380
         		3-(pyridin-3-ylmethyl)-1-[4-(quinoline-3-sulfonyl)phenyl]urea
    Figure imgb0381
         		3-(4-{[3-fluoro-5-(2-methylpropoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0382
         		N,N-dimethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0383
         		1-{4-[(3-cyanobenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0384
         		3-[(5-fluoropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea
    Figure imgb0385
         		1-{4-[(2H-1,3-benzodioxol-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0386
         		1-[4-(isoquinoline-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0387
         		3-{4-[(2-chloro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0388
         		1-(4-{3-azaspiro[5.5]undecane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0389
         		3-{4-[4-(2,4-difluorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0390
         		3-[4-(diethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0391
         		N-(2-methylpropyl)-3-[(4-{[(pyridin-3-y]methyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0392
         		3-(4-{[3-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0393
         		3-(4-{[2-methoxy-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0394
         		3-{4-[4-(2-ethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0395
         		N-ethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0396
         		3-[4-(6-methoxypyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0397
         		3-(4-{[3-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0398
         		1-{4-[(3-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0399
         		3-(4-{[(3-fluorophenyl)methyl](methyl)sulfamoyl}phen yl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0400
         		3-{4-[(3-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0401
         		1-(pyridin-3-ylmethyl)-3-{4-[4-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea
    Figure imgb0402
         		3-{4-[(3-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0403
         		3-(4-{[4-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0404
         		3-{4-[(4-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0405
         		3-{4-[(2-methoxypyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0406
         		1-[4-(4,4-difluoropiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0407
         		3-{4-[(3S)-3-methyl-4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0408
         		3-[4-(1-methyl-1H-indazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0409
         		1-{4-[4-(piperidin-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0410
         		3-[4-(butylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0411
         		3-{4-[(5-methylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0412
         		3-{4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0413
         		1-{4-[(3-cyanophenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0414
         		3-{4-[(3-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0415
         		3-[4-(dimethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0416
         		3-{4-[methanesulfonyl(piperidin-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0417
         		3-(4-{4-[(4-fluorophenyl)carbonyl]piperidine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0418
         		3-{4-[(3S)-4-(4-methoxyphenyl)-3-methylpiperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0419
         		1-(pyridin-3-ylmethyl)-3-{4-[(3S)-3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea
    Figure imgb0420
         		3-{4-[methyl(oxolan-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0421
         		1-[4-(2,3-dihydro-1-benzofuran-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0422
         		3-{4-[4-(2-methoxyethyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0423
         		1-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0424
         		3-(4-{[4-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0425
         		3-(4-{[3-methyl-4-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0426
         		3-{4-[methyl({[5-(trifluoromethyl)pyridin-2-yl]methyl})sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0427
         		1-(4-{4-[3-(morpholin-4-yl)propyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0428
         		3-(4-{[3-(propane-1-sulfonamido)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0429
         		1-{4-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0430
         		3-{4-[4-(5-chloro-2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0431
         		3-(4-{[3-chloro-4-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0432
         		1-{4-[4-(2H-1,3-benzodioxol-5-ylmethyl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0433
         		N-methyl-N-phenyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperazin-1-yl}acetamide
    Figure imgb0434
         		1-(4-{4-[(furan-2-yl)carbonyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0435
         		3-{4-[4-(5-chloro-2-methoxyphenyl)piperazine-1-sulfonyl)phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0436
         		3-{4-[4-(propan-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0437
         		3- {4-[(5-fluoropyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0438
         		3-[4-(2-methyl-3-oxopiperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0439
         		3-{4-[(3-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0440
         		3-{4-[4-(2,6-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0441
         		1-[4-(1H-indole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0442
         		3-chloro-N,N-diethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0443
         		N,N-dimethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl benzamide
    Figure imgb0444
         		1-(pyridin-3-ylmethyl)-3-[4-({[3-(trifluoromethyl)phenyl]methyl}sulfamoyl)ph enyl]urea
    Figure imgb0445
         		1-(4-{[3-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0446
         		3-(4-{[2-(2-hydroxyethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0447
         		3-{4-[(2-hydroxyethyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0448
         		1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethane)sulfonylphenyl]sulfamoyl} phenyl)urea
    Figure imgb0449
         		3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0450
         		3-{4-[(3-ethanesulfonamidobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0451
         		3-{4-[4-(4-chloro-3-methoxyphenyl)piperazine-1-sulfonyl)phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0452
         		3-[4-(1-methyl-1H-indazole-6-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0453
         		3-{4-[(2-methylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0454
         		N-(2-hydroxyethyl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0455
         		3-{4-[(3-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0456
         		3-(4-{[3-fluoro-4-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)rea
    Figure imgb0457
         		3-{4-[(3-chloro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0458
         		3-(4-{[4-fluoro-3-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0459
         		1-[4-(morpholine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0460
         		3-(4-{[(4-chlorophenyl)methyl](methyl)sulfamoyl}phen yl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0461
         		3-{4-[methyl(2-methylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0462
         		3-{4-[(4-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0463
         		3-(4-{methyl[(1R)-1-phenylethyl]sulfamoyl}phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0464
         		3-{4-[4-(2-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0465
         		3-[4-({2-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0466
         		3-(pyridin-3-ylmethyl)-1-{4-[(quinolin-6-yl)sulfamoyl]phenyl}urea
    Figure imgb0467
         		3-{4-[(2,5-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0468
         		1-(4-{[2-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0469
         		3-{4-[(3-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)rea
    Figure imgb0470
         		3-(4-{methyl[2-(4-methylphenyl)ethyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0471
         		3-{4-[(2,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0472
         		1-(pyridin-3-ylmethyl)3-{4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]phenyl}urea
    Figure imgb0473
         		1-(4-{3-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0474
         		N,N-dimethyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]phenyl}acetamide
    Figure imgb0475
         		3-[(6-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea
    Figure imgb0476
         		3-(4-{[(5-methylfuran-2-yl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0477
         		1-(4-{4-[2-oxo-2-(piperidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0478
         		1-(pyridin-3-ylmethyl)-3-[4-(3,3,5-trimethylazepane-1-sulfonyl)phenyl]urea
    Figure imgb0479
         		3-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0480
         		3-(4-{[3-(methoxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0481
         		3-[4-(1-propyl-1H-pyrazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0482
         		3-(4-{[3-fluoro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0483
         		1-(4-{[2-(morpholin-4-ylmethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0484
         		3-(4-{[2-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0485
         		3-(4-{[3-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0486
         		3-(4-{[3-fluoro-4-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0487
         		1-(pyridin-3-ylmethyl)-3-{4-[(3,4,5-trifluorophenyl)sulfamoyl]phenyl}urea
    Figure imgb0488
         		1-{4-[(pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0489
         		N,N-diethyl-4-fluoro-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0490
         		1-(4-{[4-(piperidine-1-sulfonyl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0491
         		3-{4-[(2,4-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0492
         		3-(4-{[3-(ethylsulfamoyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0493
         		1-[4-(4-cyanopiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0494
         		3-{4-[(2,2-dimethylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0495
         		1-[4-(dibenzylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0496
         		(2S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidine-2-carboxamide
    Figure imgb0497
         		1-(4-{3-oxa-8-azabicyclo[3.2.1]octane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0498
         		1-{4-[(1H-indazol-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0499
         		tert-butyl N-{5-[({[4-(piperidine-1-sulfonyl)phenyl]carbamoyl}amino)methyl]py ridin-yl}carbamate
    Figure imgb0500
         		3-{4-[benzyl(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0501
         		3-{4-[4-(3-chloropyridin-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0502
         		3-(4-{[2-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0503
         		3-{4-[(3-methanesulfonamidobenzene)sulfonyl]phenyl }-1-(Pyridin-3-ylmethyl)urea
    Figure imgb0504
         		N,N-diethyl-3-fluoro-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0505
         		3-(4-{[4-(methoxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0506
         		N,N-dimethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperidine-4-carboxamide
    Figure imgb0507
         		3-{4-[(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0508
         		1-[4-({3-[(morpholin-4-yl)carbonyl]benzene}sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0509
         		3-(4-{[(4-fluorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0510
         		3-{4-[(4-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0511
         		3-{4-[benzyl(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0512
         		3-[4-({[4-(dimethylamino)phenyl]methyl}sulfamoyl)ph enyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0513
         		3-{4-[benzyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0514
         		3-{4-[(4-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0515
         		1-[4-(4-{[(2R)-oxolan-2-yl]carbonyl}piperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0516
         		2-methyl-N-{1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperidin-4-yl}propanamide
    Figure imgb0517
         		1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethoxy)phenyl]sulfaoyl}phenyl)u rea
    Figure imgb0518
         		3-(pyridin-3-ylmethyl)-1-(4-{[4-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea
    Figure imgb0519
         		3-(4-{[(3-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0520
         		3-(4-{[3-(ethanesulfonyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0521
         		3-[4-(4-hydroxypiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0522
         		3-(4-{[3-(hydroxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0523
         		3-{4-[(3-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0524
         		3-{4-[(3-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0525
         		4-fluoro-N-(propan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0526
         		3-{4-[4-(3-chlorophenyl)-4-hydroxypiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0527
         		3-{4-[(3S)-3-methyl-4-(3-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0528
         		3-{4-[(4-chloro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0529
         		3-{4-[(2,3-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0530
         		3-{4-[4-(2,3-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0531
         		1-[4-(4-benzylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0532
         		1-(4-{[(4-phenylphenyl)methyl]sulfomoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0533
         		3-(pyridm-3-ylmethyl)-1-{4-[(5,6,7,8-tetrahydronaphthalen-1-yl)sulfamoyl]phenyl}urea
    Figure imgb0534
         		rel-3-{4-[(2R,6S)-2,6-dimethylmorpholino-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0535
         		1-[4-(decahydroquinoline-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0536
         		3-{4-[(4-fluoro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0537
         		1-{4-[(4-ethynylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0538
         		3-{4-[(3-chloro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0539
         		3-{4-[(2-chloro-4,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0540
         		3-(4-{[3-fluoro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0541
         		1-{4-[(2R)-2-benzylpiperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0542
         		3-{4-[(4-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0543
         		1-{4-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0544
         		3-{4-[4-(diethylamino)pipendine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0545
         		3-{4-[(4-fluorophenyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0546
         		3-[4-(2-methylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0547
         		1-{4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0548
         		3-{4-[(3-fluoro-5-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0549
         		3- {4-[(3-fluoro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0550
         		3-{4-[(2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0551
         		rel-3-{4-[(4aR,8aS)-decahydroisoquinoline-2-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0552
         		3-[4-(4-methanesulfonylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0553
         		3-(pyridin-3-ylmethyl)-1-{4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-sulfonyl]phenyl}urea
    Figure imgb0554
         		3-{4-[(6-methylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0555
         		3-(4-{4-[(morpholin-4-yl)carbonyl]piperidino-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0556
         		3-{4-[3-(2-chloro-4-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0557
         		3-(4-{4-[4-chloro-3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0558
         		3-(4-{[3-(2-methylpropoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0559
         		3-(4-{4-[bis(4-fluorophenyl)methyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0560
         		3-[4-(1-methyl-1H-indazole-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0561
         		1-(4-{[3-(benzyloxy)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0562
         		3-(pyridin-3-ylmethyl)-1-(4-{[3-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea
    Figure imgb0563
         		3-{4-[(4-ethoxy-3-ffuorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0564
         		3-{4-[(3,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0565
         		3-{4-[4-(3,4-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0566
         		1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)u rea
    Figure imgb0567
         		3-{4-[(2-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0568
         		3-{4-[(3-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0569
         		3-{4-[(3-methoxy-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0570
         		3-[4-(6-mefhylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0571
         		3-(pyridin-3-ylmethyl)-1-[4-(5,6,7,8-tetrahydro-1,6-naphthyridine-6-sulfonyl)phenyl]urea
    Figure imgb0572
         		3-[4-(2,4-dimethoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0573
         		3-{4-[(5-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0574
         		3-(4-{[4-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0575
         		3-{4-[(5-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0576
         		3-(4-{[2-(4-fluorophenoxy)pyridin-3-yl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0577
         		1-{4-[(4-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)rea
    Figure imgb0578
         		3-(pyridin-3-ylmethyl)-1-{4-[(pyridin-4-ylmethyl)sulfamoyl]phenyl}urea
    Figure imgb0579
         		1-{4-[4-(azepan-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0580
         		3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0581
         		1-(4-{[4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0582
         		1-{4-[(cyclohexylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0583
         		3-{4-[(4-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0584
         		3-{4-[(4-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0585
         		3-[(6-aminopyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea
    Figure imgb0586
         		3-{4-[(3,4-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0587
         		3-{4-[(4-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0588
         		1-{4-[4-(2-oxo-2,3-dihydro-1H-indol-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0589
         		3-(4-{[2-(3-chlorophenyl)ethyl](methyl)sulfamoyl}phenyl )-1-(pyridin-3-ylmethyl)urea
    Figure imgb0590
         		3-{4-[(4-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0591
         		1-(4-{[3-(1H-pyrazolo-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0592
         		3-(pyridin-3-ylmethyl)-1-{4-[3-(pyrrolidin-1-yl)pyrrolidine-1-sulfonyl]phenyl}urea
    Figure imgb0593
         		1-[4-(2H-1,3-benzodioxole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0594
         		1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)ur ea
    Figure imgb0595
         		3-{4-[methyl(2-phenylethyl)sulflamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0596
         		1-[4-(3,4-dihydro-2H-1,4-benzoxezine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0597
         		3-{4-[(3S)-3-methylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0598
         		3-[4-(tert-butylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0599
         		1-[4-(4-phenylpiperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0600
         		3-{4-[4-(5-methylpyrimidin-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0601
         		3-[4-(azepane-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0602
         		1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)u rea
    Figure imgb0603
         		3-(4-{[3-chloro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0604
         		3-{4-[(2-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0605
         		3-{4-[(4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0606
         		3-{4-[4-(4-bromo-3-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0607
         		3-[4-(piperidine-1-sulfonyl)phenyl]-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea
    Figure imgb0608
         		3-[4-(5-fluoropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0609
         		1-(4-{2-oxa-8-azapiro[4.5]decano-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0610
         		1-{4-[4-(2-phenylacetyl)pipetazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0611
         		1-{4-[4-(3-phenylprop-2-en-1-yl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0612
         		1-(pyridin-3-ylmethyl)-3-{4-[(3-sulfamoylbenzene)sulfonyl]phenyl}urea
    Figure imgb0613
         		N-methyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0614
         		3-(4-{[4-(popan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0615
         		3-{4-[(2-hydroxyethyl)(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0616
         		1-{4-[(adamantan-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0617
         		1-{4-[(2R)-2-(morpholin-4-ylmethyl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0618
         		3-{4-[4-(3,5-dichlorophenyl)piperazine-1-sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0619
         		3-{4-[(2-fluoro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0620
         		N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]phenyl}acetamide
    Figure imgb0621
         		N-methyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0622
         		3-{4-[4-(4-chlorophenyl)-4-cyanopiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0623
         		3-(4-{[4-methyl-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0624
         		1-[4-(4-phenylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0625
         		3-{4-[(3-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0626
         		3-{4-[4-(methoxymethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0627
         		3-fluoro-N,N-dimethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0628
         		3-{4-[cyclohexyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0629
         		3-{4-[4-(3,4-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0630
         		3-{4-[(4-fluoro-3-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0631
         		3-(4-{[2-ffuoro-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0632
         		3-[4-(4-{[4-(propan-2-yl)phenyl]methyl}piperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0633
         		1-(pyridin-3-ylmethyl)-3-(4-{4-[3-(trifluorromethyl)phenyl]piperazine-1-sulfonyl}phenyl)urea
    Figure imgb0634
         		1-[4-(cyclopropylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0635
         		3-{4-[(3-aminophenyl)(methanesulfonyl)sulfamoyl]ph enyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0636
         		1-4-[(2,3-dihydro-1H-inden-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0637
         		3-(4-{[3-chloro-4-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-1(pyridin-3-ylmethyl)urea
    Figure imgb0638
         		3-{4-[2-(dimethyamimo)pyridine-5-sulfonyl]henyl}-1(pyridin-3-ylmethyl)urea
    Figure imgb0639
         		3-(4-{4-[1-(3-methoxyphenyl)-4-methylcyclohexyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0640
         		3-(4-{[(5-ethylpyridin-2-yl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0641
         		3-{4-[(3-chloro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0642
         		3-{4-[(4-chloronaphthalen-1-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0643
         		3-{4-[(5-acetyl-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0644
         		3-{4-[(5-chloro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0645
         		1-{4-[(1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine]-1'-ylsulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0646
         		3-{4-[4-(2,4-dimethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0647
         		N-{l-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]piperidin-4-yl}acetamide
    Figure imgb0648
         		3-(4-{[3-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0649
         		3-{4-[(3-fluoro-4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0650
         		1-(4-{4-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0651
         		3-(4-{[2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0652
         		3-(4-{[2-methoxy-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0653
         		1-[4-(2,6-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0654
         		1-{4-[(1-phenylcyclohexyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0655
         		1-(pyridin-3-ylmethyl)-3-{4-[6-(trifluoromethyl)pyridine-3-sulfonyl]phenyl}urea
    Figure imgb0656
         		3-{4-[(4-methylpyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0657
         		3-{4-[4-(2-methylpropyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0658
         		1-(4-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0659
         		1-(pyridin-3-ylmethyl)-3-{4-[(4-sulfamoylphenyl)sulfamoyl]phenyl}urea
    Figure imgb0660
         		5-[({[4-(piperidine-1-sulfunyl)phenyl]carbamoyl}amino)methyl]py ridine-2-carboxamide
    Figure imgb0661
         		3-(4-{4-[(4-tert-butylphenyl)methyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0662
         		3-[4-(azetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0663
         		3-(pyridin-3-ylmethyl)-1-(4-{[2-(1H-pyrrol-1-yl)phenyl]sulfamoyl}phenyl)urea
    Figure imgb0664
         		3-(4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0665
         		N,N-diethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0666
         		N-ethyl-N-[(3S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidin-3-yl]acetamide
    Figure imgb0667
         		3-(pyridin-3-ylmethyl)-1-{4-[4-(pyrimidin-2-yl)piperazine-1-sulfonyl]phenyl}urea
    Figure imgb0668
         		3-{4-[(3-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0669
         		3-{4-[3-chloro-2-(morpholin-4-yl)pyridine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0670
         		3-(pyridin-3-ylmethyl)-1-(4-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea
    Figure imgb0671
         		3-{4-[(4-fluoro-3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0672
         		3-{4-[(2-phenylpropan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0673
         		3-(4-{4-[(1R)-1-(4-chlorophenyl)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0674
         		3-[4-(5-chloropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0675
         		3-{4-[4-cyano-4-(4-methylphenyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0676
         		1-{4-[(3-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0677
         		3-{4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0678
         		3-{4-[(3-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0679
         		3-{4-[(2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0680
         		3-{4-[4-(dipropylamino)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0681
         		3-{4-[(3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0682
         		3-(4-{[(4-fluorophenyl)methyl](methyl)sulfamoyl}phen yl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0683
         		3-(pyridin-3-ylmethyl)-1-{4-[(3S)-3-[(pyrrolidin-1-yl)carbonyl]piperidine-1-sulfonyl]phenyl}urea
    Figure imgb0684
         		3-{4-[(3-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0685
         		1-{4-[(2-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0686
         		3-(4-{4-[1-(4-chlorophenyl)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0687
         		N,N-dimefhyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0688
         		1-{4-[(4-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0689
         		3-{4-[(3,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0690
         		3-{4-[4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0691
         		3-[4-(4-acetyl-1,4-diazepane-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0692
         		N-cyclopentyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0693
         		3-[4-(3,3-difluoroazetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0694
         		1-(4-{[4-(morpholin-4-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0695
         		3-[4-({3-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0696
         		3-{4-[(3,5-diffuorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0697
         		3-{4-[(3,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0698
         		3-{4-[ethyl(phenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0699
         		1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethyl)phenyl]sulfamoyl}phenyl)ur ea
    Figure imgb0700
         		3-(4-{[3-(5-methyl-1,3,4-oxadiazol-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0701
         		3-[4-({4-[(1S)-1-hydroxyethyl]phenyl}sulfmoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0702
         		3-{4-[(3-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0703
         		3-{4-[(4-tert-butyl-2-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin 3-ylmethyl)urea
    Figure imgb0704
         		1-(4-{8-azabicyclo[3.2.1]octane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0705
         		1-[4-(cyclopentylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea
    Figure imgb0706
         		3-(4-{4-[2-(diethylamino)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0707
         		3-{4-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0708
         		3-(4-{[2-(3-fluorophenyl)ethyl](methyl)sulfamoyl}phenyl )1-(pyridin-3-ylmethyl)urea
    Figure imgb0709
         		3-{4-[methyl({[3-(trifluoromethyl)phenyl]methyl})sulfamoyl]p henyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0710
         		1-(4-{[3-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0711
         		3-(4-{[(2-chlorophenyl)methyl]salfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0712
         		1-(4-{8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0713
         		3-{4-[4-(4-acetylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0714
         		1-{4-[(1H-indazol-6-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0715
         		3-{4-[4-(3,4-dimethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0716
         		N,N-dimethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfona mido]benzamide
    Figure imgb0717
         		1-(4-{[3-(cyclopropylmethoxy)benzene]sulfonyl}phen yl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0718
         		(2R)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]pyrrolidine-2-carboxamide
    Figure imgb0719
         		3-(4-{[(3-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0720
         		3-{4-[(2-methylpyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0721
         		3-[4-(ethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0722
         		3-{4-[(2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0723
         		3-(4-{[2-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0724
         		1-(4-{2-azabicyclo[2.2.1]heptane-2-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0725
         		3-{4-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0726
         		1-(pyridin-3-ylmethyl)-3-(4-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea
    Figure imgb0727
         		3-[4-(2,3-dihydro-1H-indole-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea
    Figure imgb0728
         		3-{4-[(4-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0729
         		3-{4-[(4-fluoro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0730
         		1-{4-[(4-cyanophenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0731
         		3-{4-[(3-chloro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0732
         		3-{4-[(3-chloro-5-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0733
         		1-(4-(4-((2-methoxyethyl)(methyl)amino)piperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0734
         		3-{4-[(2,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0735
         		3-(pyridin-3-ylmethyl)-(4-{[2-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea
    Figure imgb0736
         		3-{4-[(3-methoxy-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0737
         		3-{4-[4-(4-nitrophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0738
         		3-{4-[4-(2-chloro-4-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)rea
    Figure imgb0739
         		3-(4-{[4-chloro-2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0740
         		3-{4-[(4-chloro-3-methylphenyl)sulfmoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0741
         		3-{4-[(2,3-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0742
         		3-(4-{[4-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0743
         		2-fluoro-N-(propan-2-yl)-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl ]benzamide
    Figure imgb0744
         		3-(4-{[2-(2-hydroxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea
    Figure imgb0745
         		3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0746
         		3-{4-[(4-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0747
         		3- {4-[4-(3-chlorophenyl)piperazine-1 - sulfonyl]phenyl }-1-(Pyridin-3-ylmethyl)urea
    Figure imgb0748
         		3-{4-[(2S)-2-ethylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-y]methyl)urea
    Figure imgb0749
         		1-(4-{[4-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea
    Figure imgb0750
         		1-{4-[(4-cyanobenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea
    Figure imgb0751
         		3-{4-[(3,4-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0752
         		3-{4-[(2-iodophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0753
         		1-{4-[2-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl} -3-(pyridin-3-ylmefhyl)urea
    Figure imgb0754
         		3-{4-[(3-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    Figure imgb0755
         		1-[4-(piperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea
  • The following compounds are not compounds of the invention but are NAMPT inhibitors:
    Figure imgb0756
         		1-(pyridin-3-ylmethyl)-3-(4-sulfamoyphenyl)thiourea
    Figure imgb0757
         		3-[4-(morpholine-4-sulfonyl)phenyl]-1-(pyridin-4-ylmethyl)thiourea
    Figure imgb0758
         		3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyridin-4-ylmethyl)thiourea
    • Examples
  • The invention is illustrated further by the following examples, which are not to be construed as limiting to the specific procedures described in them. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present disclosure, as demonstrated by the following examples. In some cases, protection of certain reactive functionalities may be necessary to achieve some of the above transformations. In general, such need for protecting groups, as well as the conditions necessary to attach and remove such groups, will be apparent to those skilled in the art of organic syntheses. Unless otherwise specified, all reagents and solvents are of standard commercial grade and are used without further purification.
  • The following are illustrative, but non-limiting, examples of certain embodiments of the present invention.
    • Definitions used in the following Schemes and elsewhere herein are:
    • CDCl3 deuterated chloroform
    • δ chemical shift (ppm)
    • DCM dichloromethane or methylene chloride
    • DIEA N, N-diisopropylethylamine
    • DMA N, N-dimethylacetamide
    • DMAP N, N-dimethylpyridin-4-amine
    • DMF dimethylformamide
    • DMSO dimethylsulfoxide
    • DMSO-d6 deuterated dimethylsulfoxide
    • EDCI N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride
    • EtOAc ethyl acetate
    • EtOH ethanol
    • GF/F glass microfiber filter
    • 1H NMR proton nuclear magnetic resonance
    • HOAc acetic acid
    • HATU 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate
    • HOBT 1H-benzo[d][1,2,3]triazol-1-ol hydrate
    • HPLC high pressure liquid chromatography
    • MHz megahertz
    • KOAc potassium acetate
    • i-PrOH isopropanol
    • LC-MS liquid chromatography/mass spectrometry
    • (M+1) mass +1
    • m-CPBA m-chloroperbenzoic acid
    • MeOH methanol
    • N2 nitrogen
    • NaHCO3 sodium bicarbonate
    • MgSO4 magnesium sulfate
    • SRB Sulforhodamine B colorimetric assay
    • TEA triethylamine
    • THF tetrahydrofuran
    • TLC thin layer chromatography
    Preparation of compounds
  • The compounds disclosed can be prepared through numerous routes well-known to those skilled in the art of organic synthesis. By way of example, compounds of the present disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Preferred methods include but are not limited to those methods described below.
  • Compounds of the present disclosure urea-sulfonamide (IV) can be synthesized by following the steps outlined in Scheme 1.
    Figure imgb0759
  • Intermediate II can be obtained by treating I with phosgene, thiophosgene, carbonyldiimidazole, or other such activating group in an inert solvent such as dichloromethane, benzene, or toluene at temperatures raging from -78 °C to 200 °C. Intermediate V can be obtained by treating I with 4-nitrophenyl carbonochloridate in an inert solvent such as dichloromethane, benzene, or toluene at temperatures ranging from -78 °C to 200 °C. The compound of present disclosure IV can be obtained by treating compound III with either II or V in an organic solvent at temperatures ranging from -78 °C to 200 °C.
  • Compounds of the present disclosure urea-sulfone (IV) can be synthesized by following the steps outlined in Scheme 2.
    Figure imgb0760
  • Intermediate II can be obtained by treating I with phosgene, thiophosgene, carbonyldiimidazole (or similar reagent) in an inert solvent such as dichloromethane, benzene, or toluene at temperatures ranging from -78 °C to 200 °C. The compound of present disclosure IV can be obtained by treating intermediate II with III in an organic solvent at temperatures ranging from -78 °C to 200 °C.
  • The compound of present disclosure urea-sulfone IV can also be synthesized by following the steps outlined in Scheme 2A.
    Figure imgb0761
  • Intermediate VI can be obtained by treating III with V in an inert solvent such as dichloromethane and benzene at temperatures ranging from -78 °C to 200 °C. Treatment of VI with agents such as NaBH4, NaI, or Na2S2O3 in a solvent such as water or THF at temperatures ranging from -78 °C to 200 °C gives intermediate VII. Compound IV can be obtained by treating VII and VIII with a suitable transition metal catalyst such as, but not limited to, Pd(PPh3)4, palladium(II) acetate, or Cu(OAc)2 in the presence of a base (eg: K2CO3 , Cs2O3, NR1R2R3, NaOR, KOR) in an inert solvent such as N, N-dialkylformamide, N, N-dialkylacetamide, or dichloromethane at temperatures ranging from -78 °C to 200 °C.
  • Those having skill in the art will recognize that the starting materials may be varied and additional steps may be employed to produce the compounds encompassed by the present disclosures (as demonstrated by the following examples). Unless otherwise specified, all reagents and solvents are of standard commercial grade and are used without further purification.
    • Preparation of Representative Urea-Sulfonamide and Urea SafoneAnalogues
  • These examples illustrate the preparation of representative substituted urea-sulfonamide and urea-sulfone analogues.
    • EXAMPLE 1 1-((5-fluoropiridin-3-yl)methyl)-3-(4-(piperidin-1-ylsulfonyl)phenyl)area
  • Figure imgb0762
  • Triphosgene (41 mg, 0.137 mmol) was dissolved in DCM (5 mL) and cooled to -10 °C under N2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (100 mg, 0.416 mmol) and TEA (127mg, 1.25 mmol) in DCM (5 mL). The mixture was stirred at -10°C for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution of 5-fluoropyridin-3-yl)methanamine (55 mg, 0.50 mmol) and TEA (127 mg, 1.25 mmol) in DCM (5 mL) was then added. The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with DCM (25 mL), washed with brine (2 x 15 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude was purified by Biotage using 5 % MeOH / DCM to afford the desired product as a white amorphous powder.
    1H NMR (300 MHz, CDCl3): δ 9.23 (s, 1H), 8.36-8.48 (m, 2H), 7.50-7.68 (m, 5H), 6.95 (t, 1H), 4.36 (d, 2H), 2.75-2.90 (m, 4H), 1.48-1.75 (m, 4H), 1.38-1.42 (m, 2H)
    LC-MS: 393.04 (M+1).
    • EXAMPLE 2 N-(naphthalen-1-yl)-4-(3-(pyridin-3-ylmethyl)ureido)benzeneslfonamide
  • Figure imgb0763
    • A: N-(naphthalen-1-yl)-4-nitrobenzenesulfonamide
  • Figure imgb0764
  • To a cooled solution of naphtbalen-1-amine (2000 mg, 13.97 mmol) in pyridine (45.0 mL) was added DMAP (171 mg, 1.4 mmol) and a solution of 4-nitrobenzene-1-sulfonyl chloride (3410 mg, 15.4 mmol) in pyridine (15.0 mL) at 0 °C. The mixture was stirred at 0 °C for 15 min and heated to 80 °C for 16 h. After being cooled to room temperature, the mixture was acidified with 2M HCl, extracted with EtOAc (3 x 50 mL), washed several times with brine, dried over MgSO4 and concentrated in vacuo. The crude was purified by Combiflash using (5% EtOAc / hexanes) to afford the title compound.
    1H NMR (300 MHz, CD3OD): δ 7.21-7.38 (m, 6H), 7.68-7.85 (m, 4H), 8.15-8.20 (m, 2H).
    LC-MS: 329.14 (M+1).
    • B: 4-amino-N-(napbthalen-1-yl)benzenesulfonamide:
  • Figure imgb0765
  • A mixture of N-(naphthalen-1-yl)-4-nitrobenzenesulfonamide (3.9 g, 12 mmol) and tin (II) chloride dihydrate (13.5 g, 60 mmol) was refluxed in EtOAc (120 mL) for 2.5 h. After being cooled to room temperature, the mixture was treated with 2N NaOH (100 mL) and stirred for 1 h, then filtered through celite and washed with EtOAc. The combined filtrates were concentrated in vacuo. The crude was purified by Combiflash using (40% EtOAc / hexanes) to afford the title compound.
    1H NMR (300 MHz, CD3OD): δ 6.45-6.51 (m, 2H), 7.12-7.18 (m, 1H), 7.25-7.38 (m, 5H), 7.65 (d, 1H), 7.72-7.76 (m, 1H), 7.91-7.98 (m, 1H).
    LC-MS: 299.04 (M+1).
    • C: N-(naphthalen-1-yl)-4-(3-(piridin-3-ylmethyl)ureido)benzenesulfonamide:
  • Figure imgb0766
  • A mixture of 4-amino-N-(naphthalen-1-yl)benzenesulfonamide (1000 mg, 3.35 mmol) and 4-nitrophenyl carbonochloridate (676 mg, 3.35 mmol) in DCM (35 mL) was stirred and cooled to 0 °C under N2 atmosphere, followed by addition of pyridine (1060 mg, 13.41 mmol). After being stirred fur 10 minutes, pyridin-3-methanamine (1087 mg, 10.5 mmol) was added and the reaction mixture was stirred for 40 minutes at room temperature. The mixture was then diluted with DCM-MeOH (100 mL, 1:1), washed with water (5 x 40 mL), dried over MgSO4, and concentrated under vacuum. The residue was purified by flash chromatography using 10 % MeOH / DCM to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): 4.21 (d, 2H), 6.82-6.88 (m, 1H), 7.10-7.16 (m, 1H), 7.32-7.55 (m, 8H), 7.58-7.68 (m, 2H), 7.85-7.89 (m, 1H), 8.05-8.10 (m, 1H), 8.40-8.46 (m, 1H), 8.52 (s, 1H), 9.08 (s, 1H), 10.08 (s, 1H).
    LC-MS: 433.25 (M+1).
    • EXAMPLE 3 1-(4-(4,4-difluoropiperidin-1-ylsulfonyl)phenyl)-3-(piridin-3-ylmethyl)urea
  • Figure imgb0767
    • A: 4-(3-(pyridin-3-ylmethyl)ureido)benzene-1-sulfonyl chloride:
  • Figure imgb0768
  • To an ice-cooled solution of 4-isocyanatobenzene-1-sulfonyl chloride (6 g, 27.6 mmol) in THE (250 mL) was added pyridin-3-ylmethanamine (2.79 mL, 27.6 mmol). The mixture was allowed to slowly warm to room temperature over 16 hours. The resulting precipitates were filtered off. The filtrate was concentrated to half volume and then treated with 200mL of anhydrous ether. The resulting precipitates were filterod again, and the mother liquor was treated with 200mL of anhydrous ether. The combined precipitates were collected as the title compound and used for next step without further purification.
    1H NMN (300 MHz, CDCl3): 4.54 (s, 2H), 7.21 (br s, 1H), 7.33 (d, 2H), 7.47 (d, 2H), 8.08 (dd, 1H), 8.55 (dt, 1H), 8.50 (m, 2H), 9.24 (s, 1H).
    • B:1-(4-(4,4-difluoropiperidin-1-ylsulfonyl)phenyl)-3(pyridin-3-ylmethyl)urea:
  • Figure imgb0769
  • To an ice-cooled solution of 4,4-difluoropiperidine hydrochloride (2 g, 12.69 mmol) and triethylamine (4.72 mL, 33.8 mmol) in anhydrous dichloromethane (100mL) was added 4-(3-(pyridin-3-ylmethyl)ureido)benzene-1-sulfonyl chloride (4.24 g, 8.46 mmol) in one portion. The mixture was stirred at 0 °C for 5 minutes and at room temperature for 16 hours. The mixture was diluted with methylene chloride and washed successively with saturated aqueous sodium bicarbonate, water, and saturated aqueous sodium chloride. The organic extract was dried over MgSO4, filtered and concentrated under vacuum. The crude was purified by Biotage using 10 % MeOH / DCM to give the title compound.
    1H NMR (300 MHz, DMSO-d6): 2.05 (m, 4H), 3.02 (t, 4H), 4.33 (d, 2H), 6.93 (t, 1H), 7.36 (dd, 1H), 7.64 (m, 4H), 7.71 (m, 1H), 8.46 (d, 1H), 8.53 (s, 1H), 9.24 (s, 1H);
    LC-MS: 410.40 (M+1)
    Anal. Calcd. for C18H20F2N4O3S: C, 52.67; H, 4.91; N, 13.65; F, 9.26; S, 7.81. Found: C, 52.44; H, 4.85; N, 13.49; F, 9.26; S, 7.53.
    • EXAMPLE 4 1-(4-(4-moroholinopiperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
  • Figure imgb0770
    • A: 4-(1-(4-nitrophenylsulfanyl)piperidin-4-yl)morpholine:
  • Figure imgb0771
  • To an ice-cooled solution of 4-nitrobenzene-1-sulfonyl chloride (4 g, 18.05 mmol) in DCM (50 mL) was added a solution of 4-piperidin-4-yl)morpholine (3.69 g, 21.66 mmol) and TEA (3.77 mL, 27.1 mmol) in DCM (920 mL). The mixture was stirred at 0 °C for 15 minutes and at room temperature for 16 hours. The mixture was diluted with DCM, washed with 1M NaOH, brine, dried over Na2SO4 and concentrated in vacuo. The residue was treated with ether and the resulting precipitates were collected to give the title compound.
    1H NMR (300 MHz, CDCl3): δ 8.32-8. 39 (m, 2H), 7.89-7.97 (m, 2H), 3.84 (d, 2H), 3.60-3.71 (m, 4H), 2.15-2.50 (m, 6H), 2.09-2.19 (m, 1H), 1.85-1.92 (m, 2H), 1.50-1.70 (m, 2H)
    LC-MS: 356.06 (M+1).
    • B: 4-(4-morpholinopiperidin-1-ylsulfonyl)aniline:
  • Figure imgb0772
  • A mixture of 4-(1-(4-nitrophenylsulfonyl)piperidin-4-yl)morpholine (6.2 g, 17.44 mmol) and Raney Ni (1.02 g) in HOAc (50 mL) was hydrogenated for 16 h at 50 psi. The reaction mixture was filtered and the filtrate was concentrated. The residue was suspended in water (50 mL) and neutralized with saturated aqueous NaHCO3. The precipitate was collected and dried under reduced pressure to afford the title compound
    1H NMR (300 MHz, DMSO-d6): δ 7.21 (d, 2H), 6.61 (d, 2H), 6.03 (br s, 2H) 3.45-3.65 (m, 6H), 2.30-2.41 (m, 4H), 1.95-2.17 (m, 3H), 1.69-1.79 (m, 2H), 1.30-1.45 (m, 2H)
    LC-MS: 326.07 (M+1)
    • C:1-(4-(4-morpholinopiperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea:
  • Figure imgb0773
  • The title compound was prepared following Example 1, substituting pyridin-3-ylmethanamine and 4-(4-morpholinopiperidin-1-ylsulfonyl)aniline for (5-fluoropyridin-3-yl)methanamine and 4-(piperidin-1-ylsulfonyl)aniline, respectively.
    1H NMR (300 MHz, DMSO-d6): δ 9.17 (s, 1H), 8.51 (d, 1H), 8.44 (dd, 1H), 7.68 (dd, 1H), 7.52-7.69 (m, 4H), 7.30-7.38 (m, 1H), 6.89 (t, 1H), 4.32 (d, 2H), 3.45-3.59 (m, 6H), 2.30-2.41 (m, 4H), 2.00-2.17 (m, 3H), 1.69-1.79 (m, 2H), 1.30-1.44 (m, 2H)
    LC-MS: 460.21 (M+1).
    • EXAMPLE 5 1-[(6-cyanopyridin-3-yl)methyl]-3-[4-(piperidine-1-sulfonyl)phenyl]urea
  • Figure imgb0774
  • Triphosgene (41 mg, 0.137 mmol) was dissolved in DCM (5 mL) and cooled to -10 °C under N2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (100 mg, 0.416 mmol) and TEA (127 mg, 1.25 mmol) in DCM (5 mL). The mixture was stirred at -10 °C for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution of 5-(aminomethyl)picolinonitrile HCl (85 mg, 0.50 mmol) and TEA (2.52 mmol) in DCM (5 mL) was then added. The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with DCM (25 mL), washed with brine (2 x 15 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude was purified by Biotage using 5 % MeOH / DCM to afford the desired product as a white amorphous powder (54 mg, 32.5% yield).
    1H NMR (300 MHz, DMSO-d6): δ 8.63 (s, 1H), 7.79 (m, 2H), 7.60 (m, 2H), 7.48-7.54(m, 3H), 6.10 (m, 1H), 4.50 (d, 2H), 2.93 (m, 4H), 1.61 (m, 4H), 1.41 (m, 2H)
    LC-MS: 400.01 (M+1).
    • EXAMPLE 6 5-((3-(4-piperidin-1-yl)phenyl)ureido)methyl)picolinamide
  • Figure imgb0775
  • To a solution of 1-((6-cyanopyridin-3-yl)methyl)-3-(4-(piperidin-1-ylsulfonyl)phenyl) urea (Example 5, 49 mg, 0.123 mmol) and potassium carbonate (33.9 mg, 0.245 mmol) in DMSO (5 mL) was added hydrogen peroxide (0.038 ml, 0.368 mmol). The mixture was stirred at room temperature for 16 hours, then was diluted with EtOAc and washed successively with 1M NaOH and brine. The extracts were dried over Na2SO4, filtered, concentrated in vacuo, and purified by Biotage using 10 % MeOH / DCM to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): δ 9.00 (s, 1H), 8.42 (m, 2H), 7.62 (dd, 1H), 7.52-7.57 (m, 3H), 7.30-7.34 (m, 1H), 6.34 (t, 1H), 3.36-3.39 (m, 2H), 2.74-2.82 (m, 4H), 1.51 (m, 4H) 1.32 (m, 2H)
    LC-MS: 418.14 (M+1).
    • EXAMPLE 7 tert-butyl N-{5-[({[4-(piperidin-1-sulfonyl)phenyl]carbamoyl}amino)methyl]pyridin-2-yl}carbamate
  • Figure imgb0776
  • Triphosgene (122 mg, 0.412 mmol) was dissolved in DCM (5 mL) and cooled to -10 °C under N2 atmosphere. To this cooled solution was added dropwise a mixture of 4-(piperidin-1-ylsulfonyl) aniline (300 mg, 1.248 mmol) and TEA (2.52 mmol) in DCM (10 mL). The mixture was stirred at -10 °C for 5 minutes and allowed to warm up to room temperature for 1 hour. A solution tert-butyl 5-(aminomethyl)pyridin-2-ylcarbamate (293 mg, 1.311 mmol) and TEA (2.52 mmol) in DCM (5 mL) was then added. The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with DCM (25 mL), washed with brine (2 x 15 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The crude was purified by Biotage using 5 % MeOH / DCM to afford the desired product as a white amorphous powder (200 mg, 32.7% yield).
    1H NMR (300 MHz, DMSO-d6): δ 8.19 (s, 1H), 7.81 (m, 1H), 7.74 (s, 1H), 7.62 (m, 4H), 4.36 (s, 2H), 2.93 (t, 4H), 1.62 (m, 4H), 1.52 (s, 9H), 1.42 (m, 2H)
    LC-MS: 489.99 (M+1).
    • EXAMPLE 8 1-((6-aminopyridin-3-yl) methyl-3-(4-(piperidine-1-ylsulfonyl) urea
  • Figure imgb0777
  • A solution of tert-butyl 5-((3-(4-(pieridin-1-ylsulfonyl) phenyl)ureido)methyl)-pyridin-2-yl carbamate (Example 7, 87 mg, 0.178 mmol) in 20 ml of 1:1 TFA/DCM was stirred at room temperature for 16 hours. After removal of the solvent, the residue was purified by Biotage using 10 % MeOH (2 M NH3) / DCM to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): δ 8.00 (s, 1H), 7.81 (m, 1H), 7.7.40-7.50 (m, 4H), 7.20-7.35 (dd, 1H), 6.38 (d, 1H). 5.77 (t, 1H), 4.18 (d, 2H), 2.85 (m, 4H), 1.53 (m, 4H), 1.32 (m, 2H)
    LC-MS: 390.02 (M+1).
    • EXAMPLE 9 4-(N-(5-chloro-2-methoxyphenyl)sulfamoyl)-N-(imidazo[1,2-a]pyridin-6-ylmethyl)benzamide
  • Figure imgb0778
    • A. N-(5-chloro-2-methoxyphenyl)-4-cyanobenzenesulfonamide:
  • Figure imgb0779
  • To a solution of 5-chloro-2-methoxyaniline (821 mg, 5.21 mmol, 1.05 eq) and DMAP (61 mg, 0.496 mmol, 0.1 eq) in pyridine (15 mL) cooled to 0 °C was added dropwise a solution of 4-cyanobenzene-1-sulfonyl chloride (1.0 g, 4.96 mmol, 1.0 eq) in pyridine (5 mL). The reaction was heated at 80 °C overnight then all volatiles were removed in vacuo. The resulting residue was dissolved in dichloromethane (20 mL), washed sequentially with 1N hydrochloric acid (20 mL), water (20 mL) and saturated sodium chloride (20 mL) then dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The resulting residue was triturated twice with hexanes (10 mL) and once with diethyl ether (10 mL) and then dried under vacuum to afford N-(5-chloro-2-methoxyphenyl)-4-cyanobenzenesulfonamide (1.19 g, 74%) as a pale purple solid a portion of which was used without further purification in the subsequent step.
    • B. 4-(N-(5-chloro-2-methoxyphenyl)sulfamoyl)benzoic acid:
  • Figure imgb0780
  • N-(5-chloro-2-methoxyphenyl)-4-cyanobenzenesulfonamide (0.387 mmol, 125 mg) was dissolved in 2-propanol (8.0 mL) and 1.8 M aqueous potassium hydroxide (6.5 mL, 11.6 mmol). The reaction was heated at 75 °C for 18 hours then cooled to ambient temperature and the 2-propanol removed on a rotary evaporator. The aqueous phase was extracted with ethyl acetate (5 mL) then the pH was adjusted to pH 2-3 with 2N hydrochloric acid and the aqueous phase was extracted thrice with ethyl acetate (10 mL). The combined organic phase was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford 4-(N-(5-chloro-2-methoxyphenyl)sulfamoyl)benzoic acid as a white solid (123 mg, 93%) which was used without further purification in the subsequent step.
    • C. 4-(N-(5-chloro-2-methoxyphenyl)sulfamoyl)-N-(imidazo[1,2-a]pyridin-6-ylmethyl)benzamide:
  • Figure imgb0781
  • To a solution of 4-(N-(5-chloro-2-methoxyphenyl)sulfamoyl)benzoic acid (116 mg, 0.340 mmol, 1 eq) in dry DMF (3 mL) was added imidazo[1,2-a]pyridin 7-ylmethanamine (50 mg, 0.340 mmol, 1 eq), followed by benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 194 mg, 0.374 mmol, 1.1 eq) and diisopropylethylamine (71 µL, 0.408 mmol, 1.2 eq). The resultant yellow solution stirred at ambient temperature for 4.5 hrs the all volatiles were removed under vacuum. The crude material was purified by flash column chromatography (eluting with 2-8 % methanol/dichloromethane) to afford the title compound as a colorless oil which upon repeated trituration with Et2O gave a white solid (91 mg, 57%).
    LCMS MH+ = 471.1
    1H NMR (DMSO): δH 9.95 (s, 1H), 9.24 (t, 1H), 8.49 (s, 1H), 8.00 (2, 2H), 7.94 (s, 1H), 7.82 (d, 2H), 7.53 (m, 2H), 7.19 (m, 3H), 6.94 (d, 1H), 4.47 (d, 2H) and 3.48 (s, 3H).
    • EXAMPLE 10 1-(4-(phenylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
  • Figure imgb0782
  • A solution of triphosgene (84 mg, 0.283 mmol) in DCM (5.0 mL) was cooled to -10 °C under N2 atmosphere and was treated dropwise with a solution of 4-(phenylsulfonyl)aniline (200 mg, 0.857 mmol) and TEA (260 mg, 2.57 mmol) in DCM (5.0 mL). The mixture was stirred at -10 °C for 5 minutes, then at ambient temperature for 1 hour, whereupon this mixture was added to a solution of pyridin-3-ylmethanamine (97 mg, 0.90 mmol) and TEA (260 mg, 2.57 mmol) in DCM (5.0 mL). The mixture was stirred for 16 hours at ambient temperature, and then was diluted with DCM (25 mL), washed with brine (2 x 15 mL), and dried over MgSO4. After filtration, the filtrate was concentrated under vacuum and purified by Biotage using 5 % MeOH / DCM to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): 4.29 (d, 2H), 6.90 (t, 1H), 7.26-7.35 (m, 1H), 7.54-7.70 (m, 6H), 7.65-7.80 (m, 2H), 7.81-7.90 (m, 2H), 8.40-8.45 (m, 1H), 8.49-8.55 (m, 1H), 9.21 (s, 1H). LC-MS: 368.15 (M+H).
    • EXAMPLE 11 1-(pyridin-3-ylmethyl)-3-(4-(2-(trifluoromethoxy)phenylsulfonyl)phenyl)urea
  • Figure imgb0783
    • A: 4-(3-(pyridin-3-ylmethyl)ureido)benzene-1-sulfonyl chloride:
  • Figure imgb0784
  • 4-Isocyanatobenzeno-1-sulfonyl chloride (6 g, 27.6 mmol) was taken up in THF (250 mL) and cooled to 0 °C, whereupon pyridin-3-ylmethanamine (2.79 mL, 27.6 mmol) was added and the resulting mixture was allowed to warm slowly to ambient temperature over 16 hours. The mixture was filtered and the filtrate was concentrated to half its original volume and was treated with 200 mL of anhydrous Et2O. The precipitates were again filtered off and the filtrate was treated with 200 mL of anhydrous Et2O. The resulting precipitates were collected by vacuum filtration and used in the next step without further purification.
    1H NMR (300 MHz, CDCl3): 4.54 (s, 2H), 7.21 (br s, 1H), 7.33 (d, 2H), 7.47 (d, 2H), 8.08 (dd, 1H), 8.55 (dt, 1H), 8.50 (m, 2H), 9.24 (s, 1H).
    • B: Ammonium 4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfinate:
  • Figure imgb0785
  • 4-(3-(Pyridin-3-ylmethyl)ureido)benzene-1-sulfonyl chloride (3.99 g, 12.25 mmol) was added to a solution of sodium sulfite (6.18 g, 49.0 mmol) and sodium bicarbonate (6.17 g, 73.5 mmol) in water (175 mL), and the resulting mixture was stirred at 80 °C for 3 hours. The mixture was then concentrated to dryness under reduced pressure, and the resulting solids were triturated with hot DMF (100 mL) and the solids filtered off. The solvent was then removed under reduced pressure, and the resulting residue was triturated with hot DCM (100 mL) and the off-white crystalline solids were collected by vacuum filtration. The solids were purified by SCX ion-exchange column (eluting with 5:1 CH3CN/NH4OH) to afford the title compound.
    1H NMR (300 MHz, CDCl3): 4.28 (d, 2H), 7.35 (m, 6H), 7.70 (dt, 1H), 8.42 (dd, 1H), 8.51 (d, 1H), 9.23 (br s, 1H). LC-MS: 292.01 (M+1)
    • C: 1-(pyridin-3-ylmethyl)-3-(4-(2-(trifluoromethoxy)phenylsulfonyl)phenyl)urea:
  • Figure imgb0786
  • A mixture of ammonium 4-(3-(pyridin-3-ylmethyl)ureido)benzenesulfinate (30.8 mg, 0.1 mmol), 2-(trifluoromethyl)phenylboronic acid (25.7 mg, 0.125 mmol), copper(II) acetate (22.7 mg, 0.125 mmol), and TEA (0.063 mL, 0.45 mmol) in DMSO (1.5 mL) was heated at 60 °C for 16 hours. The mixture was cooled to ambient temperature and was partitioned between EtOAc and brine. The organic layer was separated, dried (MgSO4), concentrated, and purified by PTLC (100% EtOAc) to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): 9.26 (s, 1H), 8.50 (d, 1H), 8.44-8.42 (m, 1H), 8.17-8.14 (m, 1H), 7.84-7.78 (m, 1H), 7.75-7.59 (m, 6H), 7.52-7.49 (m, 1H), 7.35-7.31 (m, 1H), 6.93 (t, 1H), 4.30 (d, 2H). LC-MS: 452.09 (M+1)
    • EXAMPLE 12 1-(3-aminobenzyl)-3-(4-(phenylsulfonyl)phenyl)urea
  • Figure imgb0787
    • A: tert-butyl 3-((3-(4-(phenylsulfonyl)phenyl)ureido)methyl)phenylcarbamate:
  • Figure imgb0788
  • The title compound was prepared according to Example 1, substituting tert-butyl 3-(aminomethyl) phenylcarbamate for pyridin-3-ylmethanamine.
    1H NMR (300 MHz, CDCl3): δ 7.82-7.89 (m, 2H), 7.70-7.76 (m, 2H), 7.42-7.58 (m, 4H), 7.38 (d, 2H), 7.29 (s, 1H), 7.10-7.16 (m, 2H), 6.62-6.89 (m, 1H), 6.65 (s, 1H), 5.52 (t, 1H), 4.22 (d, 2H), 1.47 (s, 9H) LC-MS: 482.08 (M+H).
    • B: 4-(3-(pyridin-3-ylmethyl)ureido)benzene-1-sulfonyl chloride:
  • Figure imgb0789
  • A solution of tert-butyl 3-((3-(4-(phenylsulfonyl)phenyl)ureido)methyl)phenyl-carbamate (390 mg, 0.810 mmol) and TFA (5 mL, 64.9 mmol) in DCM (10 mL) was stirred at ambient temperature for 16 hours. The mixture was concentrated and partitioned between DCM and saturated NaHCO3. The organic layer was washed with brine (2 x 15 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by Biotage using 10% MeOH / DCM to offer the title compound.
    1H NMR (300 MHz, DMSO-d6): 9.21 (s, 1H), 8.49-8.55 (m, 2H), 8.40-8.45 (m, 2H), 7.81-7.90 (m, 5H), 6.90 (t, 1H), 6.69 (t, 1H), 6.40-6.50 (m, 3H), 5.41 (br, s, 2H), 4.14 (d, 2H) LC-MS: 382.28 (M+H).
    • EXAMPLE 13 1-(4-(4-chlorophenylthio)phenyl)-3-(pyridin-3-ylmethyl)ureua
  • Figure imgb0790
    • A: 4-(4-chlorophenylthio)aniline:
  • Figure imgb0791
  • A solution of (4-chlorophenyl)(4-nitrophenyl)sulfane (1.71 g, 6.44 mmol) in 2:1 MeOH/EtOAc (75 mL) was treated with platinum(IV) oxide (100 mg) and the resulting mixture was placed under an atmosphere of hydrogen (45 psi) for 16 hours. The mixture was filtered through GF/F paper, rinsed with MeOH, and concentrated under reduced pressure to afford the title compound as a yellow solid.
    1H NMR (300 MHz, CDCl3): 7.32-7.27 (m, 2H), 7.19-7.14 (m, 2H), 7.05-7.01 (m, 2H), 6.70-6.65 (m, 2H), 3.83 (s, 2H).
    • B: 1-(4-(4-chlorophenylthio)phenyl)-3-(pyridin-3-ylmethyl)urea:
  • Figure imgb0792
  • The title compound was prepared according to Example 1, substituting 4-(4-chlorophenylthio)aniline for 4-(phenylsulfonyl)aniline.
    1H NMR (DMSO-d6): 8.90 (s, 1H), 8.51 (d, 1H), 8.45-8.43 (m, 1H), 7.71-7.67 (m, 1H), 7.51-7.46 (m, 2H), 7.37-7.31 (m, 5H), 7.11-7.06 (m, 2H), 6.81 (t, 1H), 4.30 (d, 2H).
    • C. 1-(4-(4-chlorophenylthio)phenyl)-3(pyridin-3-ylmethyl)urea
  • Figure imgb0793
  • A solution of 1-(4-(4-chlorophenylthio)phenyl)-3-(pyridin-3-ylmethyl)urea (50 mg, 0.135 mmol) in 10:1 DCM:MeOH (3.3 mL) was treated with m-CPBA (2.0 equiv), and the solution was stirred for 16 hours at ambient temperature. The mixture was then diluted with saturated NaHCO3 and DCM and the layers separated. The organic layer was dried over MgSO4 and purified by PTLC (6% MeOH/DCM) to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): 9.24 (s, 1H), 8.49 (s, 1H), 8.43-8.42 (m, 1H), 7.88 (d, 2H), 7.79 (d, 2H), 7.68-7.58 (m, 5H), 7.35-7.31 (m, 1H), 6.92 (t, 1H), 4.30 (d, 2H). LC-MS: 402.00 (M+1)
    • EXAMPLE 14 1-((6-(dimethylamino)pyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea
  • Figure imgb0794
    • A: 6-(dimethylamino)nicotinonitrile:
  • Figure imgb0795
  • In a sealed tube, 6-chloronicotinonitrile (510 mg, 3.68 mmol) was taken up in DMF (4 mL) and dimethylamine (4.0 mL of a 2.0M THF solution) and DIEA (3.0 mL, 17.18 mmol) were added. The mixture was heated to 140 °C for 17 hours, and was then diluted with EtOAc and washed with brine (3x) and dried (MgSO4). After filtration and concentration, the residue was purified by Biotage SP1 (100% MeOH/DCM/NH3) to afford the title compound as a pale yellow solid.
    1H NMR (300 MHz, CDCl3): 8.40 (d, 1H), 7.60-7.56 (m, 1H), 6.49-6.46 (m, 1H), 3.15 (s, 6H).
    • B: 5-(aminomethyl)-N,N-dimethylpyridin-2-amine:
  • Figure imgb0796
  • A solution of 6-(dimethylamino)nicotinonitrile (506 mg, 3.44 mmol) in 2:1 2N NH3 (75 mL) was treated with Raney Nickel and placed under a 40 psi atmosphere of hydrogen for 16 hours. The mixture was then carefully filtered through Celite (caution: to minimize danger of fire, do not allow solids to become dry), the filtrate concentrated to dryness, and purified by Biotage SP1 (DCM/MeOH/NH3). The concentrated fractions were then triturated with Et2O to afford the title compound as a white solid.
    1H NMR (300 MHz, DMSO-d6): 7.97-7.94 (m, 1H), 7.48-7.37 (m, 1H), 6.57 (d, 1H), 3.95 (d, 2H), 3.55 (br s, 2H), 2.96 (s, 6H).
    • C:1-((6-(dimethylamino)pyridin-3-yl)methyl)-3-(4-(phenylsulfonyl)phenyl)urea
  • Figure imgb0797
  • The title compound was prepared according to Example 1, substituting 5-(aminomethyl)-N,N-dimethylpyridin-2-amine for pyridin-3-ylmethanamine.
    1H NMR (300 MHz, DMSO-d6): 9.05 (s, 1H), 7.99 (d, 1H), 7.90-7.86 (m, 2H), 7.77 (d, 2H), 7.65-7.55 (m, 5H), 7.44-7.41 (m, 1H), 6.66 (t, 1H), 6.57 (d, 1H), 4.10 (d, 2H), 2.96 (s, 6H). LC-MS: 411.06 (M+1)
    • EXAMPLE 15 1-(4-(4-bromophenylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
  • Figure imgb0798
    • A: (4-bromophenyl)(4-nitrophenyl)sulfane:
  • Figure imgb0799
  • A solution of 4-bromobenzenethiol (4.97 g, 26.3 mmol) in DMF (50 mL) was cooled to 0 °C and treated with K2CO3 (4.3 g, 31.1 mmol). After addition was complete, the solution was warmed to ambient temperature over 15 minutes and then 1-fluoro-4-nitrobenzene (2.62 mL, 24.70 mmol) was added. The mixture was heated to 80 °C for 16 hours, and was then poured onto ice and diluted with EtOAc. The layers were separated and the organic layer was washed successively with saturated NaHCO3 and brine (2x). The organics were dried over MgSO4, filtered, and concentrated to afford the title compound as a yellow solid.
    1H NMR (300 MHz, DMSO-d6): 8.18-8.13 (m, 2H), 7.87-7.84 (m, 2H), 7.53-7.41 (m, 2H), 7.31-7.27 (m, 2H).
    • B: 4-bromo-2-(4-nitrophenylsulfonyl)benzene:
  • Figure imgb0800
  • A solution of (4-bromophenyl)(4-nitrophenyl)sulfane (3.942 g, 12.71 mmol) in CHCl3 (40 ml) was cooled in an ice bath and treated with m-CPBA (2.2 equiv) portionwise. The mixture was allowed to warm slowly to ambient temperature over 16 hours, then the mixture was filtered through GF/F paper and the filtrate washed with 1N NaOH and brine. The organics were dried over MgSO4, filtered, and concentrated to the crude solid. The solid can be triturated (if desired) with DCM and collected by vacuum filtration to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): 8.42-8.36 (m, 4H), 8.18-8.13 (m, 2H), 7.87-7.84 (m, 2H).
    • C: 4-(2-bromophenylsulfonyl)aniline:
  • Figure imgb0801
  • A mixture of 1-bromo-4-(4-nitrophenylsulfonyl)benzene (1.57 g, 4.59 mmol) and tin(II) chloride dihydrate (4.35 g, 22.94 mmol) was heated in EtOH (40 mL) for 2 hours at 70 °C. The volatiles were removed under reduced pressure, and the residue was taken up in EtOAc (100 mL) and 2N NaOH (40 mL). The mixture was stirred vigorously for 1 hour, then filtered through Celite. The organic layer was separated, dried over MgSO4, and purified by Biotage SP1 to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): d 7.78-7.71 (m, 4H), 7.52 (d, 2H), 6.59 (d, 2H), 6.22 (s, 2H).
    • D: 1-(4-(4-bromophenylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
  • Figure imgb0802
  • The title compound was prepared according to Example 1, substituting 4-(4-bromophenylsulfonyl)aniline for 4-(phenylsulfonyl)aniline.
    1H NMR (300 MHz, DMSO-d6): 9.26 (s, 1H), 8.50 (d, 1H), 8.44-8.42 (m, 1H), 7.83-7.70 (m, 6 H), 7.69-7.65 (m, 1H), 7.62-7.58 (m, 2H), 7.35-7.31 (m, 1H), 6.93 (t, 1H), 4.30 (d, 2H). LC-MS: 447.95 (M+1).
    • EXAMPLE 16 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea
  • Figure imgb0803
    • A: tert-butyl 5-((3-(4-(phenyleslfonyl)phenyl)ureido)methyl)pyridin-2-ylcarbrmate:
  • Figure imgb0804
  • A solution of 4-phenylsulfonylaniline (1.5 g, 6.43 mmol) in EtOAc (10 mL) was added dropwise over 30 minutes to a solution of phosgene (6 ml, 20% in Toluene) in toluene (5 mL), and was then heated to reflux for 5 hours. The volatiles were removed under reduced pressure, and DCM (50 mL), tert-butyl 5-(aminomethyl) pyidin-2-yl carbamate (1.507 g, 6.75 mol), and DIEA (4 mL) were added to the residue. The mixture was stirred at ambient temperature for 16 hours, then was diluted with DCM and washed with saturated sodium bicarbonate. The organics were dried over MgSO4, concentrated, and purified by Biotage SP1 to afford the title compound.
    1H NMR (300 MHz, DMSO-d6): δ 9.69 (s, 1H), 9.15 (s, 1H), 8.14 (s, 1H), 7.87 (dd, 2H), 7.78 (m, 2H), 7.70-7.73 (m, 1H), 7.57-7.66 (m, 6H), 6.81 (t, 1H), 4.21 (d, 2H), 1.44 (s, 9H).
    • B:1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea:
  • Figure imgb0805
  • The title compound was prepared according to Example 3B, substituting tert-butyl 5-((3-(4-(phenylsulfonyl)phenyl)ureido)methyl)pyridin-2-ylcarbamate for tert-butyl 3-((3-(4-(phenylsulfonyl)phenyl)ureido)methyl)phenyl-carbamate.
    1H NMR (300 MHz, CDCl3): δ 9.03 (s, 1H), 7.86-7.89 (m, 2H), 7.78-7.81 (m, 3H), 7.58-7.77 (m, 5H), 7.27-7.31 (dd, 1H), 6.63 (t, 1H), 6.37 (d, 1H), 5.81 (s, 2H), 4.06 (d, 2H)
    LC-MS: 383.13 (M+1).
    • EXAMPLE 17 1-(4-(phenylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea
  • Figure imgb0806
  • A mixture of (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (37.8 mg, 0.065 mmol), Cs2CO3 (319 mg, 0.980 mmol), tri(dibenzylideneacetone)dipalladium(0) (29.9 mg, 0.033 mmol), sodium 4-methylbenzenesulfinate (140 mg, 0.784 mmol), 1-(4-bromophenyl)-3-(pyridine-3-ylmethyl)urea (200 mg, 0.653 mg), and tertrabutylammonium iodide (290 mg, 0.784 mmol) in toluene (10 mL) was heated at 100 °C for 16 hours. The mixture was cooled to ambient temperature and DCM was added. The organic layer was washed successively with water and brine, dried over MgSO4, concentrated, and purified by Biotage SP1 to afford the title compound.
    1H NMR (300 MHz, CDCl3): δ 8.47 (s, 1H), 8.44 (d, 1H), 8.32 (s, 1H), 7.69-7.74 (m, 4H), 7.63 (d, 1H), 7.47-7.51 (dd, 2H), 7.26-7.46 (m, 3H), 6.12 (s, 1H), 4.38 (d, 2H), 2.37 (s, 3H) LC-MS: 382.15 (M+1).
    • EXAMPLE 18 N-(imidazo[1,2-a]pyridin-6-ylmethyl)-4-(phenylsulfonyl)benzamide
  • Figure imgb0807
    • A. 4-sulfonylbenzonitrile:
  • Figure imgb0808
     4-fluorobenzonitrile (46.5 mmol, 5.63g) and sodium benzenesulfinate (51.1 mmol, 8.39 g) were dissolved in DMSO (35.8 mL). The reaction was heated at 130 °C for 48 hours then cooled to ambient temperature and poured onto ice. The precipitated solids were collected by suction filtration, washed with water and then dried under vacuum to afford 4-sulfonylbenzonitrile (11.2 g) a portion of which was used in the subsequent step without further purification.
    • B. 4-phenylsulfonylbenzoic acid:
  • Figure imgb0809
     4-sulfonylbenzonitrile (4.11 mmol, 1.0 g) was dissolved in 2-propanol (88 mL) and 1.0 M aqueous potassium hydroxide (140 mL). The reaction was heated at 75 °C for 18 hours then cooled to ambient temperature and the 2-propanol removed on a rotary evaporator. The aqueous phase was extracted with ethyl acetate (70 mL) then the pH was adjusted to pH 2-3 with 6N hydrochloric acid and the aqueous phase was extracted thrice with ethyl acetate (100 mL). The combined organic phase was dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to afford 4-phenylsulfunylbenzoic acid as a white solid (1.01 g) a portion of which was used without further purification in the subsequent step.
    • C. N-(imidezo[1,2-a]pyridin-6-ylmethyl)-4-(phenylsulfonyl)benzamide:
  • Figure imgb0810
     Oxalyl chloride (66.7 µL, 0.763 mmol) was added dropwise to a solution of 4-phenylsulfonylbenzoic acid (100 mg, 0.381 mmol) in dichloromethane (3.81 mL) at 0 °C. The reaction stirred for 2 hours then all volatiles were removed under vacuum. The crude 4-phenylsulfonylbenzoyl chloride was re-dissolved in dichloromethane (3.8 mL) then imidazo[1,2-a]pyridin-7-ylmethanamine hydrochloride (77 mg, 0.419 mmol) and triethylamine (117 µL, 0.839 mmol) were added successively. The reaction stirred for 1 hour at ambient temperature then saturated sodium bicarbonate (3.8 mL) was added. The organic phase was separated, washed with saturated sodium chloride (3 mL), dried over anhydrous magnesium sulfate and concentrated in vacuum. The resulting residue was purified by flash column chromatography (eluting with 5% methanol/dichlormethane) to afford the title compound as a white solid (73 mg, 49%).
    LCMS MH+ = 391.9
    1H NMR (MeOD): δH 8.29 (s, 1H), 8.00 (s, 4H), 7.93 (d, 2H), 7.65-7.48 (m, 6H), 7.27 (dd, 1H) and 4.50 (s, 2H).
    • ASSAYS: ASSAY EXAMPLE 1 Biochemical Inhibition Assay NAMPT protein purification
  • Recombinant His-tagged NAMPT was produced in E. coli cells, purified over a Ni column, and further purified over a size-exclusion column by XTAL Biostructures.
    • The NAMPT enzymatic reaction
  • The NAMPT enzymatic reactions were carried out in Buffer A (50mM Hepes pH 7.5, 50mM NaCl, 5mM MgCl2, and 1mM THP) in 96-well V-bottom plates. The compound titrations were performed in a separate dilution plate by serially diluting the compounds in DMSO to make a 100X stock. Buffer A (89 µL) containing 33 nM of NAMPT protein was added to 1 µL of 100X compound plate containing controls (e.g. DMSO or blank). The compound and enzyme mix was incubated for 15 minutes at room temperature, then 10 µL of 10X substrate and co-factors in Buffer A were added to the test well to make a final concentration of 1 µM NAM, 100 µM 5-Phospho-D-ribose 1-diphosphate (PRPP), and 2.5mM Adenosine 5'-triphosphate (ATP). The reaction was allowed to proceed for 30 minutes at room temperature, then was quenched with the addition of 11 µL of a solution of formic acid and L-Cystathionine to make a final concentration of 1% formic acid and 10 µM L-Cystathionine. Background and signal strength was determined by addition (or non-addition) of a serial dilution of NMN to a pre-quenched enzyme and cofactor mix.
    • Quantification of NMN
  • A mass spectrometry-based assay was used to measure the NAMPT reaction product (NMN) and the internal control (L-Cystathionine). NMN and L-Cystathionine were detected using the services of Biocius Lifesciences with the RapidFire system. In short, the NMN and L-Cystathionine are bound to a graphitic carbon cartridge in 0.1% formic acid, eluted in 30% acetonitrile buffer, and injected into a Sciex 4000 mass spectrometer. The components of the sample were ionized with electrospray ionization and the positive ions were detected. The Q1 (parent ion) and Q3 (fragment ion) masses of NMN were 334.2 and 123.2, respectively. The Q1 and Q3 for L-Cystathionine were 223.1 and 134.1, respectively. The fragments are quantified and the analyzed by the following method.
    • % inhibitions are determined using this method.
  • First the NMN signal is normalized to the L-Cystathionine signal by dividing the NMN signal by the L-Cystathionine signal for each well. The signal from the background wells are averaged and subtracted from the test plates. The compound treated cells re then assayed for % inhibition by using this formula. % Inh = 100 − 100 * x / y
    Figure imgb0811
     wherein x denotes the average signal of the compound treated wells and y denotes the average signal of the DMSO treated wells.
    IC50s are determined using Excel and this formula. IC 50 = 10 ∧ LOG 10 X + 50 − % Inh at Cmpd Concentration 1 / XX − YY * LOG 10 X − LOG 10 Y
    Figure imgb0812
     wherein X denotes the compound concentration 1, Y denotes the compound concentration 2, XX denotes the % inhibition at compound concentration 1 (X), and YY denotes the % inhibition at compound concentration 2 (Y).
    The NAMPT-inhibitor compounds of this invetnion have IC50 values that are under 10 µM, preferably under 1µM, more preferalb under 0.1 µM, and most preferably under 0.01 µM. Results for representative compounds are provided in Table 3 below.
    • ASSAY EXAMPLE 2 In-Vitro Cell Proliferation Assay
  • A2780 cells were seeded in 96-well plates at 1 x 103 cells/well in 180 µL of culture medium (10% FBS, 1% Pen/Strep Amphotecricin B, RPMI-1640) with and without the addition of either p-nicotinamide mononucleotide (NMN) or nicotinamide (NAM). After overnight incubation at 37 °C and 5% CO2, the compound titrations were performed in a separate dilution plate by serially diluting the compounds in DMSO to make a 1000X stock. The compounds were then further diluted to 10X final concentration in culture media, whereupon 20 µL of each dilution was added to the plated cells with controls (e.g. DMSO and blank) to make a final volume of 200 µL. The final DMSO concentration in each well was 0.1%. The plates were then incubated for 72 hours at 37 °C in a 5% CO2 incubator. The number of viable cells was then assessed using sulforhodamine B (SRB) assay. Cells were fixed at 4 °C for 1 hour with the addition of 50 µL 30% trichloroacetic acid (TCA) to make a final concentration of 6 % TCA. The plates were washed four times with H2O and allowed to dry for at least 1 hour, whereupon 100 µL of a 4% SRB in 1% acetic acid solution was added to each well and incubated at room temperature for at least 30 minutes. The plates were then washed three times with 1% acetic acid, dried, and treated with 100 µL of 10mM Tris-Base solution. The plates were then read in a microplate reader at an absorbance of 570 nm. Background was generated on a separate plate with media only.
    • Method for determining % inhibition
  • First, the signals from the background plate are averaged, then the background was subtracted from the test plates. The compound-treated cells were then assayed for % inhibition by using the following formula: % Inh = 100 − 100 * x / y
    Figure imgb0813
     wherein x denotes the average signal of the compound-treated cells and y denotes the average signal of the DMSO-treated cells.
    Formula for determining IC50 values: IC 50 = 10 ∧ LOG 10 X + 50 − % Inh at Cmpd Concentration 1 / XX − YY * LOG 10 X − LOG 10 Y
    Figure imgb0814
     wherein X denotes the compound concentration 1, Y denotes the compound concentration 2, XX denotes the % inhibition at compound concentration 1 (X), and YY denotes the % inhibition at compound concentration 2 (Y).
    • Specificity of cytotoxicity.
  • Inhibition of NAMPT could be reversed by the addition of NAM or NMN. The specificity of the compounds were determined via cell viability assay in the presence of the compound and either NAM or NMN. Percent inhibitions were determined using the method given above.
  • The NAMPT-inhibitor compounds of this disclosure have IC50 values that are preferably under 1µM, more preferably under 0.1µM, and most preferably under 0.01µM. Most preferable compounds of this disclosure are compounds that have both the enzymatic IC50- value and the A2780 IC50-value under under 10µM, preferably under 1µM, more preferably under 0.1µM, and most preferably under 0.01µM.
  • Results for representative compounds is provided in Table 3 below. Table 3
    Compound Biochem IC50 uM A2780 IC50 uM
    (3S)-N,N-diethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-3-carboxamide 0.006 0.025
    1-(4-{[(1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.007 0.046
    1-(4-{[2-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.005 0.011
    1-(4-{[2-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.018
    1-(4-{[3-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.006 0.103
    1-(4-{[4-(morpholin-4-yl)phenl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.005 0.173
    1-(4-{[4-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.054
    1-(4-{2-azabicyclo[2.2.1]heptene-2-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.01 0.236
    1-(4-{2-oxa-8-azaspiro[4.5]decane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.005 0.089
    1-(4-{3-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethy)urea 0.003 0.143
    1-(4-{3-azaspiro[5.5]undecane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.011 0.145
    1-(4-{3-azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.002 0.026
    1-(4-{3-oxa-8-azabicyclo[3.2.1]octano-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.012 0.287
    1-(4-{4-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin 3-ylmethyl)urea 0.002 0.078
    1-(4-{4-[(furan-2-yl)carbonyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.168
    1-(4-{4-[2-(morpholin-4-yl)-2-oxoethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.135
    1-(4-{4-[2-oxo-2-(piperidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.009 0.021
    1-(4-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.099
    1-(4-{4-[3-(morpholin-4-yl)propyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.003 0.024
    1-(4-{8-azabicyclo[3.2.1]octane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.064
    1-(4-{8-azaspiro[4.5]decane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.004 0.343
    1-(4-{8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.007 0.029
    1-(pyzidin-3-ylmethyl)-3-(4-{[(1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea 0.08 0.091
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)urea 0.0012 0.007
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)urea 0.006
    1-(pyridin-3-ylmethyl)-3-[4-(1H-pyrrole-1-sulfonyl)phenyl]urea 0.019 1.788
    1-(pyridin-3-ylmethyl)-3-{4-[(3S)-3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea 0.003 0.029
    1-(pyridin-3-ylmethyl)-3-{4-[3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea 0.003 0.026
    1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-4-carboxamide 0.01 1.481
    1-[3-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea >30 >30
    1-[4-(2,6-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.011 0.164
    1-[4-(3,4-dihydro-2H-1,4-benzoxazine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.01 0.459
    1-[4-(3,5-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.006 0.014
    1-[4-(4,4-difluoropiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.025 0.299
    1-[4-(4-{[(2R)-oxolan-2-yl]carbonyl}piperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.008 0.030
    1-[4-(4-benzyl-1,4-diazepane-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.005 0.137
    1-[4-(4-phenylpiperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.005
    1-[4-(4-phenylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.003
    1-[4-(cycloheptylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.003 0.080
    1-[4-(cyclohexylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.001 0.204
    1-[4-(decahydroquinoline-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.011 0.014
    1-[4-(dibenzylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0008 0.0003
    1-[4-(morpholine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.023 1.35
    1-[4-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.011 0.167
    1-{4-[(1-phenylcyclopentyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.029 0.180
    1-{4-[(1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine]-1'-ylsulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.005 0.041
    1-{4-[(2-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.003 0.047
    1-{4-[(2R)-2-(morpholin-4-ylmethyl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.051 0.081
    1-{4-[(2R)-2-benzylpiperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.004 0.024
    1-{4-[(cyclohexylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.004 0.181
    1-{4-[(naphthalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.001 0.019
    1-{4-[4-(2-oxo-2,3-dihydro-1H-indol-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.003 0.058
    1-{4-[4-(azepan-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.005 0.006
    1-{4-[4-(morpholin-4-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethy)urea 0.009 0.013
    1-{4-[4-(piperidin-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.007 0.013
    2-methyl-N-{1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidin-4-yl}propanamide 0.005 0.123
    3-(4-{[(2-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.003 0.201
    3-(4-{[(2-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.008 0.097
    3-(4-{[(3-fluorophenyl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.156
    3-(4-{[(4-chlorophenyl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.484
    3-(4-{[(4-fluorophenyl)methyl](methyl)sulfanyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.003
    3-(4-{[(4-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.016 0.507
    3-(4-{[(5-ethylpyridin-2-yl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.134
    3-(4-{[2-(4-fluorophenoxy)pyridin-3-yl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.011 0.149
    3-(4-{[2-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0006 0.031
    3-(4-{[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl-1-(pyridin-3-ylmethyl)urea 0.008 0.007
    3-(4-{[2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.022
    3-(4-{[2-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.015
    3-(4-{[2-methoxy-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0001 0.002
    3-(4-{[3-chloro-4-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.001 0.024
    3-(4-{[3-methyl-4-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.108
    3-(4-{[4-chloro-2-(trifluoromethoxy)phenl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.006 0.113
    3-(4-{[4-methyl-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.179
    3-(4-{4-[(4-fluorophenyl)carbonyl]piperidine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.010 0.206
    3-(4-{4-[(morpholin-4-yl)carbonyl]piperidine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.008 0.04
    3-(4-{4-[1-(3-methoxyphenyl)-4-methylcyclohexyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.004 0.005
    3-(4-{4-[2-(diethylamino)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.004 0.023
    3-(4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)-1-(pyridin3-ylmethyl)urea 0.005 0.128
    3-(4-{4-[bis(4-fluorophenyl)methyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.007
    3-(4-{8-methyl-2,8diazaspiro[5.5]undecane-2-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.001 0.001
    3-(4-{methyl[(1S)-1-phenylethyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.001 0.008
    3-(pyridin-3-ylmethyl)-1-(4-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea 0.012 0.096
    3-(pyridin-3-ylmethyl)-1-(4-{[2-(1H-pyrrol-1-yl)phenyl]sulfamoyl}phenyl)urea 0.003 0.076
    3-(pyridin-3-ylmethyl)-1-(4-{[2-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea 0.013 0.011
    3-(pyridin-3-ylmethyl)-1-[4-(5,6,7,8-tetrahydro-1,6-naphtyridine-6-sulfonyl)phenyl]urea 0.016 0.111
    3-(pyridin-3-ylmethyl)-1-[4-(pyrrolidine-1-sulfonyl)phenyl]urea 0.037 1.399
    3-(pyridin-3-ylmethyl)-1-{4-[(3S)-3-[(pyrrolidin-1-yl)carbonyl]piperidine-1-sulfonyl]phenyl}urea 0.009 0.137
    3-pyridin-3-ylmethyl)-1-{4-[(5,6,7,8-tetrahydronaphthalen-1-yl)sulfamoyl]phenyl}urea 0.0003 0.045
    3-[(5-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea 0.048 18
    3-[(6-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea 0.008 >30
    3-[4-({[4-(dimethylamino)phenyl]methyl} sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.003 0.148
    3-[4-({2-[(2S)-2-hydroxypropoxy]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.012 0.088
    3-[4-({3-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.007 0.164
    3-[4-(2,3-dihydro-1H-indole-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.002 0.031
    3-[4-(3,3-difluoroazetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.059 7.859
    3-[4-(3-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.007 0.067
    3-[4-(4-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.004 0.254
    3-[4-(azepane-1-sulfonyl)phenyl-1-(pyridin-3-ylmethyl)urea 0.007 0.139
    3-[4-(azetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.041 1.622
    3-[4-(diethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.016
    3-[4-(piperidine-1-sulfonyl)phenyl]-1-(pyrimidin-5-ylmethyl)urea 1.14 >30
    3-[4-(piperidine-1-sulfonyl)phenyl]-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea 0.189 >30
    3-{[4-(piperidine-1-sulfonyl)phenyl]methyl}-1-(pyridin-3-ylmethyl)urea 0.017 0.547
    3-{4-[(2,2-dimethylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.017 0.159
    3-{4-[(2,3-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.030
    3-{4-[(2,3-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0009 0.074
    3-{4-[(2,4-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.189
    3-{4-[(2,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.109
    3-{4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0012 0.004
    3-{4-[(2,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.006 0.116
    3-{4-[(2-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.024
    3-{4-[(2-chloro-4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0009 0.036
    3-{4-[(2-chloro-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.032
    3-{4-[(2-chloro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0003 0.009
    3-{4-[(2-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.041
    3-{4-[(2-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.032
    3-{4-[(fluoro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.157
    3-{4-[(2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.008
    3-{4-[(2-iodophenyl)sulfmoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0008 0.039
    3-{4-[(2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.002
    3-{4-[(2-methoxypyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007 0.114
    3-{4-[(2-phenylpropan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.039
    3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.01 0.009
    3-{4-[(2S)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.060
    3-{4-[(2S)-2-ethylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.018
    3-{4-[(3,4-dichlorophenyl)sulfamoyl]phenyl)-1-(pyridin-3-ylmethyl)urea 0.006 0.122
    3-{4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.116
    3-{4-[(3,4-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.093
    3-{4-[(3,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.096
    3-{4-[(3,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.041
    3-{4-[(3-aminophenyl)(methanesulfonyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.110
    3-{4-[(3-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003
    3-{4-[(3-chloro-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0014 0.026
    3-{4-[(3-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001
    3-{4-[(3-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.057
    3-{4-[(3-methoxy-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.148
    3-{4-[(3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.010
    3-{4-[(3S)-3-methyl-4-(3-methyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.034
    3-{4-[(3S)-3-methyl-4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.095
    3-{4-[(3S)-3-methylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.105
    3-{4-[(4-chloro-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.006
    3-{4-[(4-chloronaphthelen-1-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.053
    3-{4-[(4-ethoxy-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.157
    3-{4-[(4-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ymethyl)urea 0.007
    3-{4-[(4-fluoro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007 0.116
    3-{4-[(4-tert-butyl-2-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0014 0.097
    3-{4-[(5-chloro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0009 0.003
    3-{4-[(5-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.035
    3-{4-[(5-fluoro-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0010 0.033
    3-{4-[(5-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.079
    3-{4-[3-(2-methoxyethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.089
    3-{4-[4-(2,5-dimethylphenyl)piperazine-1-sulfonyl]phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.101
    3-{4-[4-(2-ethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.006
    3-{4-[4-(2-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007 0.035
    3-{4-[4-(2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.006 0.106
    3-{4-[4-(3,5-dichloropyridin-4-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.029
    3-{4-[4-(3-chloropyridin-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.018
    3-{4-[4-(5-chloro-2-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.050
    3-{4-[4-(5-chloro-2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.162
    3-{4-[4-(diethylamino)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.014
    3-{4-[4-(dipropylamino)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.003
    3-{4-[4-(methoxymethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.022 0.130
    3-{4-benzyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0009 0.007
    3-{4-benzyl(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0011 0.107
    3-{4-[benzyl(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.026
    3-{4-[cyclohexyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.123
    3-{4-[methyl({[3-(trifluoromethyl)phenyl]methyl})sulfamoyl]phenyl)-1-(pyridin-3-ylmethyl)urea 0.007
    3-{4-[methyl(2-methylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007
    5-[({[4-(piperidine-1-sulfonyl)phenyl]carbamoyl}amino)methyl]pyridine-2-carboxamide >10 27.477
    N-(propan-2-yl)-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfamoyl]piperazin-1-yl}acetamide 0.003 0.037
    N,N-diethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide 0.008 0.006
    N,N-diethyl-1-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide 0.005 0.045
    N,N-dimethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-4-carboxamide 0.009 0.164
    N,N-dimethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide 0.016 0.055
    N-ethyl-N-[(3S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidin-3-yl]acetamide 0.006 0.079
    N-methyl-2-[(4-{[(pyridin 3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide 0.001 0.011
    N-methyl-N-phenyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide 0.008 0.030
    rel-3-{4-[(4aR,8aS)-decahydroisoquinoline-2-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.101
    tert-butylN-{5-[({[4-(piperidine-1-sulfonyl)phenyl]carbamoyl}amino)methyl]pyridin-2-yl}carbamate 3.135 9.782
    1-(4-{8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-6-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.002 0.003
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluromethoxy)benzene]sulfonyl}phenyl)urea 0.001 0.003
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethyl)benzene]sulfonyl}phenyl)urea 0.003 0.569
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea 0.001 0.083
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)benzeme]sulfonyl}phenyl)urea 0.004 0.247
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethoxy)benzene]sulfony}phenyl)urea 0.005 0.420
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethyl)benzeme]sulfonyl}phenyl)urea 0.009 0.604
    1-(pyridin-3-ylmethyl)-3-[4-(trifluoromethane)sulfonylphenyl]urea 0.226 10.0
    1-(pyridin-3-ylmethyl)-3-{4-[(2,4,6-trimethylbenzene)sulfonyl]phenyl}urea 0.011 >1
    1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea 0.003 0.081
    1-[(6-aminopyridin-3-yl)methyl]-3-{4-[(4-fluorobenzene)sulfonyl]phenyl}urea 0.002 0.043
    1-[4-(2H-1,3-benzodioxole-5-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.001 0.322
    1-[4-(cyclopentanesulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.043 1.86
    1-[6-(benzenesulfonyl)pyridin-3-yl]-3-(pyridin-3-ylmethyl)urea 0.015 2.356
    1-{4-[(2-phenoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.002 0.008
    3-(4-{[2-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.006 0.039
    3-(4-{[2-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.339
    3-(4-{[2-fluoro-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.001 0.014
    3-(4-{[2-methoxy-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.003
    3-(4-{[2-methoxy-5-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.003 0.031
    3-(4-{[2-methyl-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.021
    3-(4-{[3-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.002 0.038
    3-(4-{[3-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.004 0.079
    3-(4-{[4-chloro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.005 0.167
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-2-sulfonyl)phenyl]urea 0.869
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-3-sulfonyl)phenyl]urea 0.005 0.595
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-4-sulfonyl)phenyl]urea 0.011 0.488
    3-(pyridin-3-ylmethyl)-1-[4-(pyrimidine-5-sulfonyl)phenyl]urea 0.020 0.871
    3-[4-(1-methyl-1H-pyrazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.004 0.247
    3-[4-(2-methoxynaphthalene-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.002 0.012
    3-[4-(3,5-dimethyl-1,2-oxazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.020 0.850
    3-[4-(5-methylthiophene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.003 0.383
    3-[4-(benzenesulfonyl)phenyl]-1-{[6-(2-methoxyethoxy)pyridin-3-yl]methyl}urea 2.121 >10
    3-{[({4-[(4-chlorobenzene)sulfonyl]phenyl} arbamoyl)amino]methyl}pyridin-1-ium-1-olate 0.728 >30
    3-{4-[(2,3-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.446
    3-{4-[(2,3-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.546
    3-{4-[(2,3-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.298
    3-{4-[(2,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.827
    3-{4-[(2,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.344
    3-{4-[(2,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.047
    3-{4-[(2,4-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.018 0.967
    3-{4-[(2,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin 3-ylmethyl)urea 0.006 0.652
    3-{4-[(2,5-difluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.105
    3-{4-[(2,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.403
    3-{4-[(2,5-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.007
    3-{4-[(2,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.014 0.473
    3-{4-[(2,6-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007 0.026
    3-{4-[(2,6-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.008 0.387
    3-{4-[(2-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.326
    3-{4-[(2-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.006 0.250
    3-{4-[(2-chloro-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.008
    3-{4-[(2-chloro-6-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.007 0.336
    3-{4-[(2-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.475
    3-{4-[(2-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.0004
    3-{4-[(2-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.169
    3-{4-[(2-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.387
    3-{4-[(2-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.311
    3-{4-[(2-fluoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.517
    3-{4-[(2-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.012 >1
    3-{4-[(2-fluoro-6-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.010
    3-{4-[(2-fluorobenzene)sulfonyl]phenyl}-1-(piridin-3-ylmethyl)urea 0.003 0.493
    3-{4-[(2-methoxy-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.007
    3-{4-[(2-methoxybenzene)sulfonyl]pheny}-1-(pyridin-3-ylmethyl)urea 0.002 0.010
    3-{4-[(2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.450
    3-{4-[(3,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.214
    3-{4-[(3,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.017
    3-{4-[(3,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.284
    3-{4-[(3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.040
    3-{4-[(3-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.322
    3-{4-[(3-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.518
    3-{4-[(3-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.173
    3-{4-[(3-ffuoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.206
    3-{4-[(3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.001 0.238
    3-{4-[(3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.157
    3-{4-[(4-chloro-2-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.415
    3-{4-[(4-chloro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.006 0.755
    3-{4-[(4-chloro-3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.221
    3-{4-[(4-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.533
    3-{4-[(4-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.287
    3-{4-[(4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.171
    3-{4-[(4-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.091
    3-{4-[(4-methoxy-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.008 0.352
    3-{4-[(5-chloro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.005 0.021
    3-{4-[(5-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.002 0.004
    3-{4-[(5-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.004 0.489
    3-{4-[2-chloro-6-(propan-2-yl)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.006
    N,N-dimethyl-4-[(4-{[pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.005 0.053
    1-(4-{[2-(morpholin-4-ylmethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.0036 0.0079
    1-(4-{[3-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.0022 0.0980
    1-(4-{[3-(cyclopropylmethoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.0086 0.1-1
    1-(4-{[4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.0055 0.0550
    1-(4-{[4-(morpholin-4-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea 0.0018 0.0147
    1-(pyridin-3-ylmethyl)-3-[4-(3,3,5-trimethylazepane-1-sulfonyl)phenyl]urea 0.0020 0.0092
    1-(pyridin-3-ylmethyl)-3-{4-[(3-sulfamoylbenzene)sulfonyl]phenyl}urea 0.0038 0.1-1
    1-(pyridin-3-ylmethyl)-3-{4-[6-(trifluoromethyl)pyridine-3-sulfonyl]phenyl}urea 0.0279 1-10
    1-[4-({3-[(morpholin-4-yl)carbonyl]benzene}sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0050 0.1-1
    1-[4-(1H-indole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0016 0.0134
    1-[4-(1H-indole-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0005 0.0034
    1-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0011 0.1-1
    1-[4-(2,3-dihydro-1-benzofuran-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0011 0.0105
    1-[4-(2H-1,3-benzodioxole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0043 0.1-1
    1-[4-(isoquinoline-4-sulfonyl)phenyl]-3-(pyridin3-ylmethyl)urea 0.0014 0.0083
    1-[4-(phenoxathiine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0029 0.0018
    1-{4-[(3-benzoylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0044 1-10
    1-{4-[(3-cyanobenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0080 0.1-1
    1-{4-[(3-phenylbenzane)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0068 0.1-1
    1-{4-[(4-cyanobenzane)sulfonyl]phenyl}-3-(pyridin 3-ylmethyl)urea 0.0076 0.1-1
    1-{4-[(4-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0058 0.1-1
    1-{4-[(pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0084 1-10
    1-{4-[2-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0160 0.1-1
    1-{4-[4-(2-phenylacetyl)piperaazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0030 0.9323
    1-{4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea 0.0036 0.0304
    2-fluoro-N-(propan-2-yl)5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0209 0.1-1
    2-methyl-N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]phenyl}propanamide 0.0012 0.0101
    3-(4-{[2chloro-5-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0063 0.1-1
    3-(4-{[2-methoxy-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0014 0.0033
    3-(4-{[2-methyl-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0118 0.1-1
    3-(4-{[3-(2-methylpropoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0033 0.1-1
    3-(4-{[3-(3,5-dimethyl-1H-pyiazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0016 0.0159
    3-(4-{[3-(5-methyl-1,3,4-oxediazol-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0073 0.1-1
    3-(4-{[3-(dimethylsufamoyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0033 0.0793
    3-(4-{[3-(ethanesulfonyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0076 0.1-1
    3-(4-{[3-(ethylsulfamoyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0072 0.1-1
    3-(4-{[3-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0033 0.0933
    3-(4-{[3-(propane-1-sulfonemido)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0016 0.0860
    3-(4-{[3-chloro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0040 0.1-1
    3-(4-{[3-chloro-5-(trifluoromehyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0013 0.0255
    3-(4-{[3-fluoro-4-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0022 0.1-1
    3-(4-{[3-fluoro-4-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0055 0.1-1
    3-(4-{[3-fluoro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0041 0.1-1
    3-(4-{[3-fluoro-5-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0011 0.0297
    3-(4-{[3-fluoro-5-(2methylpropoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0040 0.0564
    3-(4-{[3-fluoro-5-(trifhioromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0007 0.0576
    3-(4-{[4-(ethoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0010 0.1-1
    3-(4-{[4-(propan-2-yl)benzene]sulfonyl}phenyl-1-(pyridin-3-ylmethyl)urea 0.0030 0.1-1
    3-(4-{[4-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0017 0.0291
    3-(4-{[4-fluoro-3-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0021 0.0234
    3-(4-{[4-fluoro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0015 0.0862
    3-(4-{4-[2-(3,4-dichlorophenyl)acetyl]pipearazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea 0.0037 1-10
    3-(pyridin-3-ylmethyl)-1-[4-({4-[(pyrrolidin-1-yl)carbonyl]benzene}sulfonyl)phenyl]urea 0.0013 0.0076
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-3-sulfonyl)phenyl]urea 0.0028 0.0280
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-6-sulfonyl)phenyl]urea 0.0027 0.0441
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-8-sulfonyl)phenyl]urea 0.0014 0.0022
    3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0080 1-10
    3-[4-(1-methyl-1H-indazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0010 0.0599
    3-[4-(1-methyl-1H-indazole-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0018 0.0925
    3-[4-(1-methyl-1H-indazole-6-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0025 0.0354
    3-[4-(1-methyl-1H-indazole-7-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0144 0.1-1
    3-[4-(1-methyl-1H-indole-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0030 0.0635
    3-[4-(1-propyl-1H-pyraaolo-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0063 0.0131
    3-[4-(2,4-dimethoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0067 0.0210
    3-[4-(2-methoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0087 0.1-1
    3-[4-(2-methylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0072 0.1-1
    3-[4-(4-{[4-(propan-2-yl)phenyl]methyl}piperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0358 1-10
    3-[4-(5-chloropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0026 0.0982
    3-[4-(5-fluoropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0087 0.1-1
    3-[4-(6-methoxynaphthalene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0016 0.1-1
    3-[4-(6-methoxypyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0050 0.1-1
    3-[4-(6-methylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0049 0.1-1
    3-{4-[(3,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0029 0.1-1
    3-{4-[(3,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0019 0.1-1
    3-{4-[(3-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0021 0.1-1
    3-{4-[(3-chloro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0013 0.0929
    3-{4-[(3-chloro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0009 0.1-1
    3-4-[(3-chloro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0046 0.1-1
    3-{4-[(3-chloro-5-mehoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0013 0.0272
    3-{4-[(3-chloro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0018 0.0671
    3-{4-[(3-ethanesulfonamidobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0011 0.0695
    3-{4-[(3-ethoxy-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0039 0.0283
    3-{4-[(3-ethoxybanzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0017 0.0837
    3-{4-[(3-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0020 0.0708
    3-{4-[(3-fluoro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0013 0.0585
    3-{4-[(3-fluoro-5-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0017 0.1-1
    3-{4-[(3-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0017 0.0993
    3-{4-[(3-methanesulfonamidobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0013 0.0761
    3-{4-[(3-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0066 0.1-1
    3-{4-[(3-methoxy-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0027 0.0179
    3-{4-[(3-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0038 0.1-1
    3-{4-[(4-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0020 0.1-1
    3-{4-[(4-acctylphanyl)sulfamoyl]phanyl}-1-(pyridin 3-ylmcthyl)urea 0.0144 1-10
    3-{4-[(4-chloro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0044 0.0632
    3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0031 0.1-1
    3-{4-[(4-ethoxy-3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0012 0.0217
    3-{4-[(4-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0022 0.1-1
    3-{4-[(4-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0020 0.0282
    3-{4-[(4-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0037 0.0446
    3-{4-[(4-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0037 0.1-1
    3-{4-[(4-methoxy-3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin 3-ylmethyl)urea 0.0021 0.0089
    3-{4-[(4-methoxybenzene)sulfonyl]phenl}-1-(pyridin-3-ylmethyl)urea 0.0024 0.1-1
    3-{4-[(5-acetyl-2methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0013 0.0017
    3-{4-[2-(dimethylamino)pyrimidine-5-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0059 0.1-1
    3-{4-[3chloro-2-(morpholin-4-yl)pyridine4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0040 0.0142
    3-{4-[4-(3-chlorophenyl)-4-hydroxypiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0052 0.9563
    3-{4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0030 0.0749
    3-chloro-N,N-diethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0035 0.0017
    3-fluoro-N,N-dimethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0015 0.0133
    4-fluoro-N-(priopan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0154 0.1-1
    N-(2-hydroxyethyl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0078 0.1-1
    N-(2-methylpropyl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0097 0.1-1
    N-(propan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0100 0.1-1
    N,N-diethyl-3-fluoro-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0012 0.0015
    N,N-diethyl-4-fluoro-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0024 0.0885
    N,N-dimethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0074 0.1-1
    N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]phenyl}acetamide 0.0015 0.0395
    N-cyclopentyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0096 0.1-1
    N-cyclopropyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0064 0.1-1
    N-ethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0067 0.1-1
    N-ethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide 0.0013 0.0402
    N-methyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyridine-2-carboxamide 0.0038 0.0838
    rel-3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.0039 0.0135
    4-[(5-chloro-2-methoxyphenyl)sulfamoyl]-N-{imidazo[1,2-a]pyridin-6-ylmethyl}benzamide 0.00216 0.0023
    3-[(5-fluoropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea 0.024 0.752
    3-[(6-aminopyridin-3-yl)methyl]-1-[4-(pipezidine-1-sulfonyl)phenyl]urea 0.0085 0.0714
    3-[4-(benzenesulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea 0.0035 0.16
    3-[4-(benzenesulfonyl)phenyl]-1-{[6-(dimethylamino)pyridin-3-yl]methyl}urea >30 27.6
    3-{4-[(4-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.003 0.239
    3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.00452 0.241
    3-{4-[(4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea 0.00433 0.141
    1-[4-(piperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea 0.0486 >2
    • Xenograft Studies:
  • C.B-17-Igh-1b-Prkdcscid mice (female) were injected s.c. with 5X106 A2780 cells (NCI) in the left flank. 10-12 days later when tumors reached 100-200 mm3 in size, mice were randomized into treatment groups of 8 mice per group including vehicle control and reference standard groups. The compounds were formulated in 60:30:10 PEG-400:D5W: Ethanol and administered p.o., at the dose volume of 10ml/kg BID for a duration of 5 or 10 days. The dose used for efficacy was selected from the MTD (Maximum Tolerated Dose) study. Mice were weighed and tumors measured using vernier calipers every alternate day. Tumor volume was calculated according to the formula (length x width2)/2. All animal work was approved by the Institutional Animal Care and Use Committee of Biological Resource Centre, Singapore.
    • Results:
  • The following compound produced tumor regression.
    1-(4-{8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea; and
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea.
  • The following compound produced tumor stasis:
    • 3-{4-[(4-chloro-2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    • 3-[4-(benzenorulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea; and
    • 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea.
  • The following compounds delayed tumor growth:
    • 1-{4-[4-(morpholin-4-yl)peridino-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    • 3-(4-{[2-methoxy-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    • 1-(4-{[(1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    • 3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    • 3-{4-[(2-chloro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    • 1-{4-[(naphtalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    • 3-{4-[(3-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    • 3-{4-[(5-chloro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea and
    • 3-{4-[(4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
  • While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art.

Claims (15)

  1. Compounds of Formula IIIA:
    Figure imgb0815
     wherein:
    Ra is 1, 2, 3 or 4 Ra groups, each independently selected from the group consisting of hydrogen, amino, oxo, halo, alkoxy, alkyl, haloalkyl, -N(alkyl)2, -NH(CO)O-alkyl, 1H-pyrazolyl, 1H-imidazolyl, and -C(O)NH2; and wherein said pyridine can comprise a N-oxide formed with its N atom member;
    R1 is -NR3R4 wherein R3 is H, alkyl or -S(O)2alkyl and R4 is alkyl, hydroxyalkyl, -S(O)2alkyl, -(CH2)qcycloalkyl,-(CH2)qheterocycloalkyl, aryl, arylalkyl-, or -(CH2)qheteroaryl;
    haloalkyl;
    cycloalkyl;
    aryl;
    heterocycloalkyl; or

    heteroaryl;
    wherein each of said cycloalkyl, aryl, heterocycloalkyl or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of:
    halo, cyano, alkyl, hydroxyl, hydroxyalkyl, hydroxyalkoxy, haloalkyl, alkoxy, alkylalkoxy, haloalkoxy, arylalkenyl-, aryloxy, benzyloxy, oxo, -(CH2)q-NkbRc, -(CH2)q-CONRbRc, -S(O)2-alkyl,-S(O)2NH-alkyl, -S(O)2-heterocycloalkyl, -S(O)2-CF3, -C(O)alkyl,-C(O)aryl, -C(O)alkylenylaryl, -C(O)O-alkyl, -(CH2)qcycloalkyl, cycloalkylalkoxy-, aryl, arylalkyl-, -(CH2)qheteroaryl, and-(CH2)qheterocycloalkyl;
    wherein each of said cycloalkyl, heterocycloalkyl, aryl or heteroaryl may be substituted by one or more halo, nitro, haloalkyl, haloalkoxy, oxo, cyano, alkyl, haloalkyl, or alkoxy;
    Rb and Rc are independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxy, aryl, alkoxyalkyl, -S(O)2alkyl and cycloalkyl or Rb and Rc can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S and O; and
    q is 0 or 1; and
    pharmaceutically acceptable salts thereof,
    with the proviso that the compounds of Formula IIIA are not:
    N-[4-(phenylsulfonyl)phenyl]-N'-(3-pyridinylmethyl)urea;
    N,N-diethyl-4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide;
    4-[[[(3-pyridinylmethyl)amino]carbonyl]amino]benzenesulfonamide;
    1-[4-(benzylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(naphthalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(2-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea; 3-(pyridin-3-ylmethyl)-1-{4-[(pyridin-3-ylmethyl)sulfamoyl]phenyl}urea;
    3-{4-[(2-chlorophenyl)sulfamoyl}phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea; or
    3-{4-[(2-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea.
  2. The compounds of claim 1, wherein:
    each Ra is independently selected from the group consisting of hydrogen, amino, oxo, halo, (C1-C6)alkoxy, (C1-C6)alkyl, halo(C1-C6)alkyl, -N(C1-C6-alkyl)2, -NH(CO)O-(C1-C6)alkyl 1H-pyrazolyl, 1H-imidazolyl, and -C(O)NH2;
    R1 is -NR3R4 wherein R3 is H, C1-C6-alkyl or -S(O)2(C1-C6)alkyl and R4 is (C1-C6)alkyl, hydroxy(C1-C6)alkyl, -S(O)2(C1-C6)alkyl, -(CH2)qcycloalkyl,-(CH2)qheterocycloalkyl, aryl, aryl(C1-C6)alkyl-, or -(CH2)qheteroaryl;
    halo(C1-C6)alkyl;
    C3-C12-cycloalkyl;
    aryl;
    heterocycloalkyl; or
    heteroaryl;
    wherein:
    each of said cycloalkyl, aryl, or heteroaryl is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of:
    halo, cyano, (C1-C6)alkyl, hydroxyl, hydroxy(C1-C6)alkyl, hydroxy(C1-C6)alkoxy, halo(C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkyl(C1-C6)alkoxy, halo(C1-C6)alkoxy, aryl(C2-C6)alkenyl-, aryloxy, benzyloxy, oxo, -(CH2)q-NRbRc, -(CH2)q-CONRbRc,-S(O)2-(C1-C6)alkyl, -S(O)2NH-(C1-C6)alkyl, -S(O)2-heterocycloalkyl, -S(O)2-CF3, -C(O)(C1-C6)alkyl, -C(O)aryl, -C(O) (C2-C6)alkylenylaryl, -C(O)O-(C1-C6)alkyl, -(CH2)qcycloalkyl, cycloalkyl(C1-C6)alkoxy-, aryl, aryl(C1-C6)alkyl-, -(CH2)qheteroaryl,
    and -(CH2)qheterocycloalkyl,
    wherein each of said cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be substituted by one or more halo, nitro, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, oxo, cyano, (C1-C6)alkyl, halo(C1-C6)alkyl, or (C1-C6)alkoxy;
    Rb and Rc are independently selected from the group consisting of H, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy, aryl, (C1-C6)alkoxy(C1-C6)alkyl, -S(O)2(C1-C6)alkyl and (C3-C6)cycloalkyl or Rb and RC can form a 5 or 6 membered heterocycloalkyl group together with the nitrogen atom to which they are attached, wherein said heterocycloalkyl group may contain one or more addional heteroatom(s) selected from N, S and O;
    wherein heterocycloalkyl groups are 5 to 13 membered heterocycloalkyl groups containing 1, 2, 3 or 4 heteroatoms selected from N, O and S; heteroaryl groups are 5 to 13 membered heteroaryl groups containing 1, 2, 3 or 4 heteroatoms selected from N, O and S.
  3. The compounds of claim 1 or 2, wherein R1 is:
    -NR3R4 wherein R3 is H and R4 is aryl; or
    trifluoromethyl; or
    selected from the group consisting of cyclopropyl, cyclopentane, cycloheptyl, azaspiro[4.5]decane, bicyclo[2.2.1]heptane, bicyclo[3.1.1]heptane, adamantane, and (1S,2S,3S,SR)-2,6,6-trimethylbicyclo[3.1.1]heptane; or
    selected from the group consisting of phenyl, naphatalene, tetrahydronaphthalene, and 1H-inden-5-yl; or
    unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or
    unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S wherein heterocycloalkyl is selected from the group consisting of azetidine, piperidine, pyrrolidine, piperazine, thiophorpholine, 2,8-diazaspiro[5.5]undecane, 8-oxa-3-azabicyclo[3.2.1]octane, 1,4-diazepane, 2-oxa-8-azaspiro[4.5]decane, and decahydroquinoline; or
    unsubstituted or substituted 5 to 12 heteroaryl comprising 1, 2 or 3 heteroatoms selected from N, O and S; or
    unsubstituted or substituted 5 to 12 membered heterocycloalkyl comprising 1, 2 or 3 heteroatoms selected from N, O and S, wherein the heteroaryl is selected from the group consisting of 1,3,4-oxadiazole, (1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine, 3,4-dihydro-2H-1,4-benzoxazine, oxo-2,3-dihydro-1H-indole, 3,4-dihydro-2H-1,5-benzodioxepine, 1,2,3,4-tetrahydroisoquinoline, indole, indazole, thiophene, pyrazole, pyridine, pyrimidine, 1,2-oxazole, 8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene, 5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl, phenoxathiine, 3-azaspiro[5.5]undecane, azatricyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene, (4aR,8aS)-decahydroisoquinoline, and 5,6,7,8-tetrahydro-1,6-naphthyridine.
  4. The compounds of claim 1, wherein the compounds are selected from the group consisting of:
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea;
    3-{4-[(4-bromobenzene)sulfonyl]phenyl}-1 -(pyridin-3-ylmethyl)urea;
    3-(4-{[2-methyl-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methoxy-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[(6-aminopyridin-3-yl)methyl]-3-{4-[(4-fluorobenzene)sulfonyl]phenyl}urea;
    3-{4-[(3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea;
    3-{4-[(4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-fluoro-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea; ,
    3-{4-[(3,4-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethyl)benzene]sulfonyl}phenyl)urea;
    3-{4-[(2,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea;
    N,N-dimethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[2-methoxy-4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(benzenesulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-bromobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)benzene]sulfonyl}phenyl)urea;
    3-{4-[(5-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(benzenesulfonyl)phenyl]-1-{[6-(dimethylamino)pyridin-3-yl]methyl}urea;
    3-{4-[(4-chloro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,3-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chloro-6-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(pyrimidine-5-sulfonyl)phenyl]urea;
    3-{4-[(3,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[6-(benzenesulfonyl)pyridin-3-yl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-difluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-2-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea; 3-[4-(2-methoxynaphthalene-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{[({4-[(4-chlorobenzene)sulfonyl]phenyl} carbamoyl)amino]methyl}pyridin-1-ium-1-olate;
    3-{4-[(3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(2H-1,3-benzodioxole-5-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(benzenesulfonyl)phenyl]-1-{[6-(2-methoxyethoxy)pyridin-3-yl]methyl}urea;
    3-{4-[(2,3-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(2-phenoxybenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,3-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(cyclopentanesulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-6-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-[4-(trifluoromethane)sulfonylphenyl]urea;
    3-{4-[(2-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(3,5-dimethyl-1,2-oxazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethyl)benzene]sulfonyl}phenyl)urea;
    3-(4-{[4-chloro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[2-chloro-6-(propan-2-yl)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxy-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-4-sulfonyl)phenyl]urea;
    3-{4-[(2-chloro-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-3-sulfonyl)phenyl]urea;
    3-{4-[(3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,6-dimethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{8-oxatricyclo[7.4.0.02,7]trideca-1(9),2(7),3,5,10,12-hexaene-6-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(pyridine-2-sulfonyl)phenyl]urea;
    3-{4-[(5-chloro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-methoxy-5-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(2,4,6-trimethylbenzene)sulfonyl]phenyl}urea;
    3-{4-[(3-fluoro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethoxy)benzene]sulfonyl}phenyl)urea;
    3-[4-(1-methyl-1H-pyrazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-[4-(5-methylthiophene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,4-difluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,6-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(2-methoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(phenylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{8-methyl-2,8-diazaspiro[5.5]undecane-2-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{4-[4-(trifluoromethyl)phenyl]piperazine-1-sulfonyl}phenyl)urea;
    3-{4-[(3,4-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-methyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyridine-2-carboxamide;
    3-{4-[(2R)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-fluoro-5-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(3-methoxyphenyl)pentan-3-yl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-fluoro-3-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methoxy-3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-chloro-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[6-(dimethylamino)pyridine-3-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(morpholin-4-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-l-(pyridin-3-ylmethyl)urea;
    1-[4-(3,5-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    (2S)-N,N-dimethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidine-2-carboxamide;
    methyl4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazine-1-carboxylate;
    3-{4-[(2-methoxyethyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(2H-1,3-benzodioxol-5-yl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-(propan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[(2-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-methyl-1H-indole-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{[4-(piperidine-1-sulfonyl)phenyl]methyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(cycloheptylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(pyrazin-2-yl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-methylpyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[(1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{4-[6-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea;
    3-{4-[(3-ethoxy-4-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(6-ethylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[3-(2-methoxyethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-methyl-1H-indazole-7-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-cyclopropyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-{4-[(4-methoxy-3,5-dimethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-methyl-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(3-methoxyphenyl)ethyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    N-[(3R)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidin-3-yl]acetamide;
    1-{4-[(4-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(dimethylsulfamoyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxy-6-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methanesulfonylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-methyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide;
    3-{4-[(4-chloro-2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-chloro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(1,5-dimethyl-1H-pyrazol-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(2-methoxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,4-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{methyl[(1S)-1-phenylethyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{8-azaspiro[4.5]decane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-chloro-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(3S)-3-cyanopiperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2S)-2-(methoxymethyl)pyrrolidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-(4-{4-[2-(morpholin-4-yl)-2-oxoethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(3-benzoylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(6-methoxypyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-ethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[4-(2-methoxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(6-methoxynaphthalene-2-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethyl)phenyl]sulfamoyl}phenyl)urea;
    3-{4-[cyclohexyl(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(4-chlorophenoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-({4-[(pyrrolidin-1-yl)carbonyl]benzene}sulfonyl)phenyl]urea;
    3-(4-{[3-(2-hydroxyethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-2,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,5-dimcehylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(3-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-bromophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methylpyridin-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-fluoro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[2-(3,4-dichlorophenyl)acetyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-({2-[(2S)-2-hydroxypropoxy]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-[4-(1H-indole-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(ethoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(1-phenylcyclopentyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea;
    1-{4-[(3-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,4-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(pyridin-2-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    (3S)-N,N-diethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-3-carboxamide;
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-6-sulfonyl)phenyl]urea;
    1-(4-{[(1S,2S,4R)-bicyclo[2.2.1]heptan-2-yl]sulfamoyl}phenyl-3-(pyridin-3-ylmethyl)urea;
    3-[(5-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea;
    3-{4-[4-(3-chlorophenyl)-4-cyanopiperidine-1-sulfbnyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(4-methanesulfonylpiperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-[4-(1H-pyrrole-1-sulfonyl)phenyl]urea;
    3-{4-[(4-ethoxy-2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-propylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-cyano-4-(4-methoxyphenyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[(4-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[3-(piperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(pyridin-3-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(thiomorpholine-4-sulfonyl)phenyl]urea;
    3-(4-{[2-chloro-5-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(pyrrolidine-1-sulfonyl)phenyl]urea;
    2-methyl-N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]phenyl}propanamide;
    1-[4-(cyclohexylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-4-carboxamide;
    3-(4-{[(4-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chloro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{3-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-(4-{[2-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(2,4,6-trimethylphenyl)sulfamoyl]phenyl}urea;
    1-[4-(4-cyclohexylpiperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chloro-4-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-fluoro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(methylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-[4-(phenoxathiine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-(propan-2-yl)-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide;
    N,N-diethyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide;
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-8-sulfonyl)phenyl]urea;
    1-(4-{[4-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3,5-dichloropyridin-4-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(cyclobutylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-[4-(4-methylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{4-[4-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea;
    1-{4-[4-(morpholin-4-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-[4-(4-benzyl-1,4-diazepane-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    N-[(3S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidin-3-yl]acetamide;
    3-(pyridin-3-ylmethyl)-1-[4-(quinoline-3-sulfonyl)phenyl]urea;
    3-(4-{[3-fluoro-5-(2-methylpropoxy)benzene]sulfonyl} phenyl)-1-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    1-{4-[(3-cyanobenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-[(5-fluoropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea;
    1-{4-[(2H-1,3-benzodioxol-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-[4-(isoquinoline-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chloro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{3-azaspiro[5.5]undecane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,4-difluorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(diethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    N-(2-methylpropyl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[3-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-methoxy-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-ethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-ethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-[4-(6-methoxypyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(3-phenylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[(3-fluorophenyl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[4-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea;
    3-{4-[(3-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(propan-2-yloxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxypyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4,4-difluoropiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3S)-3-methyl-4-(4-methylphenyl)piperazine-1-sulfbnyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-methyl-1H-indazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(piperidin-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-[4-(butylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-methylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(3-cyanophenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(dimethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[methanesulfonyl(piperidin-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[(4-fluorophenyl)carbonyl]piperidine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[4-(piperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3S)-4-(4-methoxyphenyl)-3-methylpiperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(3S)-3-(trifluoromethyl)piperidine-1-sulfonyl]phenyl}urea;
    3-{4-[methyl(oxolan-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(2,3-dihydro-1-benzofuran-7-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-methoxyethyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-methyl-4-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[methyl({[5-(trifluoromethyl)pyridin-2-yl]methyl})sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{4-[3-(morpholin-4-yl)propyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(propane-1-sulfonamido)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(5-chloro-2-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-chloro-4-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(2H-1,3-benzodioxol-5-ylmethyl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    N-methyl-N-phenyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperazin-1-yl}acetamide;
    1-(4-{4-[(furan-2-yl)carbonyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(5-chloro-2-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(propan-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-fluoropyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(2-methyl-3-oxopiperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-ethoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,6-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(1H-indole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-chloro-N,N-diethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-[2-fluoro-4-(piperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    1-(pyridin-3-ylmethyl)-3-[4-({[3-(trifluoromethyl)phenyl]methyl}sulfamoyl)phenyl]urea;
    1-(4-{[3-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(2-hydroxyethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-hydroxyethyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethane)sulfonylphenyl]sulfamoyl}phenyl)urea;
    3-{4-[(4-chlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-ethanesulfonamidobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-chloro-3-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-methyl-1H-indazole-6-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-(2-hydroxyethyl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-{4-[(3-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-fluoro-4-(trifluoromethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-fluoro-3-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[4-(morpholine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[(4-chlorophenyl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[methyl(2-methylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{methyl[(1R)-1-phenylethyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-({2-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[(quinolin-6-yl)sulfamoyl]phenyl}urea;
    3-{4-[(2,5-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[2-(piperidin-1-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{methyl[2-(4-methylphenyl)ethyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfamoyl]phenyl}urea;
    1-(4-{3-azaticyclo[7.3.1.05,13]trideca-1(13),5,7,9,11-pentaene-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-2-{4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]phenyl}acetamide;
    3-[(6-chloropyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea;
    3-(4-{[(5-methylfuran-2-yl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{44-[2-oxo-2-(piperidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-[4-(3,3,5-trimethylazepane-1-sulfonyl)phenyl]urea;
    3-(4-{[3-(3,5-dimethyl-1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(methoxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-propyl-1H-pyrazole-4-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-fluoro-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[2-(morpholin-4-ylmethyl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-fluoro-4-(2,2,2-trifluoroethoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(3,4,5-trifluorophenyl)sulfamoyl]phenyl}urea;
    1-{4-[(pyridin-2-ylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    N,N-diethyl-4-fluoro-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    1-(4-{[4-(piperidine-1-sulfonyl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(ethylsulfamoyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4-cyanopiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,2-dimethylpropyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(dibenzylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    (2S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidine-2-carboxamide;
    1-(4-{3-oxa-8-azabicyclo[3.2.1]octane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(1H-indazol-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    tert-butyl N-{5-[({[4-(piperidine-1-sulfonyl)phenyl]carbamoyl}amino)methyl]pyridin-2-yl}carbamate;
    3-{4-[benzyl(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3-chloropyridin-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methanesulfonamidobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N,N-diethyl-3-fluoro-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[4-(methoxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidine-4-carboxamide;
    3-{4-[(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-({3-[(morpholin-4-yl)carbonyl]benzene}sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-(4 {[(4-fluorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[benzyl(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-({[4-(dimethylamino)phenyl]methyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[benzyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4-{[(2R)-oxolan-2-yl]carbonyl}piperazine-l-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    2-methyl-N-{1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidin-4-yl}propanamide;
    1-(pyridin-3-ylmethyl)-3-(4-{[4-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)urea;
    3-(pyridin-3-ylmethyl)-1-(4-{[4-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea;
    3-(4-{[(3-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(ethanesulfonyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(4-hydroxypiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(hydroxymethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    4-fluoro-N-(propan-2-yl)-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-{4-[4-(3-chlorophenyl)-4-hydroxypiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3S)-3-methyl-4-(3-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,3-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,3-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4-benzylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-(4-{[(4-phenylphenyl)methyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[(5,6,7,8-tetrahydronaphthalen-1-yl)sulfamoyl]phenyl}urea;
    rel-3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-[4-(decahydroquinoline-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(4-ethynylphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-chloro-4,6-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-fluoro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(2R)-2-benzylpiperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-3-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(diethylamino)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluorophenyl)(methyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(2-methylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-{4-[6-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-5-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    rel-3-{4-[(4aR,8aS)-decahydroisoquinoline-2-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(4-methanesulfonylpiperidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-sulfonyl]phenyl}urea;
    3-{4-[(6-methylpyridin-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[(morpholin-4-yl)carbonyl]piperidine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[3-(2-chloro-4-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[4-chloro-3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-(2-methylpropoxy)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[bis(4-fluorophenyl)methyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(1-methyl-1H-indazole-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[3-(benzyloxy)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-(4-{[3-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea;
    3-{4-[(4-ethoxy-3-fluorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-dichlorobenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3,4-dimethylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)urea;
    3-{4-[(2-ethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methanesulfonylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methoxy-4-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(6-methylpyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-[4-(5,6,7,8-tetrahydro-1,6-naphthyridine-6-sulfonyl)phenyl]urea;
    3-[4-(2,4-dimethoxypyrimidine-5-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(propan-2-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-chloro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(4-fluorophenoxy)pyridin-3-yl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(4-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[(pyridin-4-ylmethyl)sulfamoyl]phenyl}urea;
    1-{4-[4-(azepan-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    1-(4-{[4-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(cyclohexylmethyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-ethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[(6-aminopyridin-3-yl)methyl]-1-[4-(piperidine-1-sulfonyl)phenyl]urea;
    3-{4-[(3,4-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-tert-butylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(2-oxo-2,3-dihydro-1H-indol-1-yl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(3-chlorophenyl)ethyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-3-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[3-(1H-pyrazol-1-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[3-(pyrrolidin-1-yl)pyrrolidine-1-sulfonyl]phenyl}urea;
    1-[4-(2H-1,3-benzodioxole-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)urea;
    3-{4-[methyl(2-phenylethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea,
    1-[4-(3,4-dihydro-2H-1,4-benzoxazine-4-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3S)-3-methylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(tert-butylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4-phenylpiperazine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(5-methylpyrimidin-2-yl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea
    3-[4-(azepane-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)urea;
    3-(4-{[3-chloro-4-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-acetylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-bromo-3-methoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(piperidine-1-sulfonyl)phenyl]-1-{[6-(trifluoromethyl)pyridin-3-yl]methyl}urea;
    3-[4-(5-fluoropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(4-{2-oxa-8-azaspiro[4.5]decane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(2-phenylacetyl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-{4-[4-(3-phenylprop-2-en-1-yl)piperazine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(3-sulfamoylbenzene)sulfonyl]phenyl}urea;
    N-methyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    3-(4-{[4-(propan-2-yloxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-hydroxyethyl)(propan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(adamantan-1-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(2R)-2-(morpholin-4-ylmethyl)piperidine-1-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3,5-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluoro-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-{3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]phenyl}acetamide;
    N-methyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    3-{4-[4-(4-chlorophenyl)-4-cyanopiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-methyl-3-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[4-(4-phenylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(methoxymethyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-fluoro-N,N-dimethyl-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-{4-[cyclohexyl(ethyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3,4-dichlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-3-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-fluoro-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(4-{[4-(propan-2-yl)phenyl]methyl}piperazine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{4-[3-(trifluoromethyl)phenyl]piperazine-1-sulfonyl}phenyl)urea;
    1-[4-(cyclopropylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-aminophenyl)(methanesulfonyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(2,3-dihydro-1H-inden-5-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[3-chloro-4-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[2-(dimethylamino)pyrimidine-5-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[1-(3-methoxyphenyl)-4-methylcyclohexyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[(5-ethylpyridin-2-yl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-propoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloronaphthalen-1-yl)sulfamoyl]phenyl}-1-(pyridin-3 -ylmethyl)urea;
    3-{4-[(5-acetyl-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(5-chloro-2-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(1R)-3-oxo-3H-spiro[2-benzofuran-1,3'-pyrrolidine]-1'-ylsulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2,4-dimethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N-{1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]piperidin-4-yl}acetamide;
    3-(4-{[3-(methoxymethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-4-methoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{4-[(2-oxopyrrolidin-1-yl)methyl]piperidine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-methoxy-5-(trifluoromethyl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-[4-(2,6-dimethylpiperidine-1-sulfonyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(1-phenylcyclohexyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[6-(trifluoromethyl)pyridine-3-sulfonyl]phenyl}urea;
    3-{4-[(4-methylpyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(2-methylpropyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]piperazine-1-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-{4-[(4-sulfamoylphenyl)sulfamoyl]phenyl}urea;
    5-[({[4-(piperidine-1-sulfonyl)phenyl]carbamoyl}amino)methyl]pyridine-2-carboxamide;
    3-(4-{4-[(4-tert-butylphenyl)methyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(azetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-(4-{[2-(1H-pyrrol-1-yl)phenyl]sulfamoyl}phenyl)urea;
    3-(4-{4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    N,N-diethyl-2-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    N-ethyl-N-[(3S)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidin-3-yl]acetamide;
    3-(pyridin-3-ylmethyl)-1-{4-[4-(pyrimidin-2-yl)piperazine-1-sulfonyl]phenyl}urea;
    3-{4-[(3-ethylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[3-chloro-2-(morpholin-4-yl)pyridine-4-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-(4-{[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl]sulfamoyl}phenyl)urea;
    3-{4-[(4-fluoro-3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-phenylpropan-2-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[(1R)-1-(4-chlorophenyl)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-(5-chloropyridine-3-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-cyano-4-(4-methylphenyl)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(3-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluoro-5-methylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methoxy-5-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(dipropylamino)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[(4-fluorophenyl)methyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-{4-[(3S)-3-[(pyrrolidin-1-yl)carbonyl]piperidine-1-sulfonyl]phenyl}urea;
    3-{4-[(3-bromophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(2-phenoxyphenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[1-(4-chlorophenyl)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-4-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    1-{4-[(4-phenylbenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-methylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(4-acetyl-1,4-diazepane-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    N-cyclopentyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-[4-(3,3-difluoroazetidine-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[4-(morpholin-4-yl)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-[4-({3-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-difluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[ethyl(phenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{[2-(trifluoromethyl)phenyl]sulfamoyl}phenyl)urea;
    3-(4-{[3-(5-methyl-1,3,4-oxadiazol-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-[4-({4-[(1S)-1-hydroxyethyl]phenyl}sulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-methoxy-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-tert-butyl-2-chlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{8-azabicyclo[3.2.1]octane-8-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-[4-(cyclopentylsulfamoyl)phenyl]-3-(pyridin-3-ylmethyl)urea;
    3-(4-{4-[2-(diethylamino)ethyl]piperazine-1-sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(3-fluorophenyl)ethyl](methyl)sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[methyl({[3-(trifluoromethyl)phenyl]methyl})sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[3-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-(4-{[(2-chlorophenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{8-oxa-3-azabicyclo[3.2.1]octane-3-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(4-acetylphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(1H-indazol-6-yl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3,4-dimethoxyphenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    N,N-dimethyl-3-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonamido]benzamide;
    1-(4-{[3-(cyclopropylmethoxy)benzene]sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    (2R)-1-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]pyrrolidine-2-carboxamide;
    3-(4-{[(3-methoxyphenyl)methyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-methylpyridin-3-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-[4-(ethylsulfamoyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[2-(difluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    1-(4-{2-azabicyclo[2.2.1]heptane-2-sulfonyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,5-dimethyl-1,2-oxazol-4-yl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(pyridin-3-ylmethyl)-3-(4-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazine-1-sulfonyl}phenyl)urea;
    3-[4-(2,3-dihydro-1H-indole-1-sulfonyl)phenyl]-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-acetylbenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-2-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[(4-cyanophenyl)sulfamoyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-chloro-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3- {4-[(3-chloro-5-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-(4-((2-methoxyethyl)(methyl)amino)piperidin-1-ylsulfonyl)phenyl)-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,4-dimethoxyphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(pyridin-3-ylmethyl)-1-(4-{[2-(pyrrolidin-1-yl)phenyl]sulfamoyl}phenyl)urea;
    3- {4-[(3-methoxy-4-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3- {4-[4-(4-nitrophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3- {4-[4-(2-chloro-4-fluorophenoxy)piperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-chloro-2-(trifluoromethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(4-chloro-3-methylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2,3-dichlorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-(4-{[4-(propan-2-yl)benzene]sulfonyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    2-fluoro-N-(propan-2-yl)-5-[(4-{[(pyridin-3-ylmethyl)carbamoyl]amino}benzene)sulfonyl]benzamide;
    3-(4-{[2-(2-hydroxyethoxy)phenyl]sulfamoyl}phenyl)-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2R,6S)-2,6-dimethylmorpholine-4-sulfonyl]phenyl}-1-(pyndin-3-ylmethyl)urea;
    3-{4-[(4-fluoro-2-methoxybenzene)sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[4-(3-chlorophenyl)piperazine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2S)-2-ethylpiperidine-1-sulfonyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-(4-{[4-(morpholin-4-yl)phenyl]sulfamoyl}phenyl)-3-(pyridin-3-ylmethyl)urea;
    1-{4-[(4-cyanobenzene)sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3,4-dimethylphenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    3-{4-[(2-iodophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    1-{4-[2-(morpholin-4-yl)pyridine-3-sulfonyl]phenyl}-3-(pyridin-3-ylmethyl)urea;
    3-{4-[(3-fluorophenyl)sulfamoyl]phenyl}-1-(pyridin-3-ylmethyl)urea;
    and pharmaceutically acceptable salts thereof.
  5. A pharmaceutical composition comprising a compound of any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
  6. The pharmaceutical composition of claim 5, further comprising a chemotherapeutic agent.
  7. The pharmaceutical composition of claim 6, wherein said chemotherapeutic agent is a DNA damaging agent, or is selected from the group consisting of:
    cytotoxic agent, cisplatin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, the epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, tipifarnib (Zarnestra®), R115777, L778,123, BMS 214662, Iressa®, Tarceva®, C225, GLEEVEC®, intron®, Peg-Intron®, aromatase combinations, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, oxaliplatin (ELOXATIN®), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, MithramycinTM, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrol acetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, Velcade, Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Ifosfomide, Rituximab, Campath, leucovorin, and dexamethasone, bicalutamide, carboplatin, letrozole, megestrol, valrubicin and vinvlastin.
  8. The pharmaceutical composition of claim 5, further comprising a cell rescuing agent.
  9. The pharmaceutical composition of claim 8, wherein said cell rescuing agent is selected from the group consisting of nicotinamide, nicotinamide mononucleotide (NMN) and nicotinic acid.
  10. A compound of any one of claims 1 to 4 or a pharmaceutical composition of any one of claims 5 to 9 for use in a method for inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal.
  11. A compound of any one of claims 1 to 4 for use in inhibiting Nicotinamide phosphoribosyltransferase ("NAMPT") in a patient.
  12. A compound of any one of claims 1 to 4 or a pharmaceutical composition of any one of claims 5 to 9 for use in treating, preventing, inhibiting or eliminating a disease or condition in a patient by inhibiting NAMPT in said patient, wherein said disease or condition is selected from the group consisting of cancer, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, bladder cancer, pancreatic cancer, leukemia, lymphoma, Hodgkin's disease, viral infections, Human Immunodeficiency Virus, hepatitis virus, herpes virus, herpes simplex, inflammatory disorders, irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, osteoarthritis, osteoporosis, dermatitis, atoptic dermatitis, psoriasis, systemic lupus erythematosis, multiple sclerosis, psoriatic arthritis, ankylosing spondylitis, graft-versus-host disease, Alzheimer's disease, cerebrovascular accident, atherosclerosis, diabetes, glomerulonephiritis, metabolic syndrome, non-small cell lung cancer, small cell lung cancer, multiple myeloma, squamous cell cancers, kidney cancer, urethral and bladder cancers, cancers of head and neck, and cancers of the brain and central nervous system.
  13. A compound or composition for use according to claim 12, wherein said disease is a cancer.
  14. A compound or composition for use according to claim 13, wherein said cancer is selected from the group consisting of cancer is selected from leukemia, lymphoma, ovarian cancer, breast cancer, uterine cancer, colon cancer, cervical cancer, lung cancer, prostate cancer, skin cancer, CNS cancer, bladder cancer, pancreatic cancer and Hodgkin's disease.
  15. Use of a compound of any one of claims 1 to 4or a pharmaceutical composition of any one of claims 5 to 9 in the preparation of a medicament for the treatment of cancer.
EP11758024.1A 2010-09-03 2011-09-02 N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer Not-in-force EP2611777B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37981910P 2010-09-03 2010-09-03
US37981210P 2010-09-03 2010-09-03
US38603710P 2010-09-24 2010-09-24
US38604410P 2010-09-24 2010-09-24
US201161478995P 2011-04-26 2011-04-26
US201161480423P 2011-04-29 2011-04-29
PCT/US2011/050320 WO2012031196A1 (en) 2010-09-03 2011-09-02 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer

Publications (2)

Publication Number Publication Date
EP2611777A1 EP2611777A1 (en) 2013-07-10
EP2611777B1 true EP2611777B1 (en) 2016-05-11

Family

ID=44653564

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11758024.1A Not-in-force EP2611777B1 (en) 2010-09-03 2011-09-02 N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer

Country Status (13)

Country Link
US (4) US20130273034A1 (en)
EP (1) EP2611777B1 (en)
JP (2) JP6038792B2 (en)
KR (1) KR20130114653A (en)
CN (2) CN106986856A (en)
AR (1) AR082887A1 (en)
AU (1) AU2011295724B2 (en)
BR (1) BR112013004858A8 (en)
CA (1) CA2809391A1 (en)
MX (1) MX342481B (en)
RU (2) RU2617424C2 (en)
TW (1) TW201217359A (en)
WO (1) WO2012031196A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2611777B1 (en) 2010-09-03 2016-05-11 Forma TM, LLC. N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
RU2617988C2 (en) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ New compounds and compositions for nampt inhibition
RU2013126657A (en) 2010-11-15 2014-12-27 Эббви Инк. NAMPT AND ROCK INHIBITORS
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
PT2820008T (en) 2012-03-02 2017-05-05 Genentech Inc Amido spirocyclic amide and sulfonamide derivatives
SG10201701894SA (en) 2012-03-02 2017-05-30 Genentech Inc Amido-Benzyl Sulfone and Sulfoxide Derivatives
CA2873060A1 (en) * 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
US9296723B2 (en) 2012-05-11 2016-03-29 Abbvie Inc. NAMPT inhibitors
CN104684906B (en) * 2012-05-11 2017-06-09 艾伯维公司 Nampt inhibitor
MA37808A1 (en) * 2012-06-27 2018-03-30 Alzheimers Institute Of America Inc Compounds and their therapeutic uses
NZ706999A (en) * 2012-10-15 2018-12-21 Agios Pharmaceuticals Inc Inhibitors of mutant isocitrate dehydrogenase and therapeutical uses thereof
WO2014074715A1 (en) * 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2015161142A1 (en) 2014-04-18 2015-10-22 Millennium Pharmaceuticals, Inc. Quinoxaline compounds and uses thereof
CA2954328A1 (en) 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
US10323018B2 (en) 2015-01-20 2019-06-18 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
EP3289873A4 (en) * 2015-04-30 2019-05-08 Kyoto University COMPOSITION CONTAINING COMPOUND ACCELERATING PHOSPHORYLATION OF AMPK AS AN EFFECTIVE COMPONENT
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3390355B1 (en) * 2016-03-22 2022-12-28 Helsinn Healthcare S.A. Benzenesulfonyl-asymmetric ureas and medical uses thereof
KR101869794B1 (en) * 2016-07-20 2018-06-21 연세대학교 산학협력단 Phamaceutical composition for preventing or treating refractory, relapsed, or metastatic cancer
TWI835714B (en) 2016-10-18 2024-03-21 美商思進公司 Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
BR112019022445A2 (en) 2017-04-27 2020-05-12 Seattle Genetics, Inc. COMPOSITION OF BINDER-DRUG CONJUGATE, FORMULATION, METHOD TO INHIBIT THE TUMOR CELL OR CANCER CELL MULTIPLICATION OR CAUSE APOPTOSIS IN A TUMOR OR CANCER CELL, AND, PHARMACEUTICAL CONNECTOR COMPOUND
EP3412651A1 (en) * 2017-06-06 2018-12-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibitors of rac1 and uses thereof for inducing bronchodilatation
WO2019089478A1 (en) * 2017-10-30 2019-05-09 Neuropore Therapies, Inc. Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
US11701334B2 (en) 2018-01-10 2023-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
KR101937126B1 (en) * 2018-06-15 2019-01-10 연세대학교 산학협력단 Phamaceutical composition for preventing or treating refractory, relapsed, or metastatic cancer
WO2020010252A1 (en) 2018-07-05 2020-01-09 Daiichi Sankyo Company, Limited Fused ring compound having urea structure
US20220125814A1 (en) * 2019-03-21 2022-04-28 Fred Hutchinson Cancer Research Center Cancer combination therapies utilizing a nicotinamide phosphoribosyltransferase inhibitor in combination with a nicotinamide adenine dinucleotide salvage pathway precursor
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
CA3146157A1 (en) * 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
ES2828464A1 (en) * 2019-11-26 2021-05-26 Univ Murcia INHIBITORS OF CELL DEATH BY PARTHANATES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES OF THE SKIN (Machine-translation by Google Translate, not legally binding)
FR3103702B1 (en) * 2019-11-28 2022-02-11 Nuvamid Sa Use of NMN for the prevention and/or treatment of ankylosing spondylitis and corresponding compositions
WO2021126902A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses
WO2021159015A1 (en) * 2020-02-07 2021-08-12 Cytokinetics, Inc. Nampt modulators
US20240124466A1 (en) * 2020-12-11 2024-04-18 Vova Ida Therapeutics, Inc. Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
BR112023024712A2 (en) 2021-05-27 2024-02-15 Metro Int Biotech Llc CRYSTALLINE SOLIDS OF NICOTINE ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MANUFACTURING AND USE
CN113278409B (en) * 2021-06-22 2022-04-29 西南石油大学 High-temperature acidizing corrosion inhibitor
CN114890990B (en) * 2022-04-13 2024-01-16 中国人民解放军海军军医大学 A compound and its application in preparing NAMPT protein autophagy degradation agent
CN115286617B (en) * 2022-06-24 2024-04-30 中国人民解放军海军军医大学 A PROTAC compound targeting degradation of NAMPT and its application
WO2024211444A2 (en) * 2023-04-03 2024-10-10 Duke University Antibiotics comprising lpxh-targeting compounds and methods of making and using the same
CN116589402B (en) * 2023-04-04 2025-09-12 中国人民解放军海军军医大学 A compound as a NAMPT-PDEδ dual-target inhibitor and its application
WO2025168575A1 (en) 2024-02-05 2025-08-14 Institut National de la Santé et de la Recherche Médicale Inhibitors of nad biosynthesis for the treatment of dengue virus infections

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931203A (en) 1973-03-19 1976-01-06 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
AR205697A1 (en) 1973-03-19 1976-05-31 Rohm & Haas NEW RODENTICIDE COMPOUNDS OF 1 - (3 - PYRIDYLMETIL) - 3 - (4 - SUBSTITUTE PHENYL OR 4-NITRONAFTIL) UREAS COMPOSITION THAT UNDERSTAND THEM AND PROCEDURE TO PREPARE THEM
DE2334355A1 (en) 1973-07-06 1975-01-16 Hoechst Ag Antiprotozoal 1,3-diphenyl-(thio)ureas - prepd. by reacting substd. phenyl iso(thio)cyanates with substd. anilines
US3994905A (en) * 1974-04-11 1976-11-30 Rohm And Haas Company 3-Pyridylmethyl aryl urea rodenticides
US4659724A (en) 1982-12-30 1987-04-21 Union Carbide Corporation Certain 1-[4-(5-cyano-2-pyridyloxy)phenyl-benzoyl ureas having pesticidal properties
DE19624704A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkanoic acid amides
DE19624668A1 (en) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Use of pyridylalkane, pyridylalken or pyridylalkynamides
DE19624659A1 (en) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab New pyridylalkene and pyridylalkanoic acid amides
DE19756235A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
DE19756261A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New aryl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756236A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Novel piperazinyl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
DE19756212A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New cyclic imide-substituted pyridylalkane, alkene and alkyarboxylic acid amides
GB9904275D0 (en) * 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
DE10053794A1 (en) * 2000-10-30 2002-05-08 Bayer Ag Amino- or amido-benzene N-phenylsulfonamide derivatives, useful for treating central nervous system disorders e.g. Alzheimer's disease, dementia, depression, are 5-HT6 receptor antagonists
JP2004517080A (en) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Benzimidazole derivatives useful as inhibitors of TIE-2 and / or VEGFR-2
ES2200617B1 (en) * 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4.
WO2002070467A1 (en) 2001-02-26 2002-09-12 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
DE10109204A1 (en) 2001-02-26 2002-09-19 4Sc Ag Use of new and known diphenylurea compounds for the preparation of a medicament for the inhibition of intracellular protein-degradation pathway
AU2002364260A1 (en) 2001-12-31 2003-07-30 Bayer Pharmaceuticals Corporation Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
US7750160B2 (en) 2003-11-13 2010-07-06 Ambit Biosciences Corporation Isoxazolyl urea derivatives as kinase modulators
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
EP1907367A4 (en) 2005-04-18 2011-05-11 Saeed R Khan Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
WO2007046513A2 (en) 2005-10-20 2007-04-26 Sumitomo Chemical Company, Limited Benzoylurea compounds and use thereof
JP2010505767A (en) 2006-09-28 2010-02-25 アレテ セラピューティクス， インコーポレイテッド Soluble epoxide hydrolase inhibitor
US8450348B2 (en) 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
RU2011111728A (en) * 2008-08-29 2012-10-10 Топотаргет А/С (Dk) NEW DERIVATIVES OF UREA AND THIRE UREA
FR2943669B1 (en) 2009-03-24 2011-05-06 Sanofi Aventis NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU2010257504B2 (en) * 2009-06-09 2015-04-09 Onxeo Dk, Branch Of Onxeo S.A., France Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase
NZ601788A (en) * 2010-03-01 2014-11-28 Myrexis Inc Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof
JP5881705B2 (en) 2010-09-03 2016-03-09 フォーマ ティーエム， エルエルシー． Novel compounds and compositions for inhibition of NAMPT
EP2611777B1 (en) * 2010-09-03 2016-05-11 Forma TM, LLC. N-(4-{[pyridin-3-yl-methyl)carbamoyl]amino}benzene-sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer
RU2617988C2 (en) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ New compounds and compositions for nampt inhibition
US9169209B2 (en) 2011-05-04 2015-10-27 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
US9555039B2 (en) 2011-05-09 2017-01-31 Forma Tm, Llc. Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
ES2620612T3 (en) 2012-03-02 2017-06-29 Genentech, Inc. Derivatives of pyridinyl and pyrimidinyl sulfoxides and sulfones
WO2013130935A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Amido-benzyl sulfoxide derivatives
SG10201701894SA (en) 2012-03-02 2017-05-30 Genentech Inc Amido-Benzyl Sulfone and Sulfoxide Derivatives
PT2820008T (en) 2012-03-02 2017-05-05 Genentech Inc Amido spirocyclic amide and sulfonamide derivatives
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives

Also Published As

Publication number Publication date
US11279687B2 (en) 2022-03-22
JP6038792B2 (en) 2016-12-07
JP2017019825A (en) 2017-01-26
RU2016116533A3 (en) 2018-11-30
KR20130114653A (en) 2013-10-17
RU2016116533A (en) 2018-11-30
CN103270023A (en) 2013-08-28
BR112013004858A2 (en) 2016-06-07
EP2611777A1 (en) 2013-07-10
US10329275B2 (en) 2019-06-25
WO2012031196A9 (en) 2013-06-13
US20180291000A1 (en) 2018-10-11
MX2013002431A (en) 2013-06-03
US20190270721A1 (en) 2019-09-05
CA2809391A1 (en) 2012-03-08
JP2013536868A (en) 2013-09-26
BR112013004858A8 (en) 2018-01-02
AR082887A1 (en) 2013-01-16
CN106986856A (en) 2017-07-28
MX342481B (en) 2016-09-30
AU2011295724B2 (en) 2016-05-12
CN103270023B (en) 2016-11-02
US20130273034A1 (en) 2013-10-17
US20200283403A1 (en) 2020-09-10
RU2617424C2 (en) 2017-04-25
US10647695B2 (en) 2020-05-12
AU2011295724A8 (en) 2013-06-20
TW201217359A (en) 2012-05-01
AU2011295724A1 (en) 2013-05-02
WO2012031196A1 (en) 2012-03-08
RU2013114844A (en) 2014-10-10

Similar Documents

Publication Publication Date Title
US11279687B2 (en) Compounds and compositions for the inhibition of NAMPT
EP2611778B1 (en) Guanidine compounds and compositions for the inhibition of nampt
AU2011367222B2 (en) Novel compounds and compositions for the inhibition of NAMPT
US20210244717A1 (en) Novel compounds and compositions for the inhibition of nampt
RU2617643C2 (en) Novel compounds and compositions for inhibiting nampt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130328

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140702

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602011026487

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07D0213540000

Ipc: A61K0045060000

RIC1 Information provided on ipc code assigned before grant

Ipc: C07C 317/42 20060101ALI20150625BHEP

Ipc: C07D 471/04 20060101ALI20150625BHEP

Ipc: C07D 213/40 20060101ALI20150625BHEP

Ipc: A61K 31/5377 20060101ALI20150625BHEP

Ipc: C07D 213/75 20060101ALI20150625BHEP

Ipc: C07D 401/12 20060101ALI20150625BHEP

Ipc: C07D 213/84 20060101ALI20150625BHEP

Ipc: C07D 317/42 20060101ALI20150625BHEP

Ipc: A61K 31/44 20060101ALI20150625BHEP

Ipc: A61K 45/06 20060101AFI20150625BHEP

Ipc: C07D 213/81 20060101ALI20150625BHEP

Ipc: A61K 31/4545 20060101ALI20150625BHEP

Ipc: C07D 213/74 20060101ALI20150625BHEP

Ipc: A61K 31/4406 20060101ALI20150625BHEP

Ipc: A61K 31/437 20060101ALI20150625BHEP

Ipc: C07D 213/54 20060101ALI20150625BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151118

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 798118

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011026487

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160811

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 798118

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160812

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160912

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011026487

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160511

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602011026487

Country of ref document: DE

26N No opposition filed

Effective date: 20170214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20160902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20170531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170401

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160902

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20110902

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160930

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160511